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Differentiated thyroid carcinoma (DTC) is a fascinating tumor for multiple aspects. 
First, from a biological point of view, DTC has many intriguing aspects. Recent 
insights into the pathogenesis of DTC have revealed a clear picture of the relation 
between genetic alterations and the different subtypes of DTC that all arise from 
the thyroid epithelium. These insights not only have added to the understanding of 
the pathogenesis of DTC, but have also provided new candidate targets for therapy. 
In addition, the pathogenesis of DTC has also revealed important knowledge about 
normal thyroid physiology, in particular the pathophysiology of molecules involved 
in iodide metabolism, like the sodium iodide symporter (NIS) and thyroid peroxidase 
(TPO). The defects in iodide metabolism in DTC that are present in advanced 
tumors, offer a model to study the contribution and signifi cance of the components 
involved in iodine metabolism and may also offer targets for redifferentiation 
approaches. The accomplishments of basic research in these areas may ultimately 
provide valuable directions for clinical management of DTC. 
Second, from a clinical point of view, DTC is fascinating because the approach to 
the patient differs essentially from many non-endocrine tumors. The central role 
of therapy with radioactive iodine is unique for DTC. Another special aspect is the 
fact that despite the good prognosis, a substantial proportion of patients develop 
metastases, that are not life threatening but may impair quality of life considerably, a 
situation that is not often encountered in general oncology. The unique features of 
DTC offer opportunities for basic and clinical research and indeed insights from the 
pathophysiology of DTC have often lead to a broader understanding of biological 
mechanisms involved in cancer.
Despite these fascinating aspects of DTC, the diagnosis and therapy remain a 
challenge to the physician. DTC has a low incidence and in general an excellent 
prognosis. Therefore, intervention studies are diffi cult to perform because to 
reach relevant endpoints high numbers of patients with long follow-up periods are 
required. As a result, most protocols are based on retrospective studies. The low 
incidence logically would require centralized treatment and registration of DTC 
patients in order to develop optimal follow-up protocols. The problem, however, is 
that treatment of DTC is often decentralized, resulting in many different follow-up 
protocols. A typical example of the decentralized follow-up is the fact that many 
different staging systems have been developed, which complicates the comparison of 
treatment results between centers. Fortunately, in recent years, several national and 
multinational guidelines have become available (published by the British, American 
and European Thyroid Associations)(1;2). Although these guidelines agree in many 
aspects, they are still based on moderate evidence levels, leaving many questions to 
be answered.   Prominent questions are the diagnostic criteria of DTC, the optimal 
follow up strategies in DTC patients and strategies to improve radioiodide (RaI) 
therapy. 
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The present thesis is focused on several clinical questions involved in treatment and 
follow-up of patients with DTC. In this chapter a general overview of DTC will be 
provided and the questions addressed in this thesis will be introduced.  
2. Characterization of thyroid carcinomas
DTC has a low incidence, varying from 2-10/100.000 (3-6) with a female to male 
preponderance of 2:1. In general, 80% of newly diagnosed thyroid carcinomas are 
differentiated tumors with a median age at diagnosis of 45 to 50 years (7). DTC has 
a relatively favourable prognosis with a 10-yr survival of 90-95% (Table 1). 
Table 1. Clinico-pathological features of thyroid cancer (adapted from ref.2)







Papillary thyroid carcinoma 85–90% 2:1–4: 1 20–50 <50% 5–7% >90%
Follicular thyroid carcinoma <10% 2:1–3: 1 40–60 <5% 20% >90%
Poorly differentiated 
thyroid carcinoma rare–7% 0.4:1–2.1: 1 50–60 30–80% 30–80% 50%
Undifferentiated 
thyroid carcinoma 2% 1.5: 1 60–80 40% 20–50% 1–17%
Medullary thyroid carcinoma 3% 1:1–1.2: 1 30–60 50% 15% 80%
Mixed medullary and 
follicular-cell carcinoma rare
This high survival rate is the result of the biological behaviour of most of these 
tumors and the effi cacy of primary therapy, consisting of surgery and RaI therapy. 
However, when distant metastases occur, the prognosis is worse because the results 
of RaI therapy, which is virtually the only curative treatment option, are moderate. 
Although these metastases are rarely life threatening, they may affect quality of life 
for years depending on the localization and size. 
The tumor-node-metastases (TNM) classifi cation system is based primarily on 
pathologic fi ndings and separates patients into four stages, with progressively poorer 
survival with increasing stage (Table 2) (8). Recently, the 6th edition of the TNM 
system has become available (9). The most important difference with he 5th edition is 
the fact hat the dimension of T1 has been extended to 2 cm, which has implications 
for the prognosis of DTC (10). Therefore, some experts propagate to continue the 








Table 2. Postoperative TNM stage of Differentiated Thyroid Carcinomas (6th Edition, Ref.  9)
T0 No primary tumor
T1 Tumor diameter < 2 cm
T2 Tumor diameter 2- 4 cm
T3 Tumor diameter > 4 cm, limited to the thyroid or with minimal extrathyroid extension
T4a
Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, 
trachea, esophagus or recurrent laryngeal nerve
T4b Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels 
N0 No metastatic nodes
N1a Metastases to level VI (pretracheal, paratracheal and prelaryngeal lymph nodes)
N1b Metastases to unilateral, bilateral, contralateral cervical or superior mediastinal nodes
M0 No distant metastases
M1 Distant metastases
3. Pathogenesis of DTC
3.1 Molecular Pathogenesis
Human thyroid tumors originate from epithelial follicular cells or from parafollicular 
C-cells. Follicular cell-derived tumors represent a wide spectrum of lesions, ranging 
from benign adenomas to differentiated (follicular and papillary) and undifferentiated 
(anaplastic) carcinomas, thus providing a good model for fi nding a correlation 
between specifi c genetic lesions and histological phenotype.
Recent developments have provided a detailed map of the role of the genetic alterations 
involved in the pathogenesis of thyroid neoplasms and DTC. The dissection of the 
genetic alterations has important implications not only for the diagnosis, but also for 
the understanding of the molecular (patho)physiology of thyroid disorders (12-14). 
Follicular adenomas and carcinomas frequently have mutations in one of the three 
RAS genes . Mutations of Gsα protein (GSP) and thyroid-stimulating hormone (TSH) 
receptor genes are associated with benign hyperfunctioning thyroid nodules and 
adenomas. The understanding of the molecular pathogenesis of papillary carcinoma 
(PTC) has improved considerably by the recent identifi cation of mutations in B-RAF, 
which are present in 40-60% of the carcinomas. B-RAF is a component of the RET, 
RAS, RAF cascade that activate MAP kinase. Indeed, mutations and rearrangements 
of B-RAF, RAS, RAF and TRK (neurotrophic tyrosine kinase receptor) account 
for almost all cases of PTC. Translocations of RET observed in DTC result in a 
chimeric protein consisting of an activated RET tyrosine kinase domain.  (13;15-30). 
MET (receptor-tyrosine kinase) overexpression in DTC is thought to be regulated 
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by transcriptional or post-transcriptional mechanisms as a secondary effect  (31). 
The situation in follicular thyroid carcinoma (FTC) is less clear (32), but a very 
interesting observation has been the presence of a rearrangement of the PAX-8 and 
PPARγ genes (33), a unique combination of genes that traditionally is associated 
with thyroid development (the transcription factor PAX-8) and cell differentiation 
and metabolism (PPARγ). The chimeric protein acts as a dominant negative 
competitor for PPARγ. Indeed, in experimental models of DTC, downregulation 
of the PPARγ signaling route has been observed (34). Anaplastic carcinomas are 
frequently associated with mutations in the p53 tumor suppressor gene (35). This is 
in contrast with many other tumors in which p-53 mutations play a role early in the 
process of tumorigenesis. 
In the pathogenesis of thyroid carcinoma, it is believed that the genetic alterations 
lead to both proliferations via multiple pathways, and the loss of thyroid specifi c 
protein expression. The disappearance of the functional expression of thyroid specifi c 
proteins is a complex chain of events, in which the mechanism is incompletely 
understood. From many observations, it is believed that there is a sequential 
disappearance of specifi c proteins. The disappearance of thyroid peroxidase (TPO) 
is believed to be an early event, followed by NIS. TSH receptor (TSHR) expression 
and thyroglobulin (Tg) expression are usually still present in advanced stages 
(36;37;37;38).  The mechanisms involved in the decreased expression of thyroid 
specifi c proteins may be genetic, involving the absence of thyroid transcription 
factors, epigenetic changes (observed for NIS and TSHR), mutations (not frequently 
observed) or by post-translational regulation (NIS) (39).
3.2  Sodium iodide symporter and iodide metabolism
The main treatment option for recurrent or metastatic thyroid carcinoma is therapy 
with radioiodide (RaI). The discovery and molecular cloning of the rat and later NIS 
have contributed greatly to the understanding of the physiology and pathophysiology 
of iodide uptake by the thyroid gland (40;41). NIS resides at the basolateral 
membrane of thyroid epithelial cells and is responsible for the uptake of iodide from 
capillaries into the thyroid epithelial cell. The relation between decreased RaI uptake 
in thyroid carcinoma and decreased NIS activity has been well established. However, 
controversy exists on the mechanism. There is evidence that genetic alterations in 
DTC lead to decreased NIS mRNA and protein expression (42). Indeed, the causal 
chromosomal rearrangements in PTC have been demonstrated to inactivate NIS 
expression by decreased expression of the transcription factors TTF-1 and PAX-8 
(43). TTF-1 and PAX-8 are involved in the gene expression of important thyroid 
proteins, including NIS. In contrast, experimental gene transfer with PAX-8 lead 
to re-expression of NIS in a dedifferentiated thyroid cell-line (44;45). In other 
studies however, a defect in targeting of NIS to the cell membrane is reported, 
which is accompanied by an intra-cytoplasmatic overexpression of NIS in about 







interventions aimed at increasing NIS expression. 
The ultimate dose of radioactivity in thyroid tumors (expressed in Gray (Gy)) is not 
only determined by the amount (activity) of RaI administered to the tumor (specifi c 
activity), the rate of uptake but also by the tumor volume and the effective half life 
of RaI, which on its turn is determined by the physical half life and the biological half 
life (46). The exact mechanism of iodide effl ux remains elusive. Although candidate 
molecules for apical iodide effl ux (pendrin) (47) have been discovered, their exact 
role in apical iodide transport has not been determined yet. The putative apical 
iodide symporter (48) has been proven not to transport iodide (49). In addition to 
iodide effl ux, organifi cation of iodide by TPO together with the three dimensional 
architecture of the thyroid is also likely to contribute to the dose of RaI achieved.
4.  Initial diagnosis of DTC
Despite the increasing standards of imaging techniques like ultrasound, fi ne needle 
aspiration (FNA) is the procedure of choice in patients presenting with thyroid 
enlargement. The sensitivity of FNA for DTC in most series is 90-95%. The specifi city 
of FNA is lower, 60-80% when all patients with a non-benign FNA are referred 
for surgery (50). As a consequence, the frequency of FTC in hemi-thyroidectomies 
performed after suspicious results from FNA is only 20-30%. The problem is that 
the distinction of benign and malignant follicular neoplasms is diffi cult to make 
by FNA, as the crucial criterion for FTC vs. adenoma (FA) is capsular invasion, 
which cannot be determined by cytology. In addition, the distinction between FA 
and Follicular variant of PTC (FVPTC) is also diffi cult, because the crucial criterion 
here is the aspect of the nuclei.  The implication is that 70-80% of the patients with 
suspicious results from FNA, who undergo thyroid surgery have a benign tumor 
(51). Therefore, approaches to improve the accuracy of FNA are warranted (51). 
Candidate molecular markers for diagnosis and prognosis can be distinguished in 3 
groups:  1) gene mutation or chromosomal rearrangements; 2) lack of thyroid specifi c 
protein expression and 3) markers associated with malignant transformation:
1) Genomic instability in DTC
As chromosomal alterations have only recently been identifi ed, their place in the 
diagnosis of DTC is still limited. B-RAF mutations can be identifi ed in FNA and 
would facilitate the diagnosis of PTC, which is however, usually not diffi cult. 
Unfortunately, B-RAF mutations are uncommon in FVPTC (52). The detection of 
a PPARγ/PAX8 rearrangement in 75% of follicular carcinoma’s and not in papillary 
carcinoma and follicular adenomas (33), suggested that this rearrangement could be 
a used as a diagnostic tool. However, in a recent study (53) the rearrangement was 
observed in 13% of follicular adenomas, which weakens the diagnostic value of this 
marker.
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2) Thyroid specifi c proteins that lose expression during thyroid dedifferentiation
Absence of TPO has been reported to be a specifi c marker both in cytology and 
histology of thyroid malignancies. In the process of dedifferentiation, TPO appears 
to be the fi rst protein with diminished expression. Clinically, this leads to decreased 
organifi cation of iodine, which may have consequences for RaI therapy. In studies 
originally initiated by De Micco et al, a cut-off value of 80% of thyroid epithelial 
cells staining positive with the anti-TPO antibody MoAb47 has been found to have 
superior sensitivity (100%) and specifi city (up to 99%) for follicular carcinoma in 
surgical specimens (54). Later studies, mostly from the same center, confi rmed 
the diagnostic value of TPO immunostaining in FNA. In the distinction between 
follicular adenoma and carcinoma, sensitivity is reported around 100%, specifi city 
varying from 61-99% (55;56). However, most of these observations have come from 
one group, suggesting that the technique (both antibody and staining procedures) 
may be relatively complicated.    
3) Markers associated with malignant transformation in general
From the non-thyroid specifi c markers, galectin-3 has been a promising marker.  The 
galectins are carbohydrate binding proteins involved in cell adhesion, cell growth and 
cell death. Galectin-3 (Gal-3) has been considered a marker with a high diagnostic 
potential to identify FTC (55-65), but in recent publications Gal-3 staining was also 
reported in benign lesions (66;67). Other immunohistochemical markers that have 
been reported of various use are HBME-1 (Hector Battifora mesothelial) (68-72) and 
Cytokeratin-19 (73-78). Other molecular markers that have been investigated include 
telomerase activity. Telomerase is an enzyme that adds nucleotides to telomeres, 
DNA sequences at the ends of chromosomes that enhance chromosomal stability. 
Assessment of telomerase in thyroid FNA reveals telomerase in 14-38% of follicular 
adenoma and in 75% of follicular carcinoma (79;80), indicating that these assays 
alone have insuffi cient diagnostic properties as compared with TPO and Gal-3.
The introduction of high-throughput techniques in molecular biology has opened 
new potential perspectives for the identifi cation of novel diagnostic molecular 
markers for thyroid carcinoma (81-85). Recent studies based on cDNA expression 
arrays have identifi ed immunohistochemical markers for the differentiation between 
thyroid neoplasms. Markers emerging from these studies are Gal-3, Fibronectin-1 
(FN-1) and CITED-1  (CBP/p300-Interacting Transactivators with glutamic acid 
[E] and aspartic acid [D]-rich C-terminal domain) were found to be overexpressed 
in PTC (85).  In most of these studies  fi xed cut-off levels for positive staining are 
used and with the exception of Casey et al (75), de Matos et al (76) and Prasad et al 
no panels of antibodies are studied. 
The introduction of tissue micro-array (TMA) facilitates a comprehensive expression 
analysis of thousands of genes at the protein level in a given tissue. Maximal 







all tissues analyzed are located on one glass section and treated under absolutely 
identical conditions. Most TMAs have been used in cancer research to investigate 
the prevalence of molecular changes and their associations with tumor progression 
and/or prognosis (86;87). 
We decided to evaluate the diagnostic value of Gal-3, HBME-1, CK-19, CITED-1, 
FN-1, NIS and PPARγ  in a TMA containing a large panel of thyroid neoplasms, using 
receiver operator curve (ROC) analyses to calculate cut-off levels and  evaluating the 
diagnostic accuracy of panels identifi ed by hierarchical cluster analysis Chapter 2. 
5.  Initial therapy of DTC
The guidelines for the initial therapy of TC have been extensively reviewed in the 
guideline papers mentioned above. In all patients with DTC except unifocal T1 (5th 
edition TNM (11)) PTC, initial therapy consists of near-total thyroidectomy followed 
by RaI ablative therapy of thyroid remnants. Although there is still some controversy 
about the extent of thyroid surgery, there are strong arguments in favor of total or 
near-total thyroidectomy (leaving only as limited thyroid tissue as is necessary to 
keep vital structures intact) in all patients (88). Total or near-total thyroidectomy 
results in a lower recurrence rate than more limited thyroidectomy, because many 
papillary carcinomas are multifocal and bilateral. Furthermore, total thyroidectomy 
facilitates total ablation with RaI and reveals a higher specifi city of Tg as a tumor 
marker (89-93). 
Although controversy exists about the routine application of RaI ablation of thyroid 
remnants, many clinics follow this procedure. Postoperatively RaI therapy is given 
for three reasons. First, it destroys any remaining normal thyroid tissue, thereby 
increasing the specifi city of detectable serum Tg and positive whole-body scintigraphy 
as markers for persistent or recurrent tumour (7;89;94). Second, RaI therapy may 
destroy occult microscopic carcinomas, thereby decreasing the long-term risk of 
recurrent disease (89;95-97). Third, the use of a large amount of RaI for therapy 
permits post ablative scanning, a test for detecting persistent carcinoma (98;99). 
However, in a recent meta-analysis (100) the benefi cial effect of RaI ablation to 
prevent recurrence or death was doubtful. A benefi cial effect was only shown in 
patients with a high risk or irradical surgery (91;95;101;102). In addition, doubts have 
arisen about the safety of routine RaI ablation, a recent paper suggesting a relation 
between excess non-thyroidal malignancies and RaI (103). This has led to a more 
careful positioning of RaI ablation in recent papers (2;104). In conclusion, there 
is consensus about the effi cacy of RaI ablation therapy in patients with: (i) tumor 
stages T2-4; (ii) evidence for remaining thyroid tumor remnants and (iii) metastases 
(105;105;106).
The effi cacy of RaI therapy depends on the effective radiation dose delivered to 
the thyroid remnant or tumor (46). The radiation dose is negatively affected by 
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decreased uptake and the shorter effective half-life of RaI in tumor tissue compared 
with normal thyroid tissue (37;42;107). 
Strategies to increase RaI uptake include the establishment of high TSH levels, 
either by thyroid hormone withdrawal or by therapy with recombinant human TSH 
(108;109). Another method to increase RaI uptake is to deplete the plasma inorganic 
iodine pool before RaI therapy. Low plasma iodine concentrations may increase 
the expression of the sodium iodine transporter (hNIS) leading to a higher specifi c 
activity of RaI which can be achieved by limiting iodide intake through a low-iodine 
diet (110). 
6.  Follow-up of patients with DTC
The purpose of follow-up protocols in DTC is to detect and prevent persistent or 
recurrent DTC. Recurrences are usually detected during the early years of follow-
up but may be detected later, even after more than 15 years after initial treatment. 
Most patients during follow up have been cured defi nitely, and, as a consequence, 
have a low pre-test probability for recurrent disease. Therefore, the sensitivity of 
the diagnostic test must be adequate to detect the few patients with evident thyroid 
carcinoma, whereas specifi city must also be high to avoid unnecessary treatments 
in patients without recurrent disease. In addition, the burden of diagnostic tests for 
the patient should be kept at a minimum. The most important tools in follow up 
protocols are serum measurements of Tg, diagnostic whole body RaI scintigraphies 
and neck-ultrasound.
Numerous studies have been performed on the diagnostic value of Tg measurements. 
The consensus is that the TSH stimulated Tg measurements have superior diagnostic 
value in DTC (111).  The interpretation of many studies and consequently of the 
guidelines on Tg performed so far is diffi cult because the analytical aspects of Tg 
measurements are complicated. 
6.1 Thyroglobulin
Tg is a glycoprotein that is produced only by normal or neoplastic thyroid follicular 
cells. It should not be detectable in patients, who have undergone total thyroid 
ablation. The presence of Tg in such patients reveals the presence of persistent and/
or recurrent disease. The type of analysis (RIA or immunometric assay) affects the 
interpretation of serum Tg values (112). Currently, the clinical interpretation of serum 
Tg levels is hampered by analytical and statistical problems. Analytical problems are 
the lack of universal standardization, leading to signifi cant inter-method variability 
(112;113), poor inter-assay precision across the relevant concentrations used for 
monitoring patients with DTC (6-12 months), “hook” effects which primarily affect 
immunometric assay methods and can lead to inappropriately low- or normal range 
Tg values in sera with very high Tg concentrations (113) and Tg auto-antibody 







Tg concentration, regardless of the type of method used (112;114-117). Statistical 
problems are the use of fi xed Tg cut-off levels without using receiver operator curve 
(ROC) analyses. The application of ROC data is essential, as a chosen cut-off level 
is a subjective choice based on the balance between desired percentages of missed 
recurrences versus unnecessary therapies. Therefore, in a recent European consensus 
paper, it was recommended to defi ne institutional Tg cut-off levels (118). In addition 
to diagnostic purposes, Tg could also be used as a prognostic factor in DTC. The few 
studies that were published on the prognostic signifi cance of Tg measurements used 
fi xed cut-off levels, contained selected subgroups of patients and included either Tg 
measurements at one time point or at undefi ned time points (119-123).
In Chapter 3, we describe a study on the diagnostic and prognostic value of Tg 
in a homogeneous group of DTC patients with respect to initial therapy, using Tg 
measurements at 5 defi ned time-points after diagnosis, in combination with ROC 
analyses. In addition, we studied the diagnostic and prognostic value of Tg antibodies 
for tumor presence or death. We also looked into the potential diagnostic use of Tg 
auto-antibodies.
6.2 New serological markers
Because of the limitations of Tg, novel serological markers have been searched for. 
Of interest is the demonstration of Tg mRNA in peripheral blood, which indicates 
the presence of circulating Tg producing cells (e.g. thyroid cancer cells). In a number 
of studies, Tg mRNA alone did not have suffi cient diagnostic power to discriminate 
between patients with active tumor and thyroid remnants (124) or thyroid carcinoma 
and healthy volunteers (125). However, the combination of Tg and Tg mRNA 
allowed the identifi cation of all patients with active disease in another study (34). 
Interestingly, RT-PCR can also be applied to detect cells that produce other thyroid 
specifi c proteins. In a study on TPO (126), RT-PCR correlated signifi cantly with 
metastatic disease. 
6.3 Iodine-131 total body scitigraphy
The result of iodine-131 whole body scitigraphy depends on the ability of thyroid-
cancer tissue to accumulate RaI in the presence of high serum TSH concentrations. 
The sensitivity of diagnostic RaI scintigraphies is much lower than that of ultrasound 
and Tg measurements and consequently, the routine use of RaI scintigraphy in the 
diagnostic follow-up of DTC patients is no longer recommended (2;127).  
6.4 Ultrasound
In recent publications, ultrasound combined with FNA had the highest sensitivity 
(even higher than Tg) for local recurrent DTC and lymphnode metastases (128-130). 
This has led to an important place for ultrasound in he follow up of DTC.
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6.5 18-F Fluorodeoxyglucose-positron emission tomography (FDG-PET)
The diagnostic accuracy of FDG-PET in patients suspected of recurrent DTC is 
not well defi ned. Many studies are biased by selection of patients or have other 
methodological problems (131). The general idea is hat FDG-PET may be useful in 
patients with elevated serum Tg levels in whom no RaI is observed after diagnostic 
or post-therapeutic scintigraphy. The sensitivity of FPG-PET is better when serum 
Tg levels are higher (132). FDG-PET during TSH stimulation may be more sensitive 
than during suppressive therapy (133).
6.6 Somatostatin Receptor Scintigraphy (SRS)
The expression of somatostatin receptors (SSTR3 and SSTR5) by DTC is the basis 
for SRS imaging and therapy. Interestingly, in a considerable proportion of DTC, 
SRS imaging shows pathological lesions, which has diagnostic and therapeutic 
consequences (134;135).
6.7 Thyroxine withdrawal versus recombinant human TSH (rhTSH)
Serum Tg measurements, thyroid ablation, diagnostic scintigraphies with RaI during 
follow-up and RaI therapy for recurrent disease are based on the responsiveness of 
DTC to TSH (136). 
High serum TSH levels can be realized by conventional thyroxin withdrawal or 
more recently by recombinant human TSH (rhTSH), which has advantages with 
respect to quality of life (137). The fi rst indication for rhTSH has been diagnostic 
RaI scintigraphy and Tg measurements (108;109;128;130;138-143). rhTSH has also 
been used for RaI therapy in active DTC (144-148). Although these studies suggest 
a comparable effi cacy with thyroxine withdrawal, no randomized studies have been 
performed. A good indication for rhTSH for RaI therapy is when contraindications 
are present for withdrawal. rhSH has also been registered for the ablation of thyroid 
remnants (149-151).  Tg measurements during rhTSH have comparable accuracy 
with thyroxine withdrawal (111;139). Some authors, however, have observed a lower 
sensitivity of diagnostic RaI scintigraphies performed after rhTSH (152;153). The 
effi cacy of RaI therapy after rhTSH may be comparable with withdrawal, but no 
randomized studies have been performed to allow a direct comparison (144;154). 
Effi cacy of RaI ablation after rhTSH was comparable after thyroxin withdrawal 
in a recent randomized trial (151), although earlier studies with lower activities 
of RaI showed a lower effi cacy (155). One of the possible explanations for the 
supposedly decreased RaI uptake during rhTSH may be that triiodothyronin (T3) 
directly infl uences iodine uptake in the thyroid. This may be relevant as patients with 
rhTSH will continue thyroxine therapy and have consequently higher T3 levels.  We 







6.8 TSH-suppressive L-thyroxine therapy
Although the rationale for this therapy is evident, it is not clear if all patients benefi t 
from suppressed TSH levels, to what extent TSH should be expressed and for how 
long. In a retrospective study, a lower relapse-free survival was found in patients 
with a consistently suppressed TSH than in patients with TSH > 1 mU/L (156). 
In a large study with a median follow-up of 5 years, the level of TSH suppression 
(undetectable vs. normal) was a signifi cant prognostic factor in high risk papillary 
carcinoma only (157). In a meta-analysis the role of TSH suppression in the follow-
up of DTC was also not clear (158). The routine use of TSH suppression is limited 
by the supposed disadvantages of TSH suppression, like osteoporosis (159) and 
cardiac side effects (160;161).
7. Therapy in metastatic disease
Distant metastases, usually in the lungs and bones, occur in 10 to 15 % of patients 
with DTC. Lung metastases are most frequent in young patients with papillary 
carcinomas. In general, bone metastases are more common in older patients and in 
those with FTC.
In case of residual disease or metastases, surgery can be attempted when the lesion is 
accessible. In other cases, RaI therapy will be given to patients with metastases that 
accumulate RaI. The remission rate in pulmonary metastases treated with iodine -131 
is 50%, varying from 90% in patients with microscopic metastases to only 10% in 
macronodular disease (106;162;163). The remission rates of bone metastases in the 
same studies are worse, varying between 7-20 %. A major problem in this category 
of patients is the diminished or lost ability of thyroid cancer cells to accumulate 
RaI, indicated by negative post-therapeutic whole body scintigraphy. In these cases 
the prognosis is poor, as alternative treatment options (external radiotherapy or 
chemotherapy) have limited success (164). 
Strategies to improve therapeutic options can be distinguished in 1) Therapies 
to improve RaI therapy or 2) Identifi cation of new targets for therapeutic 
intervention.
7.1 Strategies to improve Radioiodide Therapy
Approaches to improve RaI therapy are subdivided in 1) Tumors that still accumulate 
iodide and 2) Tumors that do not.
7.1.1 Tumors that accumulate iodide
In tumors that still accumulate iodide, improving RaI therapy is essentially aimed 
at increasing the dose of RaI, which is determined by the factors mentioned above. 
Attempts to improve RaI can be aimed at all these factors. The specifi c activity of 
RaI presented to the tumor can be improved by a low iodide diet (110).  The uptake 
rate can be infl uenced by high TSH levels, either by withdrawal of thyroxine or by 
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rhTSH. The half-life of RaI in DTC is an important factor. The loss of follicular 
architecture, and probably decreased activity of  TPO may contribute to a decreased 
effective half life and thus by a lower tumor dose (46;165). Several attempts have 
been reported to improve half-life. Transfection with TPO did not result in an 
increased iodide retention (166). Another possibility reported in the literature to 
increase the effective half-life of RaI in DTC is to use a pharmacological approach 
with lithium salts.
7.1.1.1 Lithium
Lithium salts have been associated with an increased trapping of iodide by the thyroid 
gland (167;168).  This property of lithium led to the assumption that lithium may 
enhance the dose of RaI in benign and malignant thyroid disorders. Indeed, lithium 
therapy increased RaI retention in Graves hyperthyroidism (169;170), although this 
could not be confi rmed in other studies (171;172). Reports in DTC have indicated a 
positive effect of lithium as well (167;173-176). The design of these studies, however, 
does not allow a defi nite conclusion, as they contain small numbers of patients, vary 
in the time course of lithium application and used a sequential design resulting in 
higher TSH levels during lithium therapy (171;176) (167;169;173). Although in the 
study of Koong et al (176) it was advised to add lithium to RaI therapy in patients 
with metastatic DTC, no studies have been published to our knowledge in which 
the effects of the addition of lithium to RaI on the clinical course of patients was 
investigated. We, therefore, studied the clinical effects of RaI without and with 
lithiumcarbonate in 12 patients with proven metastatic DTC in Chapter 5.
In addition, the mechanism of the supposed benefi cial effect of lithium salts is 
unclear. In the literature, however, variable effects of lithium salts on iodide uptake 
in vitro or in animal studies are reported. (177-184,185). We therefore studied the 
in vitro effects of lithium salts on iodide metabolism in a background of normal 
thyroid physiology, in a non-thyroid background and in the background of thyroid 
carcinoma, which is also reported in Chapter 5. 
7.1.2 DTC with absent iodide uptake
When iodide uptake is completely lost in DTC, attempts to improve RaI should 
be targeted at the re-induction of functional NIS expression. These attempts are 
indeed complicated by he current uncertainty about the mechanism of decreased 
functional NIS expression in DTC which may involve both genetic defects (42) and 
post-translational (traffi cking)(39) defects. 
Genetic studies to reinduce NIS expression have been reported. NIS gene transfer in 
DTC cell lines and animal studies has been proven to restore the susceptibility to RaI 
therapy (4;186). Interestingly, gene transfer with PAX-8 also leads to re-expression 
of NIS in a dedifferentiated thyroid cell-line (44;45). Although these approaches are 







to be within reach. 
Therefore, medical approaches aimed at redifferentiation, or re-induction of thyroid 
specifi c proteins have gained much interest. Compounds that have been reported 
to reinduce NIS expression are retinoids, demethylation inducing compounds and 
histone-deacetylase inhibitors.
7.1.2.1 Epigenetic therapies
One of the mechanisms by which cells can block the expression of certain genes is 
by enzymes that methylate these genes or de-acetylate the histones that envelope a 
particular gene. These mechanisms also play a role in the silencing of genes in cancer. 
Therefore, compounds that can reverse methylation or inhibit histone deacetylation 
may lead to the re-expression of genes that are silenced in cancer. 
Demethylation therapy has been proven successful in leukemia. In an in-vitro study 
in thyroid carcinoma, the demethylating agent 5-azacytidine led to re-induction of 
NIS expression, accompanied by RaI uptake in thyroid cancer cell lines (187). In 
parallel, the histone deacetylase inhibitor depsipeptide has been reported to reinduce 
NIS mRNA expression and RaI uptake in DTC (188;189), although toxicity may be 
a serious problem (190). 
7.1.2.2 Retinoids
Retinoids are derivatives of vitamin A (i.e. retinol). Benefi cial effects of retinoids 
have been reported in promyelocytic leukaemia and several types of carcinoma (191-
193). In vitro studies have reported that retinoids have benefi cial effects in DTC 
(194-197) including increased NIS mRNA expression and iodide uptake in some 
thyroid cancer cell lines (194). Interestingly, the promoter of the NIS gene has a 
retinoic acid response element (198). A limited number of human studies have been 
performed on the effects of retinoids on I-131 uptake with mixed results (199-203), 
all using the RAR agonist 13-cis retinoic acid. However, recent studies indicated 
a differential expression of both RAR and the retinoid receptor RXR in thyroid 
carcinoma cell-lines and tissues (204;205), which corresponded to the responsiveness 
to ligands for these receptors. The importance of RXR expression with respect to 
responsiveness to retinoid treatment was demonstrated in the latter study (205). We, 
therefore, decided to perform a prospective controlled clinical trial to investigate 
the effi cacy of the novel ligand Bexarotene (Targretin, Ligand Pharmaceuticals, 
San Diego), in 12 patients with metastases of DTC and decreased or absent I-131 
uptake. Bexarotene is an RXR agonist, which also induces RAR by transcriptional 
activation. The antineoplastic potential has been demonstrated in cutaneous T-cell 
lymphoma, but also in other malignant tumors (206-208). This study is described in 
Chapters 6 and 7.
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7.2 Strategies aimed at non-thyroid specifi c targets
Over the last decade, exciting developments have taken place in the identifi cation 
and molecular dissection of novel pathways involved in cancer. The avalanche of 
new approaches has lead to a considerable number of promising compounds. One 
of the disadvantages of DTC is that this low prevalent tumor is usually not included 
in initial clinical trials with these therapies. However, successful strategies that have 
survived these initial trials may well become available for thyroid carcinoma. 
7.2.1 Conventional Chemotherapy
Although differentiated thyroid carcinoma is a low prevalent malignancy, many 
chemotherapeutic protocols that have been developed over the last decades for more 
common malignancies have been tried in progressive thyroid carcinoma. Overall, 
these approaches have been disappointing. Of the classical chemotherapeutic agents, 
adriamycin, alone or combined with cisplatin and bleomycin may induce temporary 
remissions or stationary disease in about 30-50% of the patients (164;209;20;21). 
The same has been reported for paclitaxel (210). Most remissions however, last 
only a few months and at the cost of a considerable reduction in quality of life, thus 
leading to the recommendation that there is no place in principle for chemotherapy 
(2;127).
7.2.2 Neovascularization
Molecular pathways involved in neovascularization have been demonstrated in 
DTC (211). The cascade of approaches to target tumor-induced neovascularization 
has led to a number of promising compounds that are now being tested in clinical 
trials in prevalent tumors. Reports have been published on benefi cial effects of anti-
VEGF antibodies in thyroid carcinoma cell-lines (212) and endostatin in animal 
experiments (213). A recently published clinical trial, including DTC patients was 
also successful (214).
7.2.3 Tyrosine kinase inhibitors
Another intriguing development is the advent of tyrosine kinase inhibitors. The 
development of imatinib mesylate (Gleevec) is prototypical for the innovative design 
of modern drugs with the molecular pathogenic defect as a starting point. Following 
imatinib, other small molecules have been developed, aimed at other tyrosine kinase 
activated pathways such as the epithelial growth factor receptor (EGFR) activated 
pathway (13;215). Activation of tyrosine kinase pathways is relevant for thyroid 
carcinoma. Several studies have been published reporting successful treatment with 
the tyrosine kinase inhibitors aimed at RET, VEGF or the EGFR (216-218).
7.2.4 PPAR γ  agonists
An interesting new class of drugs is agonists of PPARγ. These drugs have been 







of pre-adipocytes into adipocytes, thereby increasing the fatty-acid storing capacity 
of adipose tissue. The involvement of PPARγ in differentiation processes extents 
beyond the area of adipose tissue. Indeed, altered expression of PPARγ and in 
vitro benefi cial effects of PPARγ agonists have been described in a number of 
malignancies. In DTC, these compounds infl uence differentiation (219) induced 
apoptosis in thyroid tumors and prevented their growth in nude mice (220). In a 
recently published clinical study, rosiglitazone induced RaI uptake in DTC (219).
7.2.5 Radionuclide therapy
The expression of somatostatin receptors by DTC makes these tumors candidates 
for SRS based therapy. Recent studies have reported moderate effects of indium 
labeled octreotide (221) and promising effects of lutetium octreotate (222).
8. Scope of the present thesis
In the present thesis, questions regarding the diagnosis, follow-up and therapy of 
DTC will be addressed. These questions arise from the imperfections of current 
practice in DTC in which the lack of a centralized approach together with the low 
incidence and good prognosis have until recently prevented the introduction of 
optimalized diagnostic, therapeutic and follow-up protocols. 
In Chapter 2 we describe a study aimed at the improvement of the microscopic 
distinction between follicular thyroid lesions using antibodies against Galectin-3 
(Gal-3), HBME-1, cytokeratin (CK)-19, CITED-1, Fibronectin (FN)-1, PPARγ and 
cytoplasmic NIS (cNIS). We therefore studied 156 thyroid tissues, using Receiver 
Operator Curve (ROC) analysis and the use of hierarchical cluster analysis.
In Chapter 3 we describe an investigation aimed at the optimalization of serum 
Tg measurements in the follow up of DTC by defi ning institutional cut-off levels 
in 366 consecutive patients with DTC, who had all been treated according to the 
same protocol for initial therapy and follow-up.  In addition, the prognostic values 
of serum Tg for cure and death, measured at fi xed time points after initial therapy 
were studied as well. 
In Chapter 4 we investigate the effects of triiodothyronin (T3) on iodine uptake 
and expression of the sodium iodide symporter (NIS) in the rat thyroid cell line 
FRTL-5. This study was conducted, because some reports suggest that RaI uptake 
after rhTSH is inferior to thyroid hormone withdrawal.  
In Chapter 5 we evaluate the additional value of lithium therapy on the clinical 
outcome of RaI in 12 patients with insuffi cient effects of RaI. In addition, we studied 
the potential mechanism of he supposed benefi cial effect of lithium salts on the 
uptake of RaI in the benign rat thyroid cell line FRTL-5, in the polarized non-thyroid 
MDCK cell-line stably transfected with hNIS to study lithium in a non-thyroid 
background and the human follicular thyroid carcinoma cell line FTC133-hNIS to 
study lithium effects in a background of DTC.
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In Chapter 6 we describe the results of an open prospective intervention study 
involving 12 patients with metastases of DTC, to evaluate the effects of 6-weeks 
treatment with the RXR agonist Bexarotene on the uptake of RaI.
In Chapter 7 we describe the results of subsequent high dose RaI therapy in the 
patients in whom the diagnostic study with Bexarotene revealed increased RaI 
uptake. Eight patients received 7400 MBq RaI. The results of RaI were evaluated 6 
months later, using CT scans and Tg measurements as outcome parameters.
Finally, in Chapter 8 the results of the present thesis are summarized and put into 
perspective, which is also translated into Dutch in Chapter 9.
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Background: The microscopic distinction between benign and malignant thyroid 
lesions is often diffi cult because in particular follicular lesions share many 
histological features. 
Aim: This study was performed to evaluate the diagnostic value of Galectin-3 
(Gal-3), HBME-1, cytokeratin (CK)-19, CITED-1, Fibronectin (FN)-1, PPAR-
gamma (PPARγ) and cytoplasmic NIS (cNIS) staining in a large panel of thyroid 
neoplasms. Our study differed from earlier ones with regard to the identifi cation 
of optimal semi-quantitative cut-off levels using Receiver Operator Curve (ROC) 
analysis and the use of hierarchical cluster analysis.
Methods: We used tissue arrays consisting of normal thyroid tissue (64), Graves 
disease (10), multinodular goiter (MNG, 14), follicular adenoma (FA, 12), papillary 
thyroid carcinoma (PTC, 53), follicular thyroid carcinoma (FTC, 13) and follicular 
variant of PTC (FVPTC, 11). Antibody staining was scored semi-quantitatively 
and differential expression was analysed in 2x2 tables and with hierarchical cluster 
analysis.
Results:  In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, 
HBME-1 and cNIS in malignant thyroid lesions. Gal-3, FN-1and cNIS had the 
highest accuracy in the differential diagnosis of follicular lesions. A panel of Gal-3, 
FN-1 and cNIS, identifi ed by  hierarchical cluster analysis had a 98% accuracy to 
differentiate between FA and malignant thyroid lesions. HBME-1 was found to be 
useful in the differentiation between FA and FVPTC (accuracy 88%). 
Conclusion: A combination of antibodies increases the diagnostic value in the 
differential diagnosis of thyroid neoplasms. The combination of FN-1, Gal-3 
and cNIS had the best accuracy (98%) whereas HBME-1 may be useful in the 
differentiation of FVPTC from FA.







Although thyroid nodules are common, few are malignant and require surgical 
treatment. In particular, the microscopic distinction between follicular adenoma 
(FA), follicular thyroid carcinoma (FTC) and follicular variant papillary thyroid 
carcinoma (FVPTC)) is diffi cult because these follicular lesions share overlapping 
histological features. This is underscored by substantial inter-observer variability in 
the pathological and cytological assessment of thyroid nodules (1;2). As a result, up 
to 85% of patients with suspicious cytology who subsequently undergo surgery have 
benign lesions (3). Therefore, the identifi cation of markers to distinguish benign 
from malignant tumours is important to avoid unnecessary surgery.  In recent years, 
several immunohistochemical markers have been studied to improve the differential 
diagnosis of thyroid lesions. 
The galectins are carbohydrate binding proteins involved in cell adhesion, cell 
growth and cell death. Galectin-3 (Gal-3) has been considered a marker with a high 
diagnostic potential to identify FTC (4-8), but in recent publications Gal-3 staining 
was also reported in benign lesions (9;10). HBME-1 (Hector Battifora mesothelial), 
is a monoclonal antibody developed against an unknown epitope of the microvillous 
surface of mesothelial cells and has been reported to be useful in the diagnosis 
of malignant thyroid tumours (11-15). Cytokeratins are intermediate fi lament 
proteins that are specifi c for epithelial cells.  CK-19 has been found to be strongly 
and diffusely expressed in PTC, whereas it is heterogeneously expressed in FTC 
and absent or focally expressed in FA. However, CK-19 expression has also been 
reported in normal thyroid epithelium, Hashimoto's thyroiditis, and benign thyroid 
tumors (16-21).
Recent studies based on cDNA expression arrays have identifi ed immunohistochemical 
markers for the differentiation between thyroid neoplasms. One study confi rmed 
the differential expression of Gal-3 and also identifi ed the extracellular matrix 
component Fibronectin-1 (FN-1) as a specifi c marker for PTC (22). In another 
study, Gal-3, FN-1 and the nuclear protein CITED-1 (CBP/p300-Interacting 
Transactivators with glutamic acid [E] and aspartic acid [D]-rich C-terminal domain) 
were found to be overexpressed in PTC (23).  A combined approach using  a panel 
of HBME-1, Gal-3 and CK-19 was followed by Casey et al (18), de Matos et al (19) 
and Prasad et al (24). In the study of de Matos et al, this combination had limited 
value. In contrast, in the study of Prasad et al (24) this panel had a high sensitivity 
and specifi city for carcinomas. 
In most of the before mentioned studies, fi xed cut-off levels for positive staining 
are used. Therefore, we decided to evaluate the diagnostic value of Gal-3, HBME-
1, CK-19, CITED-1, FN-1, the sodium iodide symporter (NIS) and peroxisome 
proliferator activated receptor gamma (PPARγ) in a large panel of thyroid 
neoplasms. We calculated cut-off levels for positive staining for each antibody using 
34
receiver operator curve (ROC) analyses. We not only analyzed the diagnostic value 
of each individual antibody, but also the diagnostic accuracy of panels identifi ed 
by hierarchical cluster analysis. We decided to include NIS and PPARγ because 
intracellular overexpression of NIS has been reported in a considerable percentage of 
malignant thyroid tumors (25). Apart from the pathophysiological implications, this 
expression pattern, if confi rmed, may be helpful in the distinction between benign 
and malignant lesions. In the pathogenesis of thyroid tumors, decreased expression 
of PPAR-γ has been reported (26-28). Apart from the pathogenetic signifi cance, 
PPAR γ may therefore also be used as a diagnostic marker.
Material and methods
Patients 
One hundred and seventy seven histological samples from surgically removed 
thyroid lesions, representing 7 different histological thyroid disorders and adjacent 
normal thyroid tissue were obtained from the pathological archive of the Leiden 
University Medical Center, the Netherlands. We selected normal thyroid tissue (64), 
Graves disease (10), MNG (14), FA (12), PTC (53), FTC (13, minimally invasive 5) 
and FVPTC (11). 
Tissue microarrays
Ten percent formalin-fi xed, paraffi n-embedded blocks routinely prepared from 
surgical specimens of thyroid tumours were selected for this study. Representative 
areas containing tumor or adjacent normal tissues were identifi ed by a pathologist 
(HM). Triplicate tissue cores with a diameter of 0.6 mm were taken from each 
specimen (Beecher Instruments, Silver Springs, MD, USA) and arrayed on a recipient 
paraffi n block, using standard procedures (29). 
Immunohistochemistry 
Four µm consecutive tissue sections were cut from each arrayed paraffi n block 
and prepared on pathological slides. The sections were deparaffi nised in xylene 
followed by 0.3% hydrogen peroxide methanol at room temperature for 20 minutes 
for blocking endogenous peroxidase. After rehydration, except for Gal-3, antigen 
retrieval treatment was done for CK-19, HBME-1, FN-1, CITED-1, NIS and 
PPAR-γ immunostaining by microwave treatment in 0.01 M citrate buffer at pH 6.0. 
After 2 hours cooling down, endogenous avidin activity blocking was performed for 
NIS immunostaining by incubation with egg-white for 5 minutes followed by biotin 
for 15 minutes. The sections were incubated with primary antibodies (specifi ed in 
Table 1) in PBS with 1% bovine serum albumin overnight at room temperature. The 
negative controls were stained with the primary antibody omitted. Next, sections 













































































































































































































































































































































































































































were incubated for 30 minutes with either the biotinylated rabbit-anti-mouse 
conjugate (Dako, Glostrup, Denmark, 1:200) or swine-anti-rabbit (1:400), followed 
by incubation for 30 minutes with the streptavidin-biotin-peroxidase conjugate 
(Dako, Glostrup, Denmark 1:100). This step was by a 10-minute incubation with 
3,3’-diaminobenzidinetetrachloride substrate in a buffered 0.05 M Tris/HCl (pH 7.6) 
solution containing 0.002% hydrogen peroxide. The sections were counterstained 
with haematoxylin. 
Scoring
A semi-quantitative assessment of immunohistochemical scoring was performed 
according to both the intensity of staining and the percentage of positive cells. 
The criteria are summarized in Table 2. Score results for triplicate samples were 
summarized in one total score. The resulting score ranged from 1 – 6. 
Table 2. Immunohistochemistry staining score levels according to proportion of positive 
cells and staining intensity
Cells with positive staining 
(%)
0 10 30 50 100
Intensity Score
Faint 0 1 2 3 4
Moderate 0 2 3 4 5
Intense 0 3 4 5 6
Statistical analyses
Statistical analyses were performed using SPSS 12.0. Staining scores were summarized 
and expressed as median and ranges and proportion of samples with scores above 
the cut-off level. Analyses of signifi cant differences in staining scores were analyzed 
on a 2x2 base using the Kruskall-Wallis test. Optimal cut-off values for each antibody 
were identifi ed using Receiver Operator Curve (ROC) analysis for each individual 
marker. Diagnostic validity was expressed using Bayesian statistics as sensitivity, 
specifi city and accuracy. 
In addition to individual protein markers, analysis of the diagnostic accuracy of 
panels of antibodies was performed using hierarchal clustering analysis of tissue 
microarray data using Cluster and TreeView (Cluster and TreeView 2.11, Eisen Lab, 
University of California at Berkely, California). A p value of <0.05 was considered 
signifi cant.







Protein expression in thyroid lesions
Because a distinct intracellular distribution was observed for some antibodies, their 
staining scores were categorized according to these patterns: NIS staining was 
differentially categorized as membranous (mNIS) or cytoplasmic (cNIS). Accordingly, 
FN-1 was also categorized as mFN-1 and cFN-1.  Gal-3 was categorized as cGal-3 
or nuclear Gal-3 (nGal-3). 
The median values, ranges of expression of the proteins and the proportion of 
samples with staining scores above the cut-off levels are given in Table 2. Statistically 
signifi cant differences in protein expression between all categories of thyroid tissues 
were investigated in  2x2 tables, the results of which are given in Table 3. Examples 
of staining patterns are given in Figure 1 (see color image at page 150).
In general, malignant tumors showed overexpression of Gal-3 (predominantly PTC), 
cFN-1 (all carcinomas), CK-19 (mostly PTC), HBME-1 (mostly PTC and FTC) and 
cNIS (mostly PTC and FTC). In contrast, expression of PPAR-γ and membranous 
NIS (mNIS) were low or absent in thyroid carcinomas. 
In Graves disease, expression of mNIS was abundant as expected. PPAR-γ was also 
higher in adjacent normal tissues and benign thyroid lesions. 
In general the most prominent differences were observed in PTC in comparison with 
benign lesions and adjacent normal thyroid tissues: PTC showed high expression 
levels of cFN-1 (median level 5, 96% of tumors), cGal-3 (median level 5, 92% of 
tumors), cNIS (median level 4, 83% of tumors), HBME-1 (median level 3, 74% of 
tumors), CITED-1 (median level 5, 98% of tumors) and CK-19 (median level 3, 
78% of tumors) and absence of PPARγ and mNIS. 
CK-19, Gal-3 and HBME-1 were differentially expressed between PTC and FTC.  
FN-1, CK-19, Gal-3, HBME-1 and cNIS were differentially expressed between PTC 
and FVPTC (Table 4).
FTC had high expression levels of cFN-1 (median level 5, 86% of tumors), CITED-
1 (median level 5, 86% of tumors) and cNIS (median level 4, 67% of tumors). In 
the comparison between FTC and FA, proteins differentially expressed were cFN-1 
and cNIS (Table 4).  No signifi cant differences were observed in staining patterns 
between minimally invasive FTC and widely invasive FTC. In the comparison 
between FTC and FVPTC, the only differentially expressed protein was HBME-1 
(Table 4). 
FVPTC had a high expression of FN-1 (median level 4, 89% of tumors), CITED-1 


























   










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Table 3). FVPTC differed from FA for cFN-1, PPAR-γ, HBME-1 and CK-19, 
whereas protein expression was different for FN-1, Gal-3, cNIS, HBME-1 and CK-
19 in the comparison between FVPTC and PTC (Table 4). 
Cytoplasmic NIS was mainly observed in PTC (median level 4, 83% of tumors) and 
FTC (median level 4, 67% of tumors) (Table 3). Remarkably, differences in CITED-
1 were not prominent between benign thyroid tissues (median levels 3-4 in normal 
or benign lesions, with 51-89% of tissues positive) and malignant lesions (86-100% 
positive cases) in 2x2 comparisons.  
Protein expression in follicular lesions
Because the clinical distinction between follicular lesions proves to be the most 
diffi cult, we focused our analyses on the diagnostic value of proteins found to be 
differentially expressed in follicular lesions (Tables 4 and 5). In 2x2 comparisons 
of the different follicular lesions, we fi rst identifi ed the optimal cut-off levels using 
ROC-analyses, aiming at the highest combination of sensitivity and specifi city 
for each comparison. The cut-off values are given in Table 5. We subsequently 
calculated the percentages of correct diagnoses of both lesions in a 2x2 comparison 
as well as the accuracy, using these cut-off levels. The accuracy (total percentage of 
correct diagnoses) is the best indicator of the diagnostic or discriminating value of 
the antibody. 
The highest accuracies were found in the discrimination between PTC and FVPTC, 
with the highest accuracy for cGal-3 (88%), cFN-1 (81%), CK-19 (78%) and cNIS 
(77%). In the comparison between FA and FTC, moderate accuracies were found 
for FN-1 (accuracy 71%) and cNIS (accuracy 65%). The distinction between FA and 
FVPTC had a high accuracy for HBME-1 (89%), PPAR-γ (74%) and FN-1 (74%). 
HBME-1 also gave a good discrimination between FVPTC and FTC (accuracy 
84%). 
Clustered expression pattern of Gal-3, FN-1 and cNIS distinguish benign thyroid tumors 
from thyroid carcinomas
To identify optimal combinations of antibodies, we performed an unsupervised 
hierarchical cluster analysis including all tissues and all antibodies. 
The results of this analysis are given in Figure 2. We found that 3 antibodies, 
cGal-3, cNIS and cFN-1 had the highest discriminating power to cluster benign 
and malignant thyroid lesions: all malignant lesions had positive staining for at least 
2 of the 3 antibodies cGal-3, cNIS and cFN-1 (Cluster 1), whereas lesions with 
absent staining for all 3 antibodies were all benign (Cluster 5). All malignancies were 
combined because the subgroups were too small to allow separate cluster analysis. 
Initially, there was only one case of FA in cluster 1. Strikingly, after rechecking whole 
section histological H&E slides, this adenoma was identifi ed harbouring classic focal 
papillary carcinoma and re-categorized. 






Table 4. Proteins differently expressed between thyroid lesions
Diagnosis Normal MNG Graves FA PTC FTC






















































































































MNG: Multinodular Goiter; FA: Follicular Adenoma; PTC: Papillary Thyroid Carcinoma;
FTC: Follicular Thyroid Carcinoma; FVPTC: Follicular Variant PTC
Gal-3: Galectin 3 (c=intracellular, n=nuclear); NIS: sodium iodide symporter (m=membranous); 
FN-1: Fibronectin1; CK-19: cytokeratin 19











































































































































































































































































































































































































































































































































































































































































































































































Figure 2. Hierarchical cluster analyses using 7 antibodies in all thyroid tissues. cNIS, FN-1 
and Gal-3 were identifi ed as the best predictors of benign or malignant thyroid lesions. 
Presence of 2 of these antibodies (Cluster 1) gave an almost 100% clustering of malignant 
thyroid lesions, whereas absence of these proteins (Cluster 5) was suggestive of benign 
thyroid lesions. 






We therefore used the combined staining patterns of these antibodies to discriminate 
between benign and malignant thyroid lesions and FA and malignant thyroid lesions 
(Table 6). We found that positive staining for 2 of the 3 antibodies cFN-1, cGal-3 
and cNIS had a high sensitivity (97-98%) and high specifi city for thyroid carcinoma 
(100%).  
Discussion
The present study was performed to evaluate the diagnostic value of Gal-3, HBME-
1, CK-19, CITED-1, FN-1, PPAR-γ and NIS staining in a large panel of thyroid 
neoplasms, focussing on the differential diagnosis of follicular thyroid lesions. 
Our study differed from earlier ones with regard to the identifi cation of optimal 
semi-quantitative cut-off levels using ROC analysis and the use of hierarchical 
cluster analysis. 
We initially analyzed differentially expressed antibodies comparing all thyroid tissues. 
In general, we found overexpression of FN-1, CITED-1, Gal-3, CK-19, HBME-1 
and cNIS in thyroid carcinomas, whereas membranous NIS and PPARγ showed 
decreased expression in carcinomas in comparison with benign thyroid tissues. 
The most challenging differential diagnosis is between FA and thyroid carcinoma. 
We found all proteins to be differentially expressed between FA and PTC. The 
differences between FA on the one hand and FTC and FVPTC on the other hand 
were less prominent, but we found a differential expression of PPARγ, HBME-1, 
Gal-3, cNIS and FN-1. We could not confi rm the differential expression of CITED-
1 and CK-19 between FA, FVPTC and FTC as reported by Prasad et al (24). 
CK-19 is the most commonly used cytokeratin in investigating thyroid lesions. We 
and others found that CK-19 is relatively specifi c for PTC (16;18;19). However, in 
our analyses CK-19 has limited use in the differential diagnosis of follicular thyroid 
lesions. This has also been reported by Sahoo et al (17). In the study of Prasad et al 
(24), CK-19 had a sensitivity of 64% for thyroid carcinoma. 
Several recent studies have reported that HBME-1 expression is a useful diagnostic 
marker for PTC (23;24). We found HBME-1 expression predominantly in PTC and 
FVPTC and in a limited number of FA with relatively high accuracy.  Therefore, 
HBME-1 may indeed be useful in the differential diagnosis of FVPTC and FA 
(accuracy 88%).
We found CITED-1 expression both in benign and malignant thyroid lesions. 
Although the highest proportion of positive samples was found in PTC (as 
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previously reported (23;24)) and in FVPTC, the considerable proportion of positive 
samples in benign lesions makes CITED-1 in our opinion a less attractive marker 
for differential diagnosis. 
Gal-3 was predominantly expressed in PTC (92%) and to a lesser extent in FTC and 
FVPTC. Other investigators have used Gal-3 in differentiating FTC from FA in 
fi ne-needle aspirates (7), however Gal-3 was also reported in benign thyroid lesions 
(10). We found a reasonable accuracy (88%) in the differential diagnosis between 
FA and FVPTC for Gal-3. We also found Gal-3 to be a useful marker in a panel of 
antibodies.
FN-1 was fi rst reported to be overexpressed in PTC (22;23). In a subsequent study, 
FN-1 appeared to be a valuable marker for the differentiation of FA and thyroid 
carcinomas (24). The percentage of FA (40%) positive for FN-1 in our study was 
higher than reported by Prasad et al (24). We found accuracies of 74% for the 
differentiation between FA and FVPTC and 71% for the differentiation between 
FA and FTC. Cluster analysis also identifi ed FN-1 as a useful marker.
Although some studies report decreased NIS protein expression in thyroid carcinoma 
(30), Dohan et al reported cytoplasmic overexpression of NIS in a large series of 
human thyroid cancers (25). We confi rmed cytoplasmic NIS overexpression in PTC 
(83% of tissues) and FTC (67% of tissues). As we used the same antibody as Dohan 
et al. it may well be that the differences with other studies are related to differences 
in antibody specifi city. Nevertheless, the differential expression of cNIS between 
subtypes of thyroid neoplasms makes it a candidate for differentiating between these 
lesions. The accuracies of 68% (FA vs. FTC) and 77% (PTC vs. FVPTC) however 
are moderate. Cytoplasmic NIS was also identifi ed by cluster analysis as a potential 
useful marker in the discrimination between FA and malignant carcinomas.  
PPARγ has found to be downregulated in experimental models of thyroid carcinoma 
(26-28). The importance of the downregulation of PPARγ is also illustrated in the 
PPARγ/PAX8 rearrangement (31) which was initially observed in a series of FTC. 
Although the PPARγ/PAX8 rearrangement was therefore considered a specifi c 
marker for FTC, later studies also reported the rearrangement in benign thyroid 
lesions (32;33). We found decreased PPARγ nuclear staining in malignant tumors, 
whereas in non-malignant lesions, the percentage of positive cells varied from 50-
100%. Although our results confi rm the decreased expression of PPARγ in thyroid 
carcinoma, the diagnostic accuracies for the differentiation between follicular lesions 
were limited.     
As no marker in itself has a superior diagnostic value, a combination of markers may 
be more accurate than any single marker. We performed a cluster analysis including 
all tissues and antibodies. To our knowledge, this has not been done before for im-
munohistochemistry in thyroid lesions. In this study, hierarchical clustering analysis 
on all valid samples confi rmed that thyroid carcinomas, FA and benign lesions could 






be categorized with high sensitivity, specifi city and accuracy.  Our study shows that a 
diagnostic immunohistochemical panel comprising Gal-3 and FN-1 was 97% sensi-
tive for all thyroid carcinomas, whereas specifi city was 100%. The diagnostic values 
of CK-19, CITED-1 and HBME-1 in our series were not suffi cient to be included in 
the panel, which is in line with the results of de Matos et al (19). However, HBME-1 
was found to be a useful marker for the differentiation between FA and FVPTC. 
Because the number of FVPTC was small, hierarchical clustering did not allow a 
separate analysis of this group of tumors. Prasad et al. also found a limited accuracy 
for HBME-1, CK-19 and CITED-1 (24).
In conclusion, Gal-3, FN-1 and cNIS is a useful diagnostic panel in the differential 
diagnosis of thyroid lesions. The absence of Gal-3, FN-1 and cNIS is highly 
suggestive for a benign lesion. HBME-1 may be useful in the specifi c differentiation 
of FVPTC from FA. 
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Abstract
Objective: Most studies on the diagnostic value of serum thyroglobulin (Tg) 
concentrations in differentiated thyroid carcinoma (DTC) use fi xed cut-off levels in 
heterogeneous groups of patients with respect to initial therapy and do not provide 
prognostic data. The objective of this study was to investigate the prognostic values 
of serum Tg for disease free remission and death, measured at fi xed time points after 
initial therapy using receiver operator curve (ROC) analyses.
Design:  Single-centre observational study with 366 consecutive patients with DTC, 
who had all been treated according to the same protocol for initial therapy and 
follow-up.  
Methods: Tg concentrations were measured at fi ve fi xed time points after initial surgery. 
Tg cut-off values with highest accuracy were calculated with ROC analyses. 
Results:  During follow-up of 8.3±4.6 years, 84% of the patients were cured.  
Pre-ablative Tg levels were an independent prognostic indicator for disease free 
remission (Tg cut off value 27.5 ug/L, positive predictive value 98%). Highest 
diagnostic accuracies of serum Tg for tumour presence were found during TSH 
stimulated Tg measurements, 6 months after initial therapy (Tg cut-off value 10 
ug/L: sensitivity 100%, specifi city 93%). 
DTC related mortality was 14%. TSH stimulated Tg levels before ablation and 6 
months after initial therapy were independent prognostic indicators for death. 
Conclusion:  Optimal institutional Tg cut-off levels for diagnosis and prognosis should 
be defi ned using ROC analyses for each condition and time point. Tg measurements 
6 months after initial therapy during TSH stimulation had an excellent diagnostic 
value. Tg levels are independent prognostic indicators for disease free remission 
and death. Using this strategy, high-risk patient groups can be selected based on Tg 
levels, in addition to conventionally used prognostic indicators.







Differentiated thyroid carcinoma (DTC) has an excellent prognosis with 10-year 
survival rates of 85-93 % (1). The purpose of follow-up protocols in DTC is the 
early detection of tumour recurrence or metastatic disease in order to optimize 
additional treatment. Most patients during follow up have been cured defi nitively, 
and, as a consequence, have a low pre-test probability for recurrent disease. 
Therefore, the sensitivity of the diagnostic test must be adequate to detect the few 
patients with evident thyroid carcinoma, whereas specifi city must also be high to 
avoid unnecessary treatments in patients without recurrent disease. In addition, the 
burden of diagnostic tests for the patient should be kept at a minimum. 
Serum thyroglobulin (Tg) measurements are the cornerstone in the follow-up 
in DTC. Numerous studies have been performed on the diagnostic value of Tg 
measurements. We recently published a structured meta-analysis on the diagnostic 
value of Tg including 46 articles (2).  The interpretation of many studies on Tg 
performed so far is diffi cult, because in most studies i) Heterogeneous patient groups 
with respect to initial therapy are included, ii) The time points of Tg measurements 
after diagnosis are not clearly indicated, and iii) Fixed Tg cut-off levels are used, 
without receiver operator curve (ROC) analyses. The application of ROC data 
is essential, as a chosen cut-off level is a subjective choice based on the balance 
between a desired percentage of missed recurrences versus unnecessary therapies. 
Therefore, in a recent European consensus paper, it was recommended to defi ne 
institutional Tg cut-off levels (3). Only a few studies have been published on the 
interpretation of Tg levels during follow up of DTC using ROC analyses. However, 
in those studies, heterogeneous patient groups were included and the time-points 
of Tg measurements were not clearly indicated (4;5;6).  In addition, most studies 
provide data on the diagnostic value of Tg for tumour presence, but do not give data 
on the prognostic signifi cance for disease free remission or death. One large study (7) 
studied the prognostic signifi cance of 1-month post-surgical Tg levels and found a 
signifi cant prognostic cut-off level of 10 ug/L. The few studies that were published 
on the prognostic signifi cance of Tg measurements used fi xed cut-off levels, 
contained selected subgroups of patients and included either Tg measurements at 
one time point or at undefi ned time points (8;9;10;11;12).
We therefore performed a study on the diagnostic and prognostic value of Tg in 
a homogeneous group of DTC patients with respect to initial therapy, using Tg 
measurements at 5 defi ned time-points after diagnosis, in combination with ROC 
analyses. In addition, we studied the diagnostic and prognostic value of Tg antibodies 
for tumour presence or death.
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Patients and methods
Three-hundred-and-sixty-six consecutive patients were included in the study. These 
patients had received initial therapy for DTC between January 1986 and January 
2000. All follow up data were collected until January 1, 2003. January 1986 was 
chosen as a starting date, because from that date forward, all relevant patient data 
were registered in a computerized database. Initial surgery and radioiodine ablation 
therapy were performed at the Leiden University Medical Centre or at one of the 
connected general hospitals. All hospitals are affi liated in the Regional Comprehensive 
Cancer Centre, using the same standardized protocol for the treatment and follow-
up of DTC (Table 1). 
Table 1. Patient characteristics
Parameter N Cured Patients N (%)
Patients Relapse 
after Cure N  (%)
Deaths 
N (%)
Total 366 305 (84) 46 (13) 52 (14)
Gender 
(Male/ Female) 91 / 275 72 (80) /233 (85) 13 (14)/33 (13) 13 / 39 (14 / 14 )
Stages
T1 22 21 (96) 1 (5) 0 (0)
T2 188 176 (94) 17 (9) 10 (5)
T3 56 51 (91) 9 (16) 8 (14)
T4 96 53 (55) * # 17 (18) 32 (33) * #
T unknown 4 0 (0) 0 (0) 2 (50)
N1 107 76 (71) * 15 (14) 22 (21) *
M1 52 19 (36) * # 6 (11) 27 (54) * #
Histology
Papillary 203 173 (86) 28 (14) 25 (12)
Follicular 72 58 (81) * 11 (15) 17 (24) *
Follicular variant 
papillary carcinoma 68 56 (82) 5 (7) 6 (9)












* Signifi cant at univariate analysis
# Signifi cant at multivariate analysis (see Table 4)
All patients were treated by near-total thyroidectomy, followed by routine radioiodine 
ablative therapy with 2800 MBq I-131. 






Follow-up was performed according to a standard protocol. Serum Tg levels were 
measured at the following time points: 1) After initial surgery during thyroxin 
withdrawal just before radioiodine ablation, 2) Six months after initial surgical therapy 
during thyroxin therapy, 3) Six months after initial surgical therapy after thyroxin 
withdrawal (“off”) and 4) Yearly during thyroxin therapy. Although additional TSH 
stimulated Tg measurements were performed in selected subgroups of patients at 
other time points after initial therapy, we did not include those data as these tests 
were not uniformly done in all patients, and calculations of diagnostic values would 
thus be biased. Thyroxin therapy was aimed to suppress TSH levels (below 0.1 
mU/L). Six months after initial therapy a diagnostic 185 MBq I-131 scintigraphy 
was performed after thyroxin withdrawal. 
Tumour presence during follow-up was defi ned as histologically or radiologically 
(X-ray, CT-scan, MRI-scan, FDG-PET scan or I-131 scintigraphy) within a 1-year 
interval before or after the time of Tg measurements. Although we realize that Tg 
is considered the best parameter for tumour presence, Tg was not used as a golden 
standard for tumour presence, as the diagnostic value of Tg was the subject of this 
study.
Disease free remission was defi ned as the absence of thyroid carcinoma for a 
minimum of 3 years according to the above mentioned parameters. 
The following data were registered: age at diagnosis, sex, date of diagnosis, histology, 
TNM stage, date of cure, date of recurrence, tumour localization, death cause, Tg 
levels, TSH levels, Tg antibody levels and date of last follow up or death. TNM 
stage was registered according to the 5th edition (13). This was done because most 
patients were analysed before the latest edition of the TNM classifi cation. We used 
the following end-points of follow-up: date of death (82 patients), date of emigration 
(12 patients) and date of most recent contact (272 patients).
Death causes were analysed in all 82 patients who had died during follow-up. Death 
cause was investigated using medical records, death certifi cates, enquiries with other 
physicians involved in the treatment of each patient, enquiries in other hospitals, 
enquiries with general practitioners and autopsy fi ndings. Death causes were divided 
into thyroid cancer related death and other causes.
Analyses were performed in evaluable patients defi ned as patients in whom all of 4 
conditions were fulfi lled: Alive at the time-point of Tg measurement, documented 
serum Tg measurements, documented serum TgAb measurements and documented 
golden standard parameters for presence or absence of disease. If Tg-antibodies 
were present, the Tg measurement at this time was excluded from the calculations 
because of possible interference with the Tg assay. The numbers of these patients 










































































































































































































































































































































































































































































































































































































































































































Measurements of Tg and Tg-AB
Until January 1997 serum Tg was measured using an immunoradiometric assay 
(IRMA), the Dynotest TG (Brahms Diagnostica GmbH, Germany) with a sensitivity 
of 0.3 µg/L. From January 1997, the Dynotest TG-s (Brahms Diagnostica GmbH, 
Germany) was used, with a sensitivity of 0.05 μg/l. Inter-assay variability of 0.3 μg/l. 
The comparability of the 2 methods is excellent: R2: 0.99, slope 0.99, intercept 0.09 
(14). Serum Tg-antibodies were also measured at these specifi c time points by the 
Ab-HTGK-3 IRMA (DiaSorin Biomedics, Italy). 
Statistical analyses
Data are presented as mean ± SD. All statistical analyses were performed using 
SPSS for windows version 12.0 (SPSS Inc., Chicago, IL). Data are expressed as 
number of patients (percentages), as mean ± Standard Deviation (SD) or as median 
(range). Receiver operator curves (ROC) were used to fi nd the cut-off value with 
highest accuracy. Prognostic indicators for recurrence or death were calculated 
using univariate- and multivariate Cox-regression analyses: Indicators that were 
identifi ed as signifi cant for survival in univariate analysis were entered into a stepwise 
multivariate model. A p-value of < 0.05 was considered signifi cant.
Results
Characteristics of the patients are shown in Table 1. Mean age at time of surgery was 
48 ± 18 years. Mean follow-up was 8.3 ± 4.6 years. Signifi cant prognostic factors for 
disease free remission and death are given in Table 4. 
Diagnostic value of Tg
The diagnostic values of Tg measurements at the different time points are given in 
Table 2. 
The diagnostic value of Tg before ablation therapy was reasonable in our analysis, 
with a sensitivity of 87.9% and a specifi city of 90.3% at a cut-off value of 27.5 
ug/L. 
When a cut-off level of 2 ug/L was used, sensitivity increased to 93.9%, whereas 
specifi city dropped to 45% with a positive predictive value of only 23% instead of 
62%, with similar negative predictive value. 
The highest diagnostic value of Tg was found during TSH stimulated Tg 
measurements 6 months after initial therapy (see Figure 1). The Tg cut-off value 
with highest accuracy was 10.0 ug/L, with sensitivity and specifi city of 100.0 and 
56
93.1%, respectively. When the more commonly used cut-off value of 2 ug/L was 
used, sensitivity remained similar, but specifi city dropped to 82% with a positive 
predictive value of only 54%, instead of 73% (Figure 1). We analysed the course 
of 9 patients with Tg values > 10 ug/L, 6 months after initial therapy during TSH 
stimulation: in 3 patients, tumour was detected 2-5 years after initial therapy. In 4 
patients Tg became undetectable and they were cured.  Two patients had persistent 
measurable Tg, but no tumour was detectable up to 15 years after initial therapy.
Tg measurements on thyroxin, 2 and 5 years after initial therapy had lower 
sensitivities, but had comparable specifi cities and negative predictive values albeit at 
lower Tg cut-off values. 
                 













Tg = 10 ug/L 
                 
Figure 1. Receiver Operator Curve six months after initial therapy 
during stimulated TSH to obtain optimal cut-off levels of serum Tg 
measurements for the diagnosis of active tumour in patients with 
differentiated thyroid carcinoma.
Prognostic value of Tg
Disease free remission
The prognostic value of Tg for disease free remission is given in Tables 3 and 4. 
Interestingly, Tg before ablation had a high predictive value of 97.8% for disease 
free remission at a cut-off value of 27.5 ug/L. Tg appeared to be an independent 
prognostic marker for disease free remission (likelihood ratio for disease free 
remission 43.2 for Tg < 27.5 ug/L, p<0.001), irrespective of T4, M1 and age.






Thyroid Specifi c Death
The prognostic values for Tg measurements for DTC related death are given in 
Tables 3 and 4 and Figure 2. The negative predictive value was high for all time-
points of Tg measurements. 
Tg was an independent predictor for thyroid related death during TSH stimulation, 6 
months after initial therapy (hazard ratio for Tg > 10.0 ug/L 10.9, p=0.008, Table 4, 
Figure 2), 2 years after initial therapy (hazard ratio for Tg > 2.0 ug/L 12.9, p<0.001) 
and 5 years after initial therapy (hazard ratio for Tg > 2.0 ug/L 29.1, p=0.001).
Table 3. Prognostic Value of Serum Tg Measurements for Disease free remission and Thyroid 
Carcinoma Related Death. Patients with Tg antibodies were excluded
Outcome Tg μg/L 
Cut-Off
Sensitivity









remission 27.5 84.4 ± 2.6 88.9 ± 5.6 97.8 49.1





TSH Death 2.5 72.0 ± 9.0 85.7 ± 2.6 40.9 95.7
Stimulated





TSH Death 2.0 85.0 ± 8.0 85.7 ± 2.5 38.6 98.2
Suppressed
TSH Death 2.0 82.4 ± 9.2 92.8 ± 2.2 58.3 97.7
PPV= positive predictive value, NVP = negative predictive value
Tg antibodies
The percentage of patients with Tg antibodies dropped from 27% immediately 
after initial surgery to 12% 5 years after initial therapy (see Table 2). There were no 
signifi cant differences in tumour presence between patients with and without Tg 
antibodies: 15 – 23% in patients without Tg antibodies and 16 – 33% in patients with 
Tg antibodies. The presence of Tg antibodies did not have a signifi cant prognostic 
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Figure 2. Prognostic value of Tg measurements for Differentiated Thyroid Carcinoma related 
disease free remission and mortality. 
a. Disease free remission, Tg levels pre-ablation, four weeks after surgery; X-axis: years after initial 
therpy, Y-axis: Disease free remission
b. Survival according to TSH stimulated Tg, 6 months after initial therapy; X-axis: years after initial 
therapy, Y-axis: cumulative survival with death as endpoint.
Discussion
In the present study we investigated the diagnostic and prognostic value of serum Tg 
measurements for tumour presence, disease free remission and death in the follow-
up of DTC by ROC analysis in a homogeneous group of patients with respect to 
initial therapy. 
The study differed from earlier investigations with respect to the homogeneity of the 
patient group with respect to initial therapy, the fact that multiple Tg measurements 
were analysed at fi xed time points during follow-up and the use of ROC analyses.
We found an excellent diagnostic accuracy of serum Tg values during TSH 
stimulation 6 months after initial therapy (sensitivity 100%), with a higher Tg cut-off 
level (10.0 ug/L) than commonly reported (2;15;16;10;8). When we used the more 
commonly used cut-off value of 2 ug/L, the specifi city and positive predictive values 
dropped considerably (52% instead of 72%).  We also found that Tg cut-off levels 
are dependant on the time-point of follow-up, which is an important fi nding, as in 
most papers on Tg, the time after diagnosis is not considered.
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Tg levels are not only diagnostic indicators of tumour presence, but also predict 
disease free remission or death. We found that serum Tg levels before radioiodine 
ablation are an independent predictor for disease free remission, irrespective of the 
classical prognostic indicators. In our series a patient with Tg level pre-ablation of 
< 27.5 ug/L has an almost 98% chance to be defi nitely cured irrespective of the 
prognostic indicators stage T4, follicular histology, metastases and higher age.
TSH stimulated Tg measurements 6 months after initial therapy and at 2 and 5 years 
after initial therapy were independent predictors of thyroid carcinoma related death. 
Negative predictive values for DTC related death were high (95.3 – 98.2%) at all 5 
time points of follow up, albeit with different Tg cut-off values. 
In the discussion about the diagnostic value of Tg, specifi city is a controversial issue. 
It has been argued that the specifi city of Tg is per defi nition 100%. Although from 
a biological point of view it is undoubtedly correct that Tg is only synthesized by 
thyroid cells, in the clinical practice, the meaning of measurable Tg levels is not 
always clear, even more so with the advent of high sensitive Tg assays. A less than 
100% specifi city of Tg for thyroid carcinoma can be explained by the limitations 
of current imaging techniques to detect thyroid carcinoma. In this respect, it is 
advocated to administer a high dose of radioiodine to patients with elevated Tg 
levels, a policy that we agree with (17;18;19;20). However, we also observed that 
in only 3 of the 9 patients with TSH stimulated Tg levels > 10 ug/L and without 
detectable tumour, tumour became apparent during follow up, which is in line with 
the observation of Baudin et al (8). Therefore, in our opinion, a potential solution 
to circumvent the debate about specifi city of Tg is to consider Tg as a risk indicator. 
The independent prognostic value of serum Tg values for disease free remission 
and death are arguments to include Tg in the conventional panel of risk factors. 
A potential consequence could be to administer higher dosages of radioiodine for 
ablation in patients with Tg levels higher than the above mentioned thresholds. As 
such we do not advocate that patients with Tg levels below institutionally defi ned 
cut-off levels should not be followed up carefully, but we belief that the elimination 
of Tg should not be a goal in itself.   
Tg cut-off levels are not only infl uenced by clinical considerations, but also by 
analytical aspects. Analytical problems include the lack of universal standardisation 
of the Tg assays (21), intra-assay variability, “Hook” effects and the presence of Tg 
auto-antibodies(22;23). Another important point, not addressed in this study, is the 
observation that Tg rises may be more informative than absolute Tg levels  (24;8).
The percentage of patients with Tg antibodies (initially 27%) is in line with previous 
studies (25;23;26). The percentages of active tumour in patients with and without 
Tg antibodies were comparable, conforming the lack of diagnostic value of Tg 
antibodies.    






Because our study involved a large cohort of patients studied before the introduction 
of rhTSH, we did not include rhTSH stimulated Tg measurements in our series. 
However, recent reports indicate that the diagnostic accuracy is comparable (2;15;3). 
It has been suggested that Tg cut-off levels for rhTSH should be lower than for 
thyroid hormone withdrawal (27). However, no systematic analyses have been 
published comparing optimal Tg cut-off levels for both strategies. Furthermore, in a 
large study, similar Tg cut-off values were used for rhTSH and thyroxin withdrawal 
(16).
Because our analysis is based on retrospective data, we believe that the prognostic 
Tg cut-off values as found in our study should be interpreted with some caution, as 
they should be confi rmed in a prospective study. We believe however that the main 
message, that Tg cut-off values should not be adopted from the literature, that Tg 
cut-off levels are dependant on the time of follow-up and that Tg has a prognostic 
value is valid. 
In conclusion, our studies illustrate the importance of the defi nition of institutional 
Tg cut-off levels. We analysed the diagnostic value of Tg at specifi c time points 
and detected an excellent prognostic value 6 months after initial therapy during 
TSH stimulation. Our analyses allow the defi nition of groups of patients with an 
increased risk for residual disease or mortality, in addition to conventionally used 
prognostic indicators. Based on our analysis we recommend to subject every patient, 
who has undergone thyroid surgery and thyroid remnant ablation at least once to 
TSH stimulated Tg measurements. 
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Abstract
Background:  Thyrotropin (TSH) stimulated radioiodide scintigraphy and therapy 
are important in the clinical care of patients with differentiated thyroid carcinoma 
(DTC). The introduction of recombinant human TSH (rhTSH) is an attractive 
alternative for thyroid hormone withdrawal (THW). Some reports suggest however 
that radioiodide uptake after rhTSH is inferior to THW.  One of the explanations is 
that there is a direct effect of triiodothyronine (T3) on iodide uptake.
Aim: To study the effects of triiodothyronine (T3) on iodine uptake and expression 
of the sodium iodide symporter (NIS).
Methods:  Iodide uptake (both steady state and initial rate) were studied in the rat 
thyroid cell line FRTL-5. FRLT-5 cells were cultured in medium with stripped serum 
in the absence or presence of 1pM, 2nM or 50nM T3 and all in presence of 1mU/ml 
TSH for 72 hours. NIS and TSH receptor mRNA and NIS protein expression were 
studied by quantitative PCR and Western-Blot. 
Results:  T3 inhibited iodine uptake both at initial rate and during steady state in 
a concentration dependent manner at steady state. NIS and TSHR expression at 
mRNA level were both reduced. Western blot of NIS protein showed a signifi cant 
reduction of NIS protein after 2 nM. 
Conclusion: T3 reduces radioiodine uptake and NIS and TSHR expression in FRTL-5 
cells. We speculate that this is not caused by iodide being released from T3, as this 
amount is negligible, but that these are direct genetic effects, of which the mechanism 
needs further investigation. 







The concepts of therapy and diagnostic procedures during follow-up in differentiated 
thyroid carcinoma (DTC) are based on the responsiveness of thyroid carcinoma cells 
to thyrotropin (TSH)(1). TSH stimulated radioiodine uptake is important for both 
the ablation of thyroid hormone remnants during initial therapy and treatment of 
residual or metastatic DTC. In addition, TSH stimulated serum thyroglobulin (Tg) 
measurements have superior diagnostic value to detect recurrent DTC (2). 
High serum TSH levels can be realized by conventional thyroxin withdrawal or 
more recently by recombinant human TSH (rhTSH), which has advantages with 
respect to quality of life (3). rhTSH has initially been used for diagnostic radioiodine 
scintigraphy and Tg measurements (4-13). In addition, rhTSH has also been used for 
radioiodine therapy in active DTC (14-18) and for the ablation of thyroid remnants 
(19-21). 
The assumption for rhTSH treatment is that the pharmacodynamic properties of 
rhTSH and thyroxin withdrawal are comparable and that continuation of thyroxin 
therapy does not infl uence iodide uptake and Tg synthesis.  
It is generally acknowledged that Tg measurements during rhTSH have comparable 
accuracy as thyroxine withdrawal (2;7). Some authors, however, have observed a 
lower sensitivity of diagnostic radioiodine scintigraphies performed after rhTSH 
(22;23). The effi cacy of radioiodine therapy after rhTSH may be comparable with 
withdrawal, but no randomized studies have been performed to allow a direct 
comparison (14;24). Effi cacy of radioiodine ablation after rhTSH was comparable 
after thyroxin withdrawal in a recent randomized trial (21), although earlier studies 
with lower activities of radioiodine showed a lower effi cacy (25). One of the possible 
explanations for the supposedly decreased radioiodine uptake during rhTSH may 
be that triiodothyronin (T3) directly infl uences iodine uptake in the thyroid. We 
therefore studied the in vitro effects of T3 on iodide uptake. 
Materials and Methods
Cell culture and cell proliferation assay
The rat thyroid FRTL-5 cell-line derived from the ATCC (ATCC, Manassas USA) 
expresses endogenously NIS which is subjected to TSH regulation (26). FRTL-5 
cells were routinely cultured in Coon’s F-12 modifi cation medium (Sigma, Missouri 
USA) supplemented with 5% of stripped bovine calf serum, 1 mM non-essential 
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amino acids (Life Technologies, Inc.), 10 mM glutamine, 100 units/ml penicillin, 
100 µg/ml streptomycin, and a six-hormone mixture (6H) containing insulin 
(1.3 µM), hydrocortisone (1 µM), transferrin (60 pM), L-glycyl-histidyl-lysine 
(2.5 µM), somatostatin (6.1 nM), and TSH (1 milliunits/ml) as reported previously 
(27). 
For the proliferation assay, 500 cells/well were seeded in 96-well culture plates. 
T3 was added at concentrations varying from 1 pm to 50 nM. Two nM T3 is the 
average serum T3 concentration in rats and therefore considered physiological. 
Cell growth was measured using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay in conjunction 
with the addition of the electron coupling reagent phenazine methosulfate (PMS) 
(Promega).  Briefl y, 1, 3, 6 and 16 days after addition of T3, 180 µl culture medium 
was replaced by medium containing 10 μl of MTS/PMS mixture for 3 hours and 
placed at 37°C in a humidifi ed incubator with 5% CO2. The absorbance of each well 
was measured with a microplate reader (Rainbow reader) at 570 nm wavelengths. 
Radioiodide uptake assay 
For uptake experiments, FRTL-5 cells were grown in 12-well plates. T3 was added 
in concentrations ranging from 0, 0.5, 1 and 2 nM for 72 hours prior to the uptake 
studies. For steady state iodide uptake assessments, cells were also cultured in 
medium without TSH (5H). The radioiodine uptake was performed as previous 
described (28). Briefl y, the cells were washed 3 times with Hanks Balanced Salt 
Solution (HBSS) prior to the uptake assay. For the steady state uptake experiments, 
FRTL-5 cells were incubated with HBSS containing 10 µM Na125I with a specifi c 
activity of 50 mCi/mmol for 30 min 37 °C. Thereafter, the radioiodine was washed 
twice with cold HBSS. Cells were lysed with ice-cold ethanol. Radioactivity was 
subsequently measured in a gamma emitter counter. The DNA content of each 
well was subsequently determined after trichloroacetic acid precipitation, by the 
diphenylamine method (29). Based on the specifi c activity of the substrates, the 
effi ciency of the γ-counter, and the DNA content of each well, iodide uptake was 
expressed as picomoles of substrate transported per microgram of DNA or as 
percentage of control conditions.
In the initial rate experiments, the effect of substrate concentration on uptake 
was determined by incubating washed FRTL-5 cells for 2 min in HBSS containing 
NaI from 0.625 to 160 µmol/L. After 2 min, radioiodide uptake was quantifi ed as 
indicated above.
RNA isolation and real-time quantative PCR
Total RNA of FRTL-5 cells was extracted after 72 hour culturing without or with 
1pM, 2 nM or 50 nM T3, using TRIzol LS reagent (Invitrogen Life Technologies, 
Inc.), followed by RNA cleanup with the RNeasy mini kit (Qiagen, Valencia, CA). 






RNA concentrations were determined by measuring the absorbance at 260 nm. 
RNA was reverse transcribed into cDNA using the SuperScript First-stand Synthesis 
System for RT-PCR(Gibco BRL). 
The following primer sets were used for quantitative PCR (qPCR): TSHR5’-3’ TGC 
TTTCAA TGG AAC AAA GC; 3’-5’ GGA AGG AAG AGC AGT AAC GC. NIS 
5’-3’ GGT TGT GGT AAT GCT CGT TG; 3’-5’ GGG TCA AAG TCC ATC 
AGG TT. beta-actin 5’-3’TCC TTC CTG GGT ATG GAA TC; 3’-5’ GCA CTG 
TGT TGG CAT AGA GG. All PCR amplicons spanned exon-intro boundaries. 
The qPCRs were performed in the presence of 5ul Taq Gold buffer, 1.75ul 50mM 
MgCl2, 1ul 5mM dNTPs, 0.1ul 5U Aplitaq Gold DNA polymerase, 0.25ul 10uM 
stock solution of sense and antisense primers, 1.5ul sybrgreen and 1ul 5ng/ul cDNA 
in a fi nal volume of 25ul. Water was used as a negative control. qPCR reactions 
perform on an iCycler (Biorad, Hercules, CA, USA) using the SybrGreen qPCR 
core-kit (Eurogentec, Seraing, Belgium). Cycle conditions were: 10 minutes at 94°C 
followed by 40 cycles of 10 s at 94°C and 1 minute at 60°C. Cycle threshold (Ct) 
extraction was performed using the iCycler IQ software (version 3, Biorad). The Ct 
value for NIS and TSHR are subtracted from the Ct values of actin (delta Ct values) 
(Fig.1). The relative delta Ct was calculated by 2^deltCT. The mean delta Ct value of 
an individual sample was based on three independent measurements.
Western blot analysis
Western-blot was performed as described previously (30). FRTL-5 cells were grown 
in the absence or presence of 0.5, 1 and 2 nM T3. Proteins were extracted and 
quantifi ed using the Lowry method.  All samples were diluted 1:2 with loading buffer 
and heated at 37°C for 30 min prior to electrophoresis. 
Western blot analysis was carried out as follows: Twenty-fi ve micrograms of protein 
per lane were loaded on a 9% SDS polyacrylamide gel and subjected to electophoresis 
at a constant voltage (150 V). Electroblotting to a nitrocellulose membrane was 
performed for 1 h. Blocking was done overnight using TTBS/milk (TBS, 1% Tween 
20 and 5% milk). The membrane was incubated for 1 hr with a 1:5000 dilution of 
affi nity-purifi ed anti-rNIS antibody (30), which was kindly provided by Dr. Carrasco 
(Albert Einstein College of Medicine, Bronx, USA) in TTBS/milk. After washing, 
the membrane was incubated with a 1:5.000 dilution of a horseradish peroxidase-
linked donkey anti-rabbit IgG (Amersham) in TTBS/milk. Quantitation of the signal 
intensity was performed by densitometry (Molecular Dynamics, Inc.). Membranes 




The results of the proliferation assay are given in Figure 1. Proliferation was assessed 
at 1, 3, 6 and 16 days after addition of T3. Addition of different concentrations of 
T3 (1 pM, 2nM or 50 nM) did not infl uence the proliferation. It was verifi ed that T3 
itself did not directly infl uence the MTS assay in a separate experiment in which both 
MTS and DNA concentrations were measured (data not shown).   





















Figure 1. Proliferation of FRTL-5 cells, cultured without or in the presence of 50 nM T3. Cells were 
cultured in H-6 medium with stripped serum. Proliferation was measured with the MTS assay (see 
Materials and Methods).
Iodide Uptake
Iodide uptake was measured both in steady state conditions and in an initial rate 
experiment.
In steady state conditions, as expected, iodide uptake was much higher in the 
presence of TSH than in FRTL-5 cells without TSH (Figure 2a). Addition of T3 
signifi cantly decreased iodide accumulation, in a concentration dependent manner, 
irrespective whether the cells were cultured in the presence or absence of TSH 
(Figure 2a and Figure 2b). T3 decreases uptake even with absence of TSH although 
in a less pronouced level. 
In the initial rate experiment, 1 and 2 nM T3 lowered the Vmax of iodide uptake to 
about 50% of the control curve, whereas Km was not infl uenced (Figure 2b). 
NIS mRNA and protein expression
NIS mRNA expression as assessed by quantitative PCR was signifi cantly reduced






by the addition of 1 pM, 2 nM and 50 nM T3. The relative concentration of mRNA 
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Figure 3.
a. Effects of T3 on NIS mRNA of FRTL-5 cells, cultured in H-6 medium with stripped serum. Proliferation 
expression as assessed by real time PCR, expressed as relative concentration (2^ delta delta CT)
b. NIS protein expression of FRTL-5 cells cultured in H-6 medium with stripped serum with or without T3.








































































a. FRTL-5 cells were cultured for 10 days in H-
5 medium with stripped serum. T3 was added 
in indicated concentrations in the presence of 
H-6 medium. Iodide uptake was measured at 
45 min after addition of I-125 (Specifi c activ-
ity 50 mCi/mmol. Activity was extracted from 
the cells by addition of ethanol. Uptake was 
expressed as pmol iodide/ug DNA.
b. Same as described in Fig.2a, except that 
FRTL-5 cells were cultured in H-6 throughout 
the whole experiment. 
c. Initial rate (2 min) iodide uptake by FTRL-5 
cells, cultured in H-6 medium with or without 
2 nM T3 in a concentration range of NaI of 
0.525 – 80 uM, with or without T3.
C
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Western Blot analysis showed that NIS protein expression was signifi cantly reduced 
in FRTL5 cells cultured in 2 nM T3. 
Discussion
The present study was conducted to investigate whether T3 had direct effects on 
iodide uptake in the thyroid irrespective of presence of TSH. We found indeed a 
decreased uptake of iodide in the rat cell-line FRTL-5 cultured in the presence of 
physiological concentrations of T3 even with absence of TSH although in a less 
pronouced level. Thus we speculate that T3 has TSH idenpendent effects on iodine 
uptake. This decreased uptake was accompanied by decreased NIS mRNA and 
protein expression. 
The background of this experiment is the advent of rhTSH for the preparation 
of radioiodide scintigraphy and therapy in DTC (6;21). As patients will continue 
thyroxin therapy during rhTSH therapy, the question is whether T3 itself may affect 
iodide uptake as thyroid tissue contains functional T3 receptors (31;32). There have 
indeed been some suggestions that radioiodide scintigraphies after rhTSH have a 
lower sensitivity than after thyroxin withdrawal (5;6) and that ablation with 30 mCi 
radioiodide is less effi cient after rhTSH  than after thyroxin withdrawal (25). Several 
explanations for these observations have been proposed. 
It has been suggested that the iodide content of levo-thyroxine (T4) therapy during 
rhTSH may dilute the specifi c activity of the radioiodide administered. Indeed, 65.4% 
of the molecular weight of T4 consists of iodide which may result in a net daily 
supply of  25-60 ug iodide, when taking 100 ug/day. Indeed increased urinary iodide 
excretion has been observed during rhTSH as compared with thyroxin withdrawal 
(33;34).
In our study, we found a substantial decrease in iodide uptake of up to 50% after 
T3. The amount of iodide coming from T3 in our experiment (In case of 2 nM T3: 
9 nM of iodide) cannot explain the decrease in iodide uptake, as the steady state 
experiments were performed in the presence of 10 uM NaI. The resulting dilution 
of radioactivity may thus only be 0.001, which is negligible. 
Another explanation for the diminished quality of radioiodide scintigraphies 
after rhTSH may be the altered iodide kinetics in euthyroidism as compared with 
hypothyroidism. Indeed, renal clearance of iodide is higher in euthyroidism, thereby 
reducing the whole body dose of radioiodine after rhTSH (35;36). In the latter 
study it was concluded that the effective half life of radioiodide in the thyroid after 
rhTSH was decreased but that the residence time of radioiodide in the thyroid was 
longer than after withdrawal. In our study, using an in vitro iodide uptake assay, the 
infl uence of whole body iodide kinetics was ruled out. 






From our results it seems likely that T3 has effects on NIS gene expression at least in 
FRTL5 cells, resulting in lower functional NIS protein. It has been debated whether 
the promoter for NIS contains T3 responsive elements. In one study, it was suggested 
that T3 in fact stimulates the NIS promoter (37). However, these experiments were 
not performed with stripped serum. In earlier studies, it has been observed that T3 
decreases the mRNA and protein expression of NIS as well as the uptake of iodide 
(32;38).  In several experiments, it has been found that the promoter of the TSHR gene 
contains T3 responsive elements and that T3 suppresses the expression of the TSHR 
(39;40) (41). Another explanation for the repression of TSHR gene transcription by 
T3 has been suggested by Tagami et al (42) who found that unliganded thyroid 
hormone receptor recruits histone deacetylase (HDAC) from the TSHR promoter, 
resulting in increased histone acetylation and transcriptional activation of the TSHR. 
In the presence of T3 HDAC comes available to repress TSHR promoter activity. 
However, we observed that T3 also decreased iodide uptake in FRTL5 cultured in 
medium without additional TSH.
In conclusion, we found evidence for a TSH and iodide independent effect of T3 on 
NIS gene expression. The mechanism remains to be resolved and also the question 
whether the effect is present and relevant in humans. The clinical relevance of this 
fi nding is not clear. Randomized trials with clearly defi ned endpoints can provide 
answers to this question. The similar ablation effi cacy in rhTSH treated patients 
and patients undergoing thyroxin withdrawal suggest that the contribution of T3 
induced NIS suppression may be limited.    
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Abstract
Objective: Lithium has been reported to increase radioiodide (RaI) dose in benign 
thyroid disease and differentiated thyroid carcinoma (DTC). It is not known if 
lithium infl uences the outcome of RaI therapy in DTC. We therefore studied the 
clinical effects of RaI without and with lithiumcarbonate in patients with proven 
metastatic DTC. In addition, controversy exists on the mechanism by which lithium 
increases RaI dose in DTC. We performed an in vitro study specifi cally aimed at 
lithium effects on the sodium iodide symporter (NIS).
Design: Clinical study: 12 patients were selected with metastases of DTC who had 
received previous RaI therapy without lithium (control) that had not infl uenced 
tumor progression, despite RaI accumulation in metastases. The patients received 
1200 mg lithiumcarbonate/day followed by 6000 MBq RaI. Outcome parameters 
were RaI uptake, serum thyroglobulin (Tg) levels and radiological dimensions of 
metastases as compared between RaI with lithium and control. In vitro study:  Iodide 
uptake was studied in the benign rat thyroid cell line FRTL-5, in the polarized non-
thyroid MDCK cell-line, stably transfected with hNIS to study lithium effects on 
NIS in a non-thyroid background and the human follicular thyroid carcinoma cell 
line FTC133-hNIS to study lithium effects in a background of DTC. Lithiumchloride 
was added in concentrations up to 2 mM for 0-48 hours. Both steady state iodide 
uptake (30 min) and initial rate (2 min) were studied using a specifi c activity of 
100 mCi/mmol I, the latter experiment to determine lithium effects on substrate 
dependency. Iodide effl ux studies were performed as well.
Results: Despite an increased uptake of RaI in 7 patients, no benefi cial effect of 
RaI with lithium was observed on the clinical course as assessed by serum Tg 
measurements and radiographically. 
In the in vitro studies, no effects of lithiumchloride on iodide uptake or effl ux were 
observed.
Conclusions: We conclude that the addition of lithium to RaI did not have benefi cial 
effects on the clinical course in 12 patients with metastatic DTC. No benefi cial 
effects of lithium on iodide uptake were observed in vitro. Therefore, the clinical 
value of lithium in DTC remains subject of debate.







Although the role of RaI therapy in recurrent or metastatic thyroid cancer is beyond 
dispute, the remission rate in metastases treated with I-131 is limited 1-3. Therefore, 
strategies to enhance the tumor dose of RaI are worthwhile. 
Lithium salts have been introduced decades ago for the treatment of psychiatric 
disorders 4. Lithium salts have been associated with an increased trapping of iodide 
by the thyroid gland 5,6.   This property of lithium led to the assumption that lithium 
may enhance the dose of RaI in benign and malignant thyroid disorders. Indeed, 
increased RaI retention by lithium has been confi rmed in Graves hyperthyroidism 
leading to a higher therapeutic effi cacy 7-11, although this could not be confi rmed in 
other studies 12,13. In addition, lithium has been reported to increase tumor dosages 
of RaI in DTC 5,14-17. These studies vary in the time course of lithium application: 
some studies initiated lithium administration 2 days prior to RaI therapy 12,17 whereas 
others started lithium only at the instant of RaI therapy 5,10,14. 
Despite the observation of increased RaI uptake in DTC, no studies have been pub-
lished to our knowledge in which the effects of the addition of lithium to RaI on the 
clinical course of patients were investigated. We therefore studied the clinical effects of 
RaI without and with lithiumcarbonate in 12 patients with proven metastatic DTC.
The mechanism of the enhanced RaI trapping by lithium salts in DTC is presently 
unclear. Thyroid carcinomas that accumulate iodide have in common with benign 
thyroid diseases that they express the sodium iodide symporter (NIS) that is 
responsible for iodide uptake 18, whereas thyroid cancer differs from normal thyroid 
in numerous other aspects, including the loss of follicular architecture and the loss 
of expression of many proteins involved in thyroid hormone synthesis 19. Therefore, 
the most obvious explanation for lithium effects on iodide trapping in benign and 
malignant thyroid disease would be to enhance NIS function. In the literature 
however, variable effects of lithium salts on iodide uptake in vitro or in animal 
studies are reported. Some studies found that lithium salts inhibit the uptake of 
iodide, iodotyrosin coupling and the release of thyroid hormone 20-23. Other studies 
found unaltered uptake 8,9,24,25 or increased iodide uptake 26. 
As most of these studies were performed before the cloning of NIS, we wanted 
to study the effects of lithium salts on NIS function in the background of normal 
thyroid physiology, in a non-thyroid background and in the background of thyroid 
carcinoma. As this objective cannot be addressed easily in patients, we performed 
in vitro studies, studying lithium uptake in thyroid and non-thyroid cell lines with 
endogenous NIS expression or stably transfected with hNIS.
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Patients, Materials and Methods
Clinical study  
After the publication of the study of Koong et al 17, it was decided to apply the 
treatment schedule of this study in patients with metastases of DTC that had been 
scheduled for RaI therapy and who had had an unfavorable response to prior RaI 
therapy despite the fact that their metastatic lesions accumulated RaI as revealed 
by whole body scintigraphy (WBS), 7 days after radioiodide therapy. This fi rst RaI 
therapy served as a control. Patients who were selected had to have undergone total 
thyroidectomy and RaI ablative therapy. The presence of metastases of thyroid 
carcinoma was established by measurable serum Tg levels and the presence of 
metastatic sites at post-therapeutic whole body scintigraphy, X-ray, CT or MRI after 
prior radioactive iodine therapy.  
The objectives of this study were to investigate if addition of lithium to RaI has ben-
efi cial effects on radioiodine uptake and the clinical course of the patients. Outcome 
measures were the uptake of RaI on post-therapy WBS, progression of serum Tg 
levels after RaI therapy and the change in dimensions of the metastatic sites at X-ray, 
CT or MRI. 
Twelve patients were included in the protocol (2 males, 10 females). Their clini-
cal characteristics are presented in Table 1. The mean age at diagnosis of thyroid 
carcinoma was 59 years. Most patients had papillary thyroid carcinoma. In 10 of 
the patients, metastases were already present at the time of diagnosis of thyroid 
carcinoma, most of them pulmonary. Before the RaI therapy combined with lithi-
umcarbonate and the control RaI therapy were performed, all patients had received 
extensive therapies; RaI therapy had been administered in a mean cumulative dosage 
of 28 GBq (Table 1). Six of the 12 patients had received additional non-RaI therapies 
during the course of their disease. However, none of these therapies had been ap-
plied within a 1-year period prior or after the historical control RaI therapy or the 
RaI therapy combined with lithiumcarbonate. 
Protocol
Four weeks before RaI therapies, patients were routinely switched from T4 to T3 
therapy. T3 was discontinued two weeks before RaI therapy. A low iodide diet was 
started 1 week prior to the RaI therapy. RaI was administered orally as an activity 
of 6000 MBq Na131I. Seven days after RaI administration, whole body scintigraphy 
was performed. During the second RaI therapy, lithiumcarbonate (Litarex, Dumex, 
Baarn, The Netherlands) was prescribed according to the schedule of Koong 17. 
Lithiumcarbonate 564 mg was given twice (bid) with a 12 h interval. Plasma lithium 
levels were measured by atomic absorption spectrometry. The dose was adjusted if 






necessary to achieve a lithium concentration of 0.6-1.2 mmol/L. Lithium was con-
tinued during 7 days after the RaI administration. To investigate the effects of lithi-
umcarbonate on RaI uptake, ideally a randomized crossover design with a washout 
period should be performed. The crossover design would be necessary to account 
for the continuing rise in serum TSH levels during the period of T4 withdrawal. This 
would have implicated a prolonged period of T4 withdrawal and consequently high 
TSH levels. This was considered not ethical because the RaI therapy was scheduled 
anyway and a prolonged period of increased TSH levels could theoretically have 
unfavorable effects on tumor progression 27-29. 
 
Table 1. Characteristics of 12 patients with metastases of differentiated thyroid arcinoma
          Patients (n) 12
Females / Males (n) 10/2 




Follicular variant  2
Follicular 
3 
Stage at Diagnosis (n)
T 1–3 and M-0 2 




















Na131I  whole-body scintigraphy was performed 7 days after the oral administration 
of 6000 MBq of 131I (Mallinckrodt BV, Petten, The Netherlands). The run speed 
of the dual-head gamma camera (Toshiba GCA 7200, equipped with a high-energy 
collimator) was 15 cm per minute (matrix size 256×256). WBS was followed by 
anterior and posterior planar images of the head and neck and chest region (ma-
trix size 256×256, preset time 10 min). Quantitative assessment of I-131 uptake 
was performed by calculating uptake in 2 regions of interest by 2 observers who 
were unaware of treatment modality. These regions were carefully chosen in such 
a way that they had not been subjected to other treatment modalities. Two regions 
were chosen to assess whether a potential effect of lithium was uniform or not. 
Quantitative uptake on WBS performed after lithium was compared with control in 
corresponding regions of interest, and expressed as ‘increased’, ‘stable’, ‘decreased’ 
or ‘mixed’. ‘Mixed’ was used when the result of lithium in the 2 regions of interest 
differed. 
Thyroglobulin increments are expressed as the differences in the natural logarithms 
(Ln) of the Tg values during suppressive T4 therapy observed at the end of the 
observation period after RaI therapy and the last Tg value during T4 before RaI, 
divided by the duration of the observation period; in formula: Delta LnTg:
(LnTgend-LnTgstart)/months. 
Radiological measures were scored semi-quantitatively as: ‘stable’, ‘progression’, 
‘regression’ or ‘cure’. ×256, preset time 10 min). 
Laboratory measurements
Serum TSH was determined with on a Modular Analytics E-170 system (Roche 
Diagnostic Systems, Basle, Switzerland), intra-assay variability: 0.88-10.66%, inter-
assay variability: 0.91-12.05%). Serum Tg was measured. Serum Tg was determined 
with IRMA (Tg kit, Brahms, Berlin Germany) on a Wallac gammacounter (Wallac, 
Turku, Finland), intra-assay variability: 0.14-13.9%, inter-assay variability: 12.3-17.4 
%). Serum Tg antibodies were determined with IRMA (Sorin Biomedica, Amsterdam, 
The Netherlands) on a Wallac gammacounter (Wallac, Turku, Finland) intra-assay 
variability: 3.6-4.1%, inter-assay variability: 11.6%).
In vitro studies
Cell lines and culturing conditions 
Three cell-lines were studied: The rat thyroid FRTL-5 cell-line derived from the 
ATCC (ATCC, Manassas, New York) expresses endogenously NIS which is 
subjected to TSH regulation 30. FRTL-5 were grown in Ham’s F-12 media (Life 
Technologies, Inc.) supplemented with 5% calf serum, 1 mM non-essential amino 
acids (Life Technologies, Inc.), 10 mM glutamine, 100 units/ml penicillin, 100 µg/ml 






streptomycin, and a six-hormone mixture (6H) containing insulin (1.3 µM), hydro-
cortisone (1 µM), transferrin (60 pM), L-glycyl-histidyl-lysine (2.5 µM), somatostatin 
(6.1 nM), and TSH (1 mU/ml) as reported previously 31.
Recent studies suggest striking similarities between polarized protein sorting in 
thyrocytes and MDCK epithelial cells. We have therefore used MDCK clones 
stably transfected with hNIS 32(donated by N. Carrasco, Albert Einstein College 
of Medicine, New York) to study direct effects of lithium on NIS in a non-thyroid 
background.
To study if lithium infl uences NIS function in the background of a thyroid carci-
noma, the follicular thyroid carcinoma cell line FTC133 was used. FTC133 (kindly 
donated by Dr. Goretzki and Dr. Simon, University of Düsseldorf, Germany) 
was derived from a 42-year-old male with metastatic follicular thyroid carcinoma 
27. We have stably transfected this cell line with hNIS 33,34. Cells were cultured in 
Dulbecco’s modifi ed Eagle’s medium (DMEM) and modifi ed HAM-F12 medium 
1:1 supplemented with 10% fetal bovine serum, penicillin/streptomycin and geneti-
cin to maintain an advantageous environment for transfected cells, in a humidifi ed 
incubator at 37ºC and 5% CO2. Lithiumchloride was added to the culturing fl uids in 
various concentrations and time schedules as indicated.
In vitro iodide uptake
For uptake experiments, cells were grown in 12-well plates. LiCl was added in con-
centrations ranging from 0 to 2 mM either 48 hours prior to the uptake studies or 
at the moment of uptake studies (acute). Culturing media were carefully checked for 
pH after addition of Lithium. Prior to the uptake studies, the cells were washed 3 
times in Hanks Balanced Salt Solution (HBSS), buffered with 10 mM Hepes (pH 7.5) 
Thereafter, HBSS containing 20 µM Na125I with a specifi c activity of 100 mCi/mmol 
was added to the cells. Cells were incubated at 37 °C in a humidifi ed atmosphere. 
Three types of uptake studies were performed: steady state, initial rate and effl ux 
studies.
In all experiments, reactions were terminated by aspirating the radioactive mixture 
and washing three times with the ice cold HBSS. Accumulated 125I was determined 
by permeabilizing the cells with 500 ul ethanol for 20 min at –20 0 C and quantitating 
the released radioisotope in a γ counter. The DNA content of each well was sub-
sequently determined after trichloroacetic acid precipitation, by the diphenylamine 
method 18. Based on the specifi c activity of the substrates, the effi ciency of the 
-counter, and the DNA content of each well, iodide uptake was expressed as pico-
moles of substrate transported per microgram of DNA or as percentage of control 
conditions.
For steady state experiments, the radioactive cells were incubated for 30 minutes 
with the radioactive solutions. 
84
In the initial rate experiments, the effect of substrate concentration on uptake 
was determined by incubating washed cells for 2 min in medium containing 9 
concentrations of iodide, ranging between 0.625 and 160 µmol/L. Uptake reactions 
were then terminated and substrate uptake was quantitated as indicated above. 
Iodide effl ux was studied in a subsequent experiment; after addition of HBSS 
with 20 µM Na125I with a specifi c activity of 100 mCi/mmol during 30 min in the 
presence or absence of LiCl in concentrations from 50-2000 umol/L, the radioactive 
supernatant was removed and HBSS with or without lithium was added to the 
cells for 5-min intervals up to 30 min after removal of the radioactive supernatant. 
Radioactivity was counted in all fl uids. The sum of all radioactivity counts in all 
washing fl uids was considered the accumulated radioactivity at the beginning of the 
effl ux.
All experiments were performed in hexaplicate.
Immunofl uorescence
FRTL-5 cells in the presence of TSH were seeded onto poly-(lysine)-coated coverslips. 
Cells were cultured with or without LiCl 2 mM for 48 hours. Cells were washed 3× 
with PBS/CM, fi xed with 2% paraformaldehyde in PBS for 20 min at RT, and rinsed 
with PBS/CM. Cells were permeabilized with 0.1% Triton in PBS/CM plus 0.2% 
BSA (PBS/CM/TB) for 10 min at RT. Cells were quenched with 50 mM NH4Cl in 
PBS/CM for 10 min at RT and rinsed with PBS/CM/TB. Cells were incubated with 
8 nM anti-rat NIS antibodies 35(donated by N. Carrasco), washed, and incubated 
with 1:700 dilution of fl uorescein-labeled goat anti-rabbit antibodies (Vector 
Laboratories). After washing, cells on the coverslips were mounted onto microscope 
slides using an antifade kit from Molecular Probes. Coverslips were sealed with quick-
dry nail polish and allowed to dry in the dark for 2 h at RT and stored at 4 °C. NIS 
immunofl uorescence was analyzed with a Bio-Rad Radiance 2000 Laser Scanning 
Confocal MRC 600, equipped with a Nikon Eclipse epifl uorescent microscope.
Statistical analyses
Continuous data are expressed as mean ± SD when distributed normally, as tested 
by the Kolmogorov-Smirnov test, otherwise as medians and ranges. Continuous data 
between groups were compared with a paired Students T-test or the Wilcoxon test, 
in case data were not distributed normally. Proportional data were compared with 
the Chi-square test. In the iodide effl ux studies, half-life of accumulated radioactivity 
was calculated by linear regression analysis of the radioactivity-time curve. A p value 
of < 0.05 was considered signifi cant.








The control RaI therapy and the RaI therapy with lithiumcarbonate were not different 
with regard to serum TSH and Tg levels during T4 withdrawal. (Table 2). No adverse 
events were observed during lithiumcarbonate administration. All 12 patients had 
lithium levels > 0.6 mmol/L. In two patients, the lithiumcarbonate dose had to 
be increased to 564 mg three times per day (tid) to achieve these concentrations. 
The post-therapeutic increments in Tg levels are given in Table 2. Uptake of RaI 
was increased after addition of lithium in 7 patients. Two patients had a mixed 
pattern, some lesion showing increased uptake, other stable or decreased uptake. 
Median increments in the natural logarithm of Tg levels did not differ signifi cantly 
between the fi rst RaI therapy (0.08 vs. 0.11, p=0.228). The number of subjects with 
positive or negative Tg increments after RaI therapy did not differ either between 
RaI therapies without and with lithiumcarbonate. The same pattern was observed 
for the radiological evaluation of metastatic sites: the number of subjects with 
stabile, progressive or regressive metastatic sites was not different after the historical 
control RaI therapy as compared with RaI combined with lithium. Therefore, we 
were unable to document a benefi t of the administration of lithium in these patients.
Table 2. Effects of RaI therapy with 6000 MBq I-131 on clinical course in patients with progressive 
differentiated thyroid carcinoma without (control) or with addition of lithiumcarbonate (lithium) 
Control Lithium p-value 1
Serum TSH at therapy (mU L-1) 96 ± 56 99 ± 87 0.831 &
Serum thyroglobulin Levels (µg L-1)
 During withdrawal 2320 (104-277960) 3518 (668-1310000) 0.328 &
Increment Post-Therapy
(Delta LnTg(Ln µg L-1 month-1)) 0.08 (-0.08-0.26) 0.11 (-0.19-1.04) 0.228 &
Delta Ln Tg  positive/negative (n) 9 / 3 10 / 2 0.615 *
Whole body scintigraphy
Iodide uptake in ROI vs. Lithium vs. Control




Radiological evaluation (X-ray, CT, MRI)
Regression (n patients) 3 2 0.091 *
 Stabile 5 1
Progression 4 9
1: lithium  vs. control; 2 : 2 regions of interest with different effects of lithium; ∗: Chi-square test;  &: Wilcoxon –test
86
In vitro study
Steady state Iodide uptake
We studied the 30 min accumulation of iodide in FRTL5, MDCK-hNIS and FTC133 
hNIS after acute or 48 hours incubation with LiCl in concentrations of 50, 100, 500, 
1000 and 2000 umol/L. We did not observe any effect of either acute or 48 hour 
addition of lithiumchloride in any concentration on steady state iodide uptake in the 
3 cell lines.
The results for 500, 1000 and 2000 umol/L are shown for FRTL5, MDCK-hNIS 
and FTC133 hNIS  (Figure 1a). 












































































































Figure 1. a. Acute and 48 hours effects of  500, 1000 and 2000 uM LiCl on iodide uptake in 
3 cell-lines: FRTL-5, MDCK-hNIS and FTC133-hNIS. Incubation media consisted of 
HBSS with 20 µM Na125I with a specifi c activity of 100 mCi/mmol. Experiments were 
terminated after 30 minutes. Iodide uptake was expressed as percentage of control uptake. 
Mean values for iodide uptake without lithium were: FRTL-5: 12.3±6.6 pmol/ug DNA, 
for MDCK-hNIS: 49.5±8.3 pmol/ug DNA and FTC133-hNIS: 23.4±0.5 pmol/ ug DNA.
b. Two minutes iodide uptake by FRTL-5. Incubation media contained Na125I in concentrations 
from 0.625 uM to 160 uM, all with a specifi c activity of 100 mCi/mmol. All uptake values 
were expressed as a percentage of the maximum uptake in FRTL5 without lithium.






Initial rate iodide uptake
We studied the 2 minutes iodide uptake and the effects of substrate concentration in 
FRTL-5, MDCK-hNIS and FTC133 hNIS after acute or 48 hours incubation with 
LiCl in concentrations of 50, 100, 500, 1000 and 2000 umol/L. We did not observe 
any effect of either acute or 48 hour addition of lithium salts in any concentration 
on initial rate uptake of the 3 cell lines. The results for acute addition of 2 mM LiCl 
are given in Figure 1b.
 
























































































































Figure 2. Infl uence of LiCl 2 mM, added during 48 hours or during the effl ux experiment (acute) on 
iodide effl ux in FRTL-5, MDCK-hNIS or FTC133-hNIS.  Iodide effl ux was studied after addition of 
HBSS with 20 µM Na125I with a specifi c activity of 100 mCi/mmol during 30 min in the presence or 
absence of LiCl. Thereafter, the radioactive supernatant was removed and HBSS with or without lithium 
was added to the cells for 5-min intervals up to 30min after removal of the radioactive supernatant.
 Control 
LiCl 2 mM 
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Iodide effl ux
To study whether the absence of an effect of lithium salts on iodide uptake may be 
theoretically explained by an effect of similar magnitude on iodide effl ux, we studied 
iodide effl ux or retention in FRTL5, MDCK-hNIS and FTC133 hNIS after acute 
or 48 hours incubation with LiCl in concentrations of 50, 100, 500, 1000 and 2000 
umol/L. We did not observe any effect of either acute or 48 hour addition of lithium 
salts in any concentration on steady state iodide uptake in the 3 cell lines.
The results for acute and 48 hours addition of 2 mM LiCl for FRTL5, MDCK-hNIS 
and FTC133-hNIS are shown for FRTL5 (Figure 2). 
NIS immunofl uorescence
No effects of the addition of 2 mM LiCl for 48 hours on NIS staining were observed 
(Figure 3).
 
Figure 3. NIS immunostaining of FRTL-5 cells, cultured during 48 hours without 
(a) or with (b) LiCl 2 mM. No effect on immunofl uorescence was seen. Magnifi cation 60 x.
a         b
Discussion
We performed the present study to investigate whether the addition of lithium to 
RaI in patients with metastasized DTC has benefi cial effects on the clinical course 
of the disease. In addition, we studied whether the reported benefi cial effects of 
lithium on RaI uptake in patients with benign or malignant thyroid diseases may be 
explained by a direct effect of lithium on NIS or alternatively that the effects must 
be attributed to other mechanisms as suggested in a number of studies 20,21,23.In the 
clinical study, we did not fi nd any evidence for a positive effect of lithiumcarbonate 






on the clinical course of DTC.  Several explanations for the lack of success can be 
hypothesized. First, the category of patients could have been different from the 
study of Koong et al 36.  However, in both studies patients with iodide accumulating 
metastases were included. In both studies, papillary carcinomas were predominant 
and most patients had pulmonary metastases. Second, in our study, the clinical 
course was compared after two high dose RaI therapies with a longer interval than in 
the study of Koong et al. It can be hypothesized that the longer time interval may 
have given rise to changes in biological tumor characteristics or alternatively, that 
the historical control RaI therapy may have selected radioresistant tumor cells 37. 
However, in all patients, RaI accumulating lesions were present after the second RaI 
therapy as well. In addition, although Tg levels were progressive in most patients, 
their long-term increment rates were not altered substantially after the fi rst RaI 
therapy, so it is unlikely that this explanation is true. Third, it could be hypothesized 
that the response of thyroid carcinoma cells to lithium combined with high activities 
of RaI is different from lithium combined with tracer doses: with high doses of 
RaI, thyroid cancer cell necrosis could lead to a faster release of radioactivity from 
the cells 14: however, if this were true in our patient group, this would have lead to 
a favorable response on RaI. A fourth explanation could be that even if lithium 
had led to higher iodide retention in our patients, no additional therapeutic effect 
of RaI therapy was achieved. Effi cacy of RaI therapy is the result of tumor dose 
on the one hand and radiosensitivity on the other hand. If lithium had resulted in 
an increased tumor dose, this could still have been insuffi cient to establish growth 
arrest of thyroid carcinoma.
In addition, some patients underwent alternative treatments like embolization or 
external irradiation that might confound the potential effect of lithium. However, 
we carefully chose indicator metastases that were not subjected to these alternative 
therapies. In the experimental studies we investigated whether the benefi cial effects 
of lithium salts on RaI uptake in patients with benign or malignant thyroid diseases 
may be attributed to a direct effect on NIS or that the effects must be attributed 
to other mechanisms as suggested in a number of studies 20,21,23. This hypothesis 
was based on the fact that benign thyroid disease and iodide accumulating thyroid 
carcinoma have in common the expression of NIS, whereas virtually every other 
aspect of thyroid hormone physiology is different. In addition, we studied the ef-
fects of addition of lithium to RaI therapy on the clinical course in 12 patients with 
metastatic DTC. In the in vitro experiments, we included 3 cell-lines: FRTL5, in 
which NIS expression is subjected to normal regulation. MDCK-hNIS is a polarized 
cell-line in which traffi cking of thyroid proteins resembles that in normal thyroid 
cells 32 but where lithium effects on NIS can be studied in the absence of normal 
thyroid regulation. FTC133-hNIS is a follicular thyroid carcinoma cell line, stably 
transfected with hNIS 34, in which effects of lithium salts on NIS in a background of 
thyroid carcinoma can be studied. 
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In our experiments, no effects of lithiumchloride were found on iodide uptake, 
neither when added acutely, nor when added 48 hours before the uptake experiments. 
Uptake was studied both in steady state and initial rate experiments. To exclude 
the theoretical possibility that lithium salts may affect uptake and effl ux to the 
same magnitude, effl ux studies were performed as well, again with no effect of 
lithiumchloride. These results are the fi rst reported on in vitro effects of lithium salts 
on NIS function in a benign or malignant thyroid background and in a non-thyroid 
background.  
Although of course we have not studied all steps of iodide physiology, we believe that 
an explanation via NIS is highly unlikely and thereby confi rm earlier studies in which 
no effect of lithium salts on iodide uptake were found 8,9,20,22-25. Haberkorn et al. 38 
did not fi nd an effect of lithium salts on iodide trapping in NIS transfected thyroid 
carcinoma in an animal study. In another study in NIS transfected colon carcinoma 
cells, even an inhibiting effect of lithium was found 39. It is suggested that for the 
enhancement of iodide trapping by lithium intact organifi cation is necessary which 
then is inhibited by lithium 38. This may explain the absence of lithium effects in 
thyroid- or non-thyroid tumors with a short half-life and absence of organifi cation. 
In conclusion, our data indicate that if a benefi cial effect of lithium in thyroid 
carcinoma would be present, it would not be by enhancing NIS activity. The clinical 
data presented in this study raise doubt if there is a benefi cial effect at all in enhancing 
the effects of RaI treatment in thyroid carcinoma. Therefore, the clinical value of 
lithium in DTC remains a subject of debate.
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Abstract
Objective: Treatment options of metastases of differentiated thyroid carcinoma (DTC) 
are limited due to decreased uptake of radioiodide (I-131). Therefore, strategies to 
improve I-131 uptake are mandatory. It has been suggested that retinoids have 
benefi cial effects on iodide uptake in vitro and in humans. However, to date, only 
studies with 13-cis retinoic acid have been performed in humans. We therefore 
decided to study the effects of 6-weeks treatment with the retinoid receptor RXR 
activator Bexarotene on I-131 uptake in patients with metastatic DTC.
Design: Open prospective intervention study.
Methods: Twelve patients with metastases of DTC, with insuffi cient uptake of I-131 
received 6-weeks treatment with 300 mg Bexarotene/day. Prior to, and after this 
intervention, I-131 uptake was measured by whole body scintigraphy and single 
photon emission tomography (SPECT) 3 days after 185 MBq I-131. Diagnostic 
imaging was preceded by 2 consecutive injections with recombinant human 
thyrotropin.
Results: Bexarotene treatment induced I-131 uptake in metastases of 8/11 patients 
(one patient died for reasons not related to the study). However, uptake was only 
discernable at SPECT and had incomplete matching with metastases as visualized 
by CT scanning.
Conclusions: Bexarotene partially restores I-131 uptake in metastases of DTC. The 
clinical relevance of this observation may be limited due to the differential responses 
of the different metastases within each patient and the low intensity of I-131 
uptake.   
 







Differentiated thyroid carcinoma (DTC) in general has a favourable prognosis due 
to the effect of combined treatment of surgery and radioactive iodide (I-131) and 
the biological behaviour of the tumor (1,2). However, about 50% of patients with 
distant metastases of DTC die within 10 years after the diagnosis (3). Although the 
role of I-131 in recurrent or metastatic thyroid cancer is beyond dispute (4 - 6), the 
effi cacy of this therapy is hampered by the decreased expression and/or function of 
the sodium iodide symporter (NIS) in DTC during the process of dedifferentiation 
(7 - 9). Therefore, strategies to improve iodide uptake by DTC are mandatory.  
Retinoids are derivatives of vitamin A (i.e. retinol). Benefi cial effects of retinoids 
have been reported in promyelocytic leukaemia and several types of carcinoma (10 
- 12). In vitro studies have reported that retinoids have benefi cial effects in thyroid 
carcinoma (13 - 16) including increased NIS mRNA expression and iodide uptake 
in some thyroid cancer cell lines (13). Interestingly, the promoter of the NIS gene 
has a retinoic acid response element (17). A limited number of human studies have 
been performed on the effects of retinoids on I-131 uptake. In 4 publications - 3 
from the same group - 13-cis retinoic acid therapy increased I-131 uptake in 26-40% 
of the patients (18 - 21), but failed to do so in another study (22).  The only retinoid 
used so far in human studies in DTC is 13-cis retinoic acid. This compound is 
a ligand for the retinoic acid receptor RAR. However, 13-cis retinoic acid has a 
lower affi nity for RAR than other retinoids as retinoic acid and all-trans retinoic 
acid (23). In addition, recent studies indicated a differential expression of both RAR 
and the retinoid receptor RXR in thyroid carcinoma cell-lines and tissues (24,25), 
which corresponded to the responsiveness to ligands for these receptors. The 
importance of RXR expression with respect to responsiveness to retinoid treatment 
was demonstrated in the latter study (25). We therefore, decided to perform a 
prospective controlled clinical trial to investigate the effi cacy of the novel ligand 
Bexarotene (Targretin, Ligand Pharmaceuticals, San Diego), in 12 patients with 
metastases of DTC and decreased or absent I-131 uptake. Bexarotene is an RXR 
agonist, which also induces RAR by transcriptional activation. The antineoplastic 
potential has been demonstrated in cutaneous T-cell lymphoma, but also in other 
malignant tumors (26 - 28).
Patients and Methods
Design
The study was a 6-week open study with 12 patients. Patients underwent diagnostic 
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I-131 whole body scintigraphy (WBS) before, and after 6-weeks treatment with 
Bexarotene 300 mg/day. An open study design was chosen, because the study 
parameters can be assessed by objective criteria. Each patient served as his/her own 
control. An interval of 6 weeks between the two observations was chosen to allow 
normalization of serum TSH concentrations after the fi rst application of rhTSH 
and to enable complete disappearance of the fi rst I-131 dose from the tumor. The 
objective of this study was to investigate if addition of Bexarotene has benefi cial 
effects on radioiodine uptake in metastatic lesions of patients with DTC.
Patients
The Leiden University Medical Center is a large referral center for differentiated 
thyroid carcinoma in the Netherlands. With the exception of unifocal T-1,N-0,M-0 
tumors, initial therapy consists of near-total thyroidectomy followed by routine I-131 
ablative therapy with 3700 MBq I-131. Follow-up is performed according a standard 
protocol, involving serum thyroglobulin (Tg) measurements, both during Thyroxine 
suppressive therapy and after Thyroxine withdrawal as well as I-131 scintigraphy 
after Thyroxine withdrawal. In case of recurrent disease or metastases, surgery will 
be attempted if the lesion is solitary and accessible, followed by additional radio-
iodide therapy (7400 MBq). 
For the present study, 12 consecutive patients were selected with metastases of 
DTC as proven by measurable serum Tg levels and the presence of metastases or 
recurrent disease at post-therapeutic whole body scintigraphy, X-ray, CT or MRI. 
A CT scan performed < 3 months prior to the study served as anatomical reference 
for the number, extent and localization of metastases. Patients who were selected 
had to have undergone total thyroidectomy and I-131 ablative therapy. Uptake of 
I-131 or effectiveness of earlier I-131 therapies had to be insuffi cient as indicated by 
progressive tumor growth despite I-131.
Exclusion criteria were pregnancy, contraindications for the application of 
recombinant human thyrotropin (rhTSH), contraindications for the use of 
Bexarotene such as hematological malignancies, leukopenia or coagulopathy, a 
history of pancreatic disease and severe hypertriglyceridemia (fasting triglyceride 
levels > 4.5 mmol/l).
The institutional review board approved the study, and all patients gave written 
informed consent.
Protocol
A CT scan performed < 3 months prior to the study served as anatomical reference 
for the number, extent and localization of metastases. After inclusion, the patients 
underwent a fi rst diagnostic scintigraphy 3 days after intravenous administration 
of 185 MBq I-131. Patients were prescribed a low iodide diet from 7 days prior 






to the administration of I-131 (29). The patients received i.m. injections with 0.9 
mg rhTSH (Thyrogen®, Genzyme, Naarden) on 2 consecutive days before the I-
131 administration. rhTSH instead of Thyroxine withdrawal was used to avoid the 
methodological and clinical disadvantages of persistent high TSH levels during a 
long withdrawal period.
The day after the fi rst WBS, patients started treatment with Bexarotene 300 mg/day 
at the evening meal to prevent interference with Thyroxine absorption. 
Six weeks after initiation of Bexarotene therapy, the I-131 imaging study was 
repeated. Bexarotene was continued until the WBS was performed. Patients visited 
the hospital every week for a physical examination and assessment of laboratory 
safety parameters. When the intervention was successful (see below), patients were 
offered high dose I-131 therapy, again preceded by 6 weeks Bexarotene therapy. 
Evaluation of the study objectives
The main outcome parameter of the study is the effect of Bexarotene therapy 
on I-131 uptake in metastases at WBS. Uptake was investigated as follows: a 
quantitative assessment of I-131 uptake was performed by calculating uptake in a 
region of interest using a reference I-131 source (see below).  In addition, uptake 
was compared between the fi rst and the second WBS in comparable regions and 
expressed as “increased”, “stable”, “decreased” or “mixed”. “Mixed” was used when 
both lesions with increased, stable or decreased uptake were present. It was studied 
also if there was a complete or incomplete matching of areas with I-131 uptake at 
WBS and metastatic locations as visualized by CT scanning. 
A “complete response” was defi ned as increased I-131 uptake in all lesions visible 
on CT. A “partial response” was defi ned as increased I-131 uptake as compared 
with the fi rst WBS, but not in all lesions visible at CT. “No response” was defi ned 
as absent or similar I-131 uptake in both WBS. The study was defi ned as successful 
when at least 50% of the patients had at least a partial response. 
Whole body scintigraphy with 185 MBq I-131
131I whole-body scintigraphy was performed 3 days after the oral administration 
of 185 MBq of 131I (Mallinckrodt BV, Petten, The Netherlands). The run speed 
of the dual-head gamma camera (Toshiba GCA 7200, equipped with a high-energy 
collimator) was 15 cm per minute (matrix size 256×256). WBS was followed by 
anterior and posterior planar images of the head and neck and chest region (matrix 
size 256×256, preset time 10 min). Finally, single photon emission computed 
tomography (SPECT) of the head and neck and chest was performed (128x128 
matrix, 6o step angle and 1 min. per step). Two experienced observers visually 
analyzed all images. A Na131I standard was used to quantify the uptake in the area 
of interest at WBS.
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Laboratory parameters
The following laboratory parameters were assessed: TSH, free-T4, free-T3 and Tg 
were measured before both injections of rhTSH, before the administration of I-131 
and during the WBS. Tg antibodies were measured before both rhTSH injections. 
Safety parameters were a hematological profi le as well as serum levels of sodium, 
potassium and creatinine, lipids, renal and liver function. They were assessed every 
week.  Urinary iodine excretion was measured to exclude iodine contamination.
Serum TSH was determined with on a Modular Analytics E-170 system (Roche 
Diagnostic Systems, Basle, Switzerland), intra-assay variability: 0.88-10.66%, inter-
assay variability: 0.91-12.05%). Serum Tg was determined with IRMA (Tg kit, Brahms, 
Berlin Germany) on a Wallac (Wallac, Turku, Finland), intra-assay variability: 0.14-
13.9%, inter-assay variability: 12.3-17.4 %). Serum Tg antibodies were determined 
with IRMA (Sorin Biomedica, Amsterdam, The Netherlands) on a Wallac (Wallac, 
Turku, Finland) intra-assay variability: 3.6-4.1%, inter-assay variability: 11.6%).
Statistical Methods
Data are reported as mean ± SD. The effects of bexarotene on outcome variables 
were analyzed using the two-tailed Student’s t-test for paired data. Data without 
normal distribution were analyzed using the Wilcoxon test. Proportional data were 
analyzed using Chi-square. Differences were considered statistically signifi cant at 





Twelve patients were included in the protocol (5 males, 7 females). Their clinical 
characteristics are presented in Table 1. The mean age at diagnosis of DTC was 
49 ± 11 years. Most patients had papillary thyroid carcinoma. In 3 of the patients, 
metastases were already present at the time of diagnosis of thyroid carcinoma, most 
of them pulmonary. Most patients had received extensive therapies; I-131 therapy 
had been administered in a median cumulative activity of 16 GBq (Table 1). Seven 
of the 12 patients had received additional therapies during the course of their disease 
(surgery and/or external radiotherapy). 
One patient (nr 3) died during the study. She was admitted to the hospital and 
underwent acute surgery for intestinal volvulus. This event was considered to have 
no relation with the study. The other patients tolerated the Bexarotene treatment 
well. However, in 2 patients (nr. 6 and 9), the dose had to be reduced because 

















































































































































































































































































































































































of hypertriglyceridemia that stabilized after dose reduction. One patient (nr 2), 
experienced an episode of leucopenia, which also lead to a dose reduction of 
Bexarotene. 
Biochemical parameters
No differences in TSH levels without and after rhTSH stimulation were observed 
before and after 6 weeks Bexarotene treatment (Table 2). There was a remarkable 
decrease in serum free T4 and serum free T3 levels after 6 weeks Bexarotene 
treatment. Serum Tg levels before and after rhTSH were not different before and 
after Bexarotene therapy. No iodine contamination was observed according to 
urinary iodine measurements. 







Free Thyroxine (pmol/L) 25.7 ± 6.5 13.2 ± 3.4 <0.001
Free T-3 (pmol/L) 3.6 ±1.3 2.1 ± 1.0 0.016
Thyrotropin (mU/L) 0.025 (<0.005 – 2.18)
0.024
(<0.005 – 1.06) 0.652
Thyroglobulin (ug/L) 108 (2.4 – 880) 158 (3.7 – 1145) 0.892
After rhTSH
Free Thyroxine 24 h (pmol/L) 25.7 ± 5.6 13.6 ± 3.3
Thyrotropin 24 h (mU/L) 190.5 (89.2 – 324) 165.6 (100-312) 0.561
Thyrotropin 72 h (mU/L) 17.7 (10.2 – 44.3) 19.6 (12.0 – 56.1) 0.538
Thyroglobulin 24 h (ug/L) 112 (14.7 - 1390) 163 (20.9 – 1905) 0.704
Thyroglobulin 72 h (ug/L) 123 (25.7 – 2650) 165 (45.2 – 1558) 0.747
Cholesterol (mmol/L) 5.4 ± 1.0 7.8 ± 1.2 <0.001
Triglycerides (mmol/L) 1.6 ± 0.7 3.7 ± 1.5 <0.001
Evaluation of the study objectives
The main outcome parameter of the study is the effect of Bexarotene therapy on I-131 
uptake in metastases at WBS. No patients with a complete response were observed 
(Table 3). A partial response was observed in 8 patients. In 7 of these patients, 
increased uptake was only visible at SPECT, indicating that the accumulation of 
iodide was low. Scans of 2 of these patients(nr5 and 6) are depicted in Figure 1. 





























































































































































































































































































































































































































































































































































































































































Figure 1. I-131 uptake 
before and after treatment 
of 6 weeks with 300 mg/day 
Beaxoretene in 3 patients 
with pulmonary metastases of 
DTC. In all patients, a subtle 
increase in I-131 uptake was 
observed after Bexarotene 
therapy at SPECT imaging, 
3 days after 185 MBq I-131. 
The protocol for image 
processing is described in 
the Methods.  In patient 8, 
new lesions (boxes) became 
apparant after bexarotene 
therapy.
The number of lesions with increased or visible I-131 uptake was lower than visible 
at the reference CT scan. In 1 patient, pulmonary metastases were visible at the 
baseline WBS. Because the matching of these metastases was incomplete, it was 
decided to include her in the study. After 6 weeks Bexarotene, WBS revealed uptake 
in additional lesions that were not visible before (Figure 1, patient 8).
Although it was attempted to quantify I-131 by calculating uptake in a region of 
interest using a reference I-131 source, uptake in regions of interest as visualized by 
SPECT were too low to allow quantifi cation.  







The present study investigated the effectiveness of 6-weeks Bexarotene treatment 
in reinducing I-131 uptake in metastases of patients with DTC with absent or 
insuffi cient uptake of I-131 during earlier I-131 therapies. Bexarotene treatment 
induced I-131 uptake in the majority of the patients (8/11), but the uptake was only 
discernable at SPECT and not present in all metastases, visualized by CT scanning. 
Therefore, the clinical relevance of these fi ndings remains to be determined.
All clinical studies performed so far with retinoids in DTC used 13-cis retinoic acid 
(18 - 22).  The study with the best design (22), however, failed to demonstrate any 
positive effect. Because 13-cis retinoic acid has a limited specifi city and affi nity for 
the retinoic acid receptor (23) and the importance of RAR subtypes and RXR have 
been demonstrated in recent studies (24,25), we hypothesized that a ligand with 
RXR affi nity and also affi nity for RAR may have benefi cial effects (26 - 28,30). 
Several factors may be involved in the partial success of the intervention. I-131 
accumulation is not only determined by the trapping of iodide by NIS, but also 
by the effective half life. The effective half-life of I-131 is diminished in DTC by 
several factors including decreased organifi cation of iodide due to decreased thyroid 
peroxidase expression as well as the loss of follicular architecture (31,9). Therefore, 
enhancing NIS expression may not be adequate to reach suffi cient radiation exposure 
to I-131, even if we used a low iodide diet (29) to increase the specifi c activity 
of the I-131 administered. Alternatively, the regulation of NIS may be defective 
at multiple transcriptional and post-transcriptional levels (32), which can only be 
partially restored by retinoids.
An interesting observation was that in one patient (nr. 8), a new lesion became 
apparent after Bexarotene, which did not accumulate iodide earlier. This is an 
interesting illustration of the heterogeneity in DTC metastases with respect to iodide 
metabolism.
Free serum Thyroxine and triiodothyronin levels decreased markedly in all patients 
without increase in TSH levels. Although the effects of Bexarotene on TSH have 
been well established (33), the fact that Bexarotene decreases thyroid hormone levels 
in patients in whom thyroid hormone levels are TSH independent suggests an effect 
on thyroid hormone metabolism. We do not believe that the differences in thyroid 
hormone levels after Bexarotene have affected the study results, as TSH induction 
after rhTSH was comparable before and after Bexarotene.
We conclude that Bexarotene treatment may partially restore I-131 uptake in some, 
but not all, metastases of DTC. The clinical importance of this observation remains 
to be demonstrated but may be limited by the incomplete matching and the low 
intensity of I-131. 
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Objective: To evaluate the effects of pre-treatment with the RXR agonist Bexarotene 
on the effi cacy of radioiodine therapy of metastases of differentiated thyroid 
carcinoma (DTC) with limited uptake of radioiodine (I-131). 
Design: Open prospective intervention study.
Methods: Eight patients with metastases of DTC, with insuffi cient uptake of I-131 
who showed increased uptake of radioiodine after previous treatment with 300 
mg Bexarotene were treated with radioiodine (7400 MBq), preceded by 6 weeks of 
treatment with Bexarotene 300 mg/day. Outcome parameters were serum Tg levels 
and dimension of metastases at CT, measured before, and 6 months after, therapy. 
Tissue of the primary tumor was stained with antibodies against RAR and RXR 
subtypes.
Results: Bexarotene pre-treatment induced radioiodine uptake in metastases in all 
8 patients, although uptake was only discernable at SPECT and had incomplete 
matching with the metastases visualized by CT scanning. Six months after radioiodine 
therapy 6 patients had progressive disease (defi ned as a >10% increase in serum 
Tg and/or a >25% increase in tumor dimensions), whereas 2 patients had stable 
disease.   No relation was observed between retinoid receptor staining pattern and 
the outcome of therapy.
Conclusions: Bexarotene partially restores I-131 uptake in metastases of DTC, but this 
did not result in susceptibility to radioiodine therapy. 







The effi cacy of radioiodine therapy in metastatic thyroid carcinoma is limited by 
decreased uptake of radioiodine, which is likely related to decreased expression 
or function of the sodium iodide symporter (NIS) in DTC during the process of 
dedifferentiation  (1,2,3). Therefore, strategies to improve iodide uptake by DTC 
are mandatory.  
Retinoids are derivatives of vitamin A (i.e. retinol). Benefi cial effects of retinoids have 
been reported in vitro in thyroid carcinoma (4,5,6,7) including increased NIS mRNA 
expression and iodide uptake in some thyroid cancer cell lines (4). Interestingly, the 
promoter of the NIS gene has a retinoic acid response element (8). A limited number 
of human studies all performed with 13-cis retinoic acid reported variable results 
(9,10,11,12)(13).  The only retinoid used so far in human studies in DTC is 13-cis 
retinoic acid. As 13-cis retinoic acid has a lower affi nity for RAR than other retinoids 
(14) and the retinoid receptor RXR may also be important in thyroid carcinoma 
(15,16), we performed a prospective controlled clinical trial to investigate the effi -
cacy of the novel ligand Bexarotene (Targretin, Ligand Pharmaceuticals, San Diego) 
(17,18,19), in 12 patients with metastases of DTC and decreased or absent I-131 
uptake (20). We found increased uptake in metastases in 8 of these patients. Here, 
we report the results of high dose I-131 therapy after preparation with Bexarotene 
in these 8 patients.
Patients and Methods
Patients
Patients in whom 6-weeks therapy with Bexarotene 300 mg/day increased 
radioiodine uptake in metastases of DTC (20) were offered therapy with 7400 MBq 
radioiodine.
Detailed inclusion criteria and clinical data of the patients in this study are given in 
our previous study (20) and are summarized in Table 2. In summary, patients were 
selected with metastases of DTC, who had previously undergone total thyroidectomy 
and I-131 ablative therapy. Uptake of I-131 or effectiveness of earlier I-131 therapies 
had to be insuffi cient as indicated by progressive tumor growth despite I-131.
Exclusion criteria were pregnancy, contraindications for the application of 
recombinant human thyrotropin (rhTSH), contraindications for the use of 
Bexarotene such as hematological malignancies, leukopenia or coagulopathy, a 
history of pancreatic disease and severe hypertriglyceridemia (fasting triglyceride 
110
levels > 4.5 mmol/l). Of the original 12 patients that enrolled in the fi rst study, 8 
patients were eligible for treatment with high dose radioiodine. 
Protocol
Radioiodine therapy (7400 MBq, Mallinckrodt BV, Petten, The Netherlands) was 
given after a new 6-weeks treatment with Bexarotene (300 mg/day). A new treatment 
course with Bexarotene was given because it was not known how long the effects of 
the fi rst course of Bexarotene would last.  
Prior to radioiodine therapy, patients received i.m. injections with 0.9 mg rhTSH 
(Thyrogen®,, Genzyme, Naarden) on 2 consecutive days before the I-131 
administration. rhTSH instead of withdrawal of L-thyroxin substitution was used 
because Bexarotene is reported to inhibit pituitary TSH production (21).  Patients 
were prescribed a low iodide diet from 7 days prior to the administration of I-131 
(22). 
Evaluation of the study objectives
The main outcome parameter of the study was the effect of treatment on the 
progression of metastases of DTC 6 months following  I-131 therapy with 
pretreatment of Bexarotene. 
Study objectives were evaluated with CT scans and serum thyroglobulin (Tg) 
measurements as assessed before Bexarotene therapy and 6 months after radioiodine 
treatment.
A CT scan obtained before radioiodine therapy served as anatomical reference for 
the number, extent and localization of metastases. The response was determined as 
complete response (no disease demonstrable), incomplete response (decrease in Tg 
> 10%, decrease in radiological dimensions of metastases > 25%), stable disease 
(difference between serum Tg levels < 10% and progression in radiological tumour 
dimensions < 25%) or progressive disease (difference between serum Tg levels 
> 10% or progression in radiological tumour dimensions > 25% or the appearance 
of new metastatic lesions). 
Outcome of radioiodine therapy was related to retinoid acid receptor expression in 
a subset of patients.  
131-I whole-body scintigraphy was performed 3.5 and 7 days after the radioiodine 
therapy. The run speed of the dual-head gamma camera (Toshiba GCA 7200, equipped 
with a high-energy collimator) was 15 cm per minute (matrix size 256×256). WBS 
was followed by anterior and posterior planar images of the head and neck and chest 
region (matrix size 256×256, preset time 10 min). Finally, single photon emission 
computed tomography (SPECT) of the head and neck and chest was performed 
(128x128 matrix, 6o step angle and 1 min. per step). Two experienced observers 






visually analyzed all images. A Na131I standard was used to quantify the uptake in the 
area of interest at WBS.
Immunohistochemistry 
Immunhistochemstry was performed on tissue blocks obtained from the primary 
tumors. Tissues from 2 patients, who did not respond to Bexarotene in an earlier 
study (20), (Pat NI-1 and Pat NI-2), were also included in the staining procedure.  
Ten percent formalin-fi xed, paraffi n-embedded blocks routinely prepared from 
surgical specimens of primary thyroid tumours were selected for this study. Four 
µm consecutive tissue sections were cut from each arrayed paraffi n block and pre-
pared on pathological slides. The sections were deparaffi nised in xylene followed 
by 0.3% hydrogen peroxide methanol at room temperature for 20 minutes for 
blocking endogenous peroxidase. After rehydration, antigen retrieval treatment was 
done for CK-19, HBME-1, FN-1, CITED-1, NIS and PPAR-gamma but Gal-3 
immunostaining by microwave treatment in 0.01 M citrate buffer at pH 6.0. After 
2 hours cooling down, endogenous avidin activity blocking was performed for NIS 
immunostaining by incubation with egg-white for 5 minutes followed by biotin for 
15 minutes. The sections were incubated with primary antibodies against RAR and 
RXR (Table 1) in PBS with 1% bovine serum albumin overnight in room tempera-
ture. The negative controls were stained with the primary antibody omitted. Next, 
sections were incubated for 30 minutes with either the biotinylated rabbit-anti-mouse 
conjugate (Dako, Glostrup, Denmark, 1:200) or goat-anti-rabbit (1:400), followed by 
incubation for 30 minutes with the streptavidin-biotin-peroxidase conjugate (Dako, 
Glostrup, Denmark 1:100). This step was by a 10-minute incubation with 3,3’-di-
aminobenzidinetetrachloride substrate in a buffered 0.05 M Tris/HCl (pH 7.6) solu-
tion containing 0.002% hydrogen peroxide. The sections were counterstained with 
haematoxylin. A semi-quantitative assessment of immunohistochemical scoring was 
performed according to both the intensity of staining and the percentage of positive 
cells. Ranging from 1 – 6. 
Laboratory parameters
The following laboratory parameters were assessed: plasma levels of TSH, free-
T4, free-T3 and Tg were measured before both injections of rhTSH, before the 
administration of I-131 and during the WBS. Tg antibodies were measured before 
both rhTSH injections. Safety parameters were a hematological profi le as well as 
serum levels of sodium, potassium and creatinine, lipids, renal and liver function. 
They were assessed every week.  Urinary iodine excretion was measured to exclude 
iodine contamination.
Serum TSH was determined with on a Modular Analytics E-170 system (Roche 
Diagnostic Systems, Basle, Switzerland, intra-assay variability: 0.88-10.66%, inter-
112





























































































































































































































































































































































































































assay variability: 0.91-12.05%). Serum Tg was determined by IRMA (Tg kit, Brahms, 
Berlin Germany) on a Wallac (Wallac, Turku, Finland, intra-assay variability: 0.14-
13.9%, inter-assay variability: 12.3-17.4 %). Serum Tg antibodies were determined 
with IRMA (Sorin Biomedica, Amsterdam, The Netherlands) on a Wallac (Wallac, 
Turku, Finland) (intra-assay variability: 3.6-4.1%, inter-assay variability: 11.6%).
Statistical Methods
Data are reported as mean ± SD. The effects of bexarotene on outcome variables 
were analyzed using the two-tailed Student's t-test for paired data. Data without 
normal distribution were analyzed using the Wilcoxon test. Proportional data were 
analyzed using Chi-square. Differences were considered statistically signifi cant at 




Eight patients were included in this treatment protocol (4 males, 4 females). Their 
clinical characteristics are presented in Table 2. The mean age at diagnosis of DTC 
was 52 ± 10 years. In 2 of the patients, metastases were already present at the time of 
diagnosis of thyroid carcinoma, most of them pulmonary. Most patients had received 
extensive therapies; I-131 therapy had been administered in a median cumulative 
activity of 15 GBq (Table 1). Four of the 8 patients had received additional therapies 
during the course of their disease (surgery and/or external radiotherapy). 
The patients tolerated the Bexarotene treatment well, despite temporary increases in 
serum triglyceride levels in 5 subjects. In 1 patient the dose of Bexarotene had to be 
reduced because of an episode of leucopenia. 
Evaluation of the study objectives
The main outcome parameters of the study were the treatment effects 6 months 
following I-131 therapy after preparation with Bexarotene on the progression of 
metastases of DTC.
No incomplete or complete responses were observed. Six patients had an increase in 
serum Tg levels of >10% (Table 2). One patient had a relatively low serum Tg level 
(2.4 ug/L) but this level rose to 64.8 ug/L after TSH stimulation. Three patients 
























































































































































































































































































































































































































































































































































































































































    

























































































































































































































































































































































































appeared. In 3 patients, there was progression at CT but less than 25%. 
All patients had received a previous course of Bexarotene to prove increased radio 
uptake during diagnostic scintigraphy. No differences were observed between 
diagnostic scintigraphy after this fi rst Bexarotene treatment and the post-therapeutic 
whole body scans, and, except in one patient (nr. 5) in whom discrete pulmonary 
lesions became visible at SPECT after post-therapeutic WBS (Table 3).  In all 
patients, there was an incomplete matching of lesions observed at post-therapeutic 
WBS with the CT scans.
Although it was attempted to quantify I-131 by calculating uptake in a region of 
interest using a reference I-131 source, uptake in regions of interest as visualized by 
SPECT were too low to allow quantifi cation.  
Immunohistochemstry
Data for immunohistochemstry are given in Table 2. Apparently there was no 
uniform pattern in staining for RAR and RXR subtypes (Figure 1) (see color image 
on page 151), and no relation was apparent with staining pattern and outcome of 
therapy.
Discussion
The present study investigated the effectiveness of radioiodine therapy after 6-weeks 
pre-treatment with the RXR agonist Bexarotene on metastases of patients with DTC 
with absent or insuffi cient uptake of I-131 during previous I-131 therapies. Although 
Bexarotene treatment had shown to induce I-131 uptake in these 8 patients (20), no 
clinically relevant response to radioiodine was observed. As the initially observed 
uptake of radioiodine was only discernable at SPECT and not present in all me-
tastases as visualized by CT scanning, the clinical effi cacy of Bexarotene therapy is 
limited.  
The background of our study was that the compound used in clinical studies in 
DTC has been 13-cis retinoic acid  (9,10,11,12,13) which had inconsistent effects. 
Following the observation that the RXR may be important in DTC (15,16), we 
decided to treat patients with an RXR agonist which also has affi nity for the RAR 
(17,18,19,21). 
The lack of success may be explained by several factors. The dose of radioiodine that 
is realized in a metastatic lesion is determined not only by the trapping of iodide by 
NIS, but also by the effective half life of the radioisotope, which may be decreased 
in DTC by decreased organifi cation of iodide due to decreased thyroid peroxidase 






expression as well as the loss of follicular architecture (23,3). Alternatively, the 
regulation of NIS may be defective at multiple transcriptional and post-transcriptional 
levels (24), which can apparently only be partially restored by retinoids.
An important observation was that there was only incomplete matching between the 
metastases identifi ed by radiological imaging and post-therapeutic WBS. Although 
this is an interesting observation, illustrating the heterogeneity of DTC metastases 
with respect to iodide metabolism, this incomplete matching suggests that the 
benefi cial effects of Bexarotene may be present, at best, in a subset of metastases. 
However, even if these metastases become susceptible to radioiodine, this does not 
prevent the progression of other lesions.    
The question is whether patients with other characteristics might have a better 
response to Bexarotene. To investigate this issue, we performed RAR and RXR 
staining in a subset of patients. However, we did not fi nd a relation between staining 
pattern and outcome of therapy. A limitation in this respect is that we only had 
materials of the primary tumor and it may be that the retinoid receptor expression 
pattern in the metastases was different.
We conclude that Bexarotene treatment partially restores I-131 uptake in some, but 
not all, metastases of DTC, at least in the patients selected for this study. Due to 
inhomogeneous effects of Bexarotene on I-131 uptake by the different metastases 
within each patient and the low intensity of I-131 uptake, the clinical effi cacy of 
Bexarotene pretreatment is limited. 
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Chapter 8
Summary & Disscussion 
120
1. Introduction
Differentiated thyroid carcinoma (DTC) has a low incidence and a relatively good 
prognosis. This relatively favourable prognosis is the result of the biological behaviour 
of most of these tumors and the effi cacy of initial therapy. However, the therapeutic 
arsenal in DTC is very limited. Once distant metastases have occurred, usually in the 
lungs or bones, the prognosis is worse, because the results of RaI therapy, which is 
virtually the only curative treatment, are moderate. A major problem in progressive 
or metastatic disease is the diminished, or lost, ability of thyroid cancer cells to 
accumulate RaI, indicated by negative post-therapeutic whole body scintigraphy. In 
these cases, the prognosis is poor, because alternative treatment options (external 
radiotherapy or chemotherapy) have only limited success. 
Because of the low incidence and favourable prognosis, diagnostic and therapeutic 
strategies are hard to investigate: the follow-up time is too long and the numbers 
too small to reach signifi cant endpoints in prospective randomized trials. As a result, 
many of the current treatment and follow-up protocols are derived from large 
retrospective studies, mostly from single centers, with many sources of bias. Another 
aspect is the decentralised approach of the disease. Despite the low incidence, many 
centers treat patients with DTC. One of the examples of this decentralised approach 
is the existence of many staging systems, which make comparisons between centers 
diffi cult. 
DTC is a unique malignant disease in which fascinating biological phenomena are 
present, like the pathophysiology of iodide transport. This makes DTC an attractive 
model to study the molecular mechanisms of iodide transport, and to fi nd targets 
to re-establish iodide transport. This unique position, however, also adds to the 
somehow isolated situation: DTC is a type of cancer that is less well recognized 
in the mainstream of novel anti-cancer drugs trials. An example of an unresolved 
diagnostic dilemma is that the diagnosis of DTC is still largely dependent on 
conventional histological staining procedures. Despite experimental studies with 
gene- and protein expression profi les, no important innovation has been introduced 
in the past decades with respect to diagnosis. This has important implications for the 
many patients who present with DTC, because in particular the distinction between 
follicular thyroid carcinoma (FTC) and follicular adenoma (FA) is impossible to 
make with cytology. As a consequence, many patients will undergo surgery who do 
not have DTC. 
In every follow-up protocol of DTC serum thyroglobulin (Tg) measurements are 
the backbone of diagnosis of recurrent DTC. However, the many analytical and 
statistical aspects of Tg measurements are not always refl ected in the choice of Tg 
cut-off values. Indeed, they are defi ned on some retrospective studies from large 
centers. An important approach would be to defi ne institutional cut-off values which 







in addition to conventional ones like TNM stage, histology and age is an interesting 
and potentially clinically important issue that has not been addressed extensively in 
the literature.  
A fascinating aspect of DTC is the pathophysiology of iodide transport. The most 
important molecule for iodide transport, the sodium iodide symporter (NIS) is less 
functional in DTC. Although decreased expression is important, in this thesis, it was 
found and confi rmed that defective NIS traffi cking may be important as well, which 
may have not only consequences for future research, but also for the diagnosis of 
DTC. 
The introduction of recombinant human TSH (rhTSH) has been important for 
the patient to avoid the negative aspects of thyroxine withdrawal. The assumption, 
however, that continuation of thyroid hormone therapy does not directly infl uence 
iodide transport has not been properly investigated.
Different approaches to improve iodide transport in DTC can be distinguished. 
Much attention has been focussed on lithium salts to improve iodide uptake and 
addition of lithium to radioiodine therapy in metastatic DTC has been recommended 
in the literature. In the present thesis, these diagnostic and therapeutic dilemmas 
in differentiated thyroid carcinoma (DTC) are approached from a clinical and 
experimental perspective. 
2. Improving the diagnosis of DTC
The histological diagnosis of DTC, and in particular follicular thyroid lesions, is an 
important dilemma evaluated in Chapter 2 with huge implications for general health 
care is. Although the prevalence of DTC is low, that of thyroid nodular disease 
is not, and improvements in the current practice in which patients with follicular 
proliferation are referred for surgery could prevent many surgical procedures. Many 
genetic and immunohistochemical candidate markers have been identifi ed, but none 
of those has successfully been introduced in routine diagnostic procedures. We 
chose to investigate the diagnostic value of a panel of proteins (Galectin-3 (Gal-3), 
HBME-1, CK-19, CITED-1, Fibronectin-1 (FN-1), the sodium iodide symporter 
(NIS) and peroxisome proliferator activated receptor (PPAR) in 177 benign and 
malignant thyroid tissues. Our study differed from earlier ones with regard to the 
identifi cation of optimal semi-quantitative cut-off levels using ROC analysis and the 
use of hierarchical cluster analysis. 
We found all proteins to be differentially expressed between FA and PTC. The 
differences between FA on the one hand and FTC and Follicular Variant of Papillary 
Thyroid Carcinoma (FVPTC) on the other hand were less prominent, but we found 
a differential expression of PPARγ, HBME-1, Gal-3, cNIS and FN-1. 
The accuracies of HBME-1, FN-1 and Gal-3 for the differential diagnosis of FVPTC 
and FA were fair. For FN-1 the accuracy was 71% for the differentiation between 
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FA and FTC. 
We confi rmed cytoplasmic NIS overexpression in PTC and FTC. The differential 
expression of cNIS between subtypes of thyroid neoplasms makes it a candidate for 
differentiating between these lesions. Cytoplasmic NIS was also identifi ed by cluster 
analysis as a potential useful marker in the discrimination between FA and malignant 
carcinomas.  
PPARγ has been found to be downregulated in experimental models of thyroid 
carcinoma. The importance of the downregulation of PPARγ is also illustrated in the 
PPARγ/PAX8 rearrangement which was initially observed in a series of FTC. We 
found decreased PPARγ nuclear staining in malignant tumors, but as the percentage 
of positive cells varied from 50-100% in benign lesions, the diagnostic accuracies for 
the differentiation between follicular lesions were limited.     
Cluster analysis showed that a diagnostic immunohistochemical panel comprising 
Gal-3 and FN-1 was 97% sensitive for all thyroid carcinomas, whereas specifi city was 
100%. However, HBME-1 was found to be a useful marker for the differentiation 
between FA and FVPTC. Because the number of FVPTC was small, hierarchical 
clustering did not allow a separate analysis of this group of tumors. 
In conclusion, Gal-3, FN-1 and cNIS is a useful diagnostic panel in the differential 
diagnosis of thyroid lesions. The absence of Gal-3, FN-1 and cNIS is highly 
suggestive for a benign lesion. HBME-1 may be useful in the specifi c differentiation 
of FVPTC from FA. 
Perspective
The fi ndings of Chapter 2 need to be confi rmed in a follow-up study in which the 
candidate markers are tested in cytological samples. These samples will be scored 
according to routine criteria and clinical decisions will be based on those. The scores 
of the candidate markers will be compared with the fi nal histological diagnosis of 
those thyroid glands that will be removed and a comparison will also be made with 
the staining patterns of the candidate markers in the surgical samples. 
3. The diagnostic and prognostic value of serum Tg in the follow-up of DTC
Serum Tg levels are the most important diagnostic markers in the follow-up of 
DTC. Recently, guidelines for the follow-up of DTC have been published by the 
British Thyroid Association (under the auspices of the Royal College of Physicians), 
the American Thyroid Association and the European Thyroid Association. In the 
Netherlands, the medical associations involved in DTC and the Dutch Institute 
for Healthcare Improvement (CBO) have also completed a consensus paper. 
The cut-off values for Tg levels that are advised in these documents are often not 







centers. Indeed, it is advised to defi ne institutional cut-off values. The problem with 
the defi nition of Tg cut-off values is, as with any diagnostic procedure, the gold 
standard that is used to the defi ne presence or absence of disease. In DTC, Tg is 
considered a better marker than for instance radioiodide scintigraphy, so using iodide 
scintigraphies as a gold standard may lower the specifi city for Tg. In addition, the 
levels of Tg cut-off values are dependent on what is considered the most acceptable 
ratio between unnecessary therapies or missed recurrent tumors.  This is a subjective 
choice and may be different in different countries or areas. Therefore, insight into 
the quantitative relation between sensitivity and specifi city of Tg is important, which 
is the base of receiver operator curve (ROC) analysis. Nevertheless, despite the 
analytical and methodological problems, in Chapter 3 we investigated the diagnostic 
and prognostic value of serum Tg measurements for tumor presence, cure and death 
in the follow-up of DTC by ROC analysis in a homogeneous group of 366 patients 
with respect to initial therapy. 
We found an excellent diagnostic accuracy of serum Tg values during TSH 
stimulation 6 months after initial therapy (sensitivity 100%), albeit with a higher 
Tg cut-off level than commonly reported. The explanation for this higher cut-off 
value may be related to a lower initial ablation rate in our institute as compared with 
others, analytical differences or the use of the ROC technique. We also found that 
serum Tg levels before RaI ablation are an independent predictor for cure, with 
a cut-off level of < 27.5 ug/L. TSH stimulated Tg measurements 6 months after 
initial therapy and at 2 and 5 years after initial therapy were independent predictors 
of DTC related mortality. Notwithstanding the less than 100% specifi city of Tg for 
DTC, which can indeed be explained by the limitations of gold standards used in 
our study, we agree with the policy to administer a high dose of RaI to patients with 
elevated Tg levels. In our opinion, a potential solution to circumvent the debate 
about specifi city of Tg is to consider Tg a risk indicator. The independent prognostic 
value of serum Tg values for cure and death are arguments to include Tg in the 
conventional panel of risk factors.  The percentage of patients with Tg antibodies 
(initially 27%) is in line with previous studies. The percentages of active tumor in 
patients with and without Tg antibodies were comparable, confi rming the lack of 
diagnostic value of Tg antibodies.    
In conclusion, our studies illustrate the importance of the defi nition of institutional 
Tg cut-off levels. Our analyses allow the defi nition of groups of patients with an 
increased risk for residual disease or mortality, in addition to conventionally used 
prognostic indicators. 
Perspective
Given the multiple analytical and methodological aspects that are involved in Tg 
measurements, we believe that  inter-institutional harmonization of Tg measurements 
should be propagated, preferably in an international context, but certainly at a national 
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level.  In addition, uniformization of treatment protocols and standardized criteria 
for DTC disease activity should be established, that enable the structured follow 
up of DTC patients and the defi nition of Tg cut-off values on a multi-institutional 
level.
4. Triiodothyronine suppresses in vitro iodide uptake and expression of NIS
The introduction of rhTSH for the diagnosis, initial therapy (ablation) and under 
certain circumstances the treatment of DTC  is without doubt an important 
innovation for patients with DTC, to avoid the disadvantages of thyroid hormone 
withdrawal. Although in general the diagnostic properties of rhTSH are similar to 
thyroxine withdrawal, the iodide uptake kinetics may not be entirely comparable. 
One of the aspects is that patients with rhTSH  are per defi nition euthyroid. The 
assumption is that thyroid hormone does not directly affect iodide uptake. We 
studied in Chapter 4 whether this assumption is correct. We used the rat thyroid cell 
line FRTL-5 and cultured this cell-line in the presence or absence of physiological 
concentrations of T3 and studied proliferation, iodide uptake and NIS mRNA and 
protein expression. We found indeed a decreased uptake of iodide. This decreased 
uptake was accompanied by decreased NIS mRNA and protein expression. 
Although it has been suggested that the iodide content of levo-thyroxine (T4) therapy 
during rhTSH may dilute the specifi c activity of radioiodide, and that this may be 
responsible for decreased radioiodine uptake, we believe that this cannot explain our 
fi ndings, as the amount of iodide coming from T3 in our experiment is negligible 
related to the cold iodide concentration of 10 uM. In addition, differences in whole 
body iodide kinetics, another potential explanation for differences between rhTSH 
and withdrawal, cannot explain our fi ndings either. From our results, it seems likely 
that T3 has effects on NIS gene expression resulting in lower functional NIS protein. 
It has been debated whether the promoter for NIS contains T3 responsive elements. 
Another explanation can be that the effects of T3 are via repression of the TSHR 
promoter, but our experiments do not point in that direction.  
In conclusion, we found evidence for a TSH and iodide independent effect of T3 on 
NIS gene expression. The mechanism remains to be resolved and also the question 
whether the effect exists in humans. The clinical implications of this fi nding are 
not clear, but they may add to explanations of the suggested differences in iodide 
accumulation in rhTSH or conventionally treated patients. 
Perspective
We believe that the introduction of rhTSH is an important improvement in the 
impact of DTC for patients. It is, however, important to study relevant aspects that 
are involved in the physiology of iodide metabolism, including T3. An interesting 
development is that there is experimental evidence that T3 may also act as a tumor 







therapy may be advantageous.  
5. Improving radioiodide therapy in DTC
Therapeutic options for metastases of DTC are limited. RaI may be effective in 
about half of the patients with pulmonary metastases and a small proportion of 
patients with bone metastases. However, the effi cacy of RaI therapy is often limited 
by decreased iodide uptake of metastatic DTC. Strategies to improve therapeutic 
options can be distinguished in therapies to improve RaI therapy or identifying 
other targets. 
Improving RaI therapy is a broad theme. Two main subthemes can be distinguished. 
First tumors that still accumulate iodide, second tumors in which iodide accumulation 
is lost. 
In tumors that still accumulate iodide, improving radioiodide therapy is essentially 
aimed at increasing the dose of RaI. The dose of RaI is the result of the amount 
(activity) of RaI administered to the tumor (specifi c activity), the rate of uptake, the 
tumor volume and the effective half life of RaI, which on its turn is determined by 
the physical half life and the biological half life. All these contributing factors can 
be optimalized: the amount of RaI presented to the tumor can be improved by a 
low iodide diet that increases the specifi c activity.  The uptake rate can be infl uenced 
by high TSH levels. The half-life of RaI in DTC is an important factor. The loss of 
follicular architecture and probably decreased activity of thyroid peroxidise (TPO) 
may contribute to a decreased effective half life and thus by a lower tumor dose. We 
focussed on this problem and studied the potential effects of lithium salts on iodide 
accumulation in Chapter 5.
5.1 Effects of lithium on iodide uptake and clinical outcome of radioiodide therapy
The relation between lithium salts and the thyroid has been known for long, as many 
patients with bipolar depression, treated with lithium salts develop hypothyroidism. 
The mechanism is not clear but some experimental studies have suggested that 
lithium inhibits the release of thyroid hormone, or in other words, confi nes iodide 
to the thyroid.  Because of these properties, lithium has been used to increase the 
dose of RaI in benign and malignant thyroid disease. The problem however is that it 
is not clear if lithium infl uences the outcome of RaI therapy in DTC. We therefore 
studied the clinical effects of RaI without and with lithiumcarbonate in patients with 
proven metastatic DTC. In addition, controversy exists on the mechanism by which 
lithium increases RaI dose in DTC. We performed an in vitro study specifi cally 
aimed at lithium effects on the NIS.
We studied 12 patients with metastases of DTC that still accumulate RaI. These 
patients had received previous unsuccessful RaI therapy without lithium (control) 
that. The patients received 1200 mg lithiumcarbonate/day followed by RaI therapy. 
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Despite an increased uptake of RaI in 7 patients, no benefi cial effect with lithium 
was observed on the clinical course as assessed by serum Tg measurements and 
radiographically. An explanation for the lack of success can be that the longer time 
interval between the 2 RaI therapies may have given rise to changes in biological 
tumor characteristics or alternatively, that the fi rst therapy may have selected tumor 
cells that do not accumulate iodide (radioresistant tumor cells). We think that this 
is unlikely as in all patients; RaI accumulating lesions were present after the second 
therapy as well. In addition, although Tg levels were progressive in most patients, 
their long-term increment rates were not altered substantially after the fi rst therapy. 
Another explanation may be that tumor cells have become resistant to RaI, in 
other words that apoptotic mechanisms have become defective a phenomenon 
that is regularly observed in oncology. Of course, it may also be that lithium did 
not infl uence the RaI kinetics at all. We studied the effects of lithiumchloride in 
different physiological concentrations on iodide uptake in the benign rat thyroid 
cell line FRTL-5, in the polarized non-thyroid MDCK cell-line, stably transfected 
with hNIS and in the human follicular thyroid carcinoma cell line FTC133-hNIS. 
Both steady state iodide uptake, initial rate uptake and iodide effl ux studies were 
performed. The aim of these studies was to study whether lithium salts have a direct 
effect on NIS.  No effects of lithiumchloride were found on iodide uptake or effl ux, 
irrespective of the concentrations. We have not studied all steps of iodide physiology. 
As it is suggested that for the enhancement of iodide trapping by lithium intact 
organifi cation is necessary we cannot rule out that in the 3-dimensional context 
of the thyroid, lithium may indeed inhibit the release of organifi ed iodide, which 
explains the absence of lithium effects in thyroid- or non-thyroid tumors with a 
short half-life and absence of organifi cation. 
The results of our study challenge the reported benefi cial effects of lithium in 
DTC. 
Perspective
We believe that lithium salts have no place in RaI therapy of DTC. Alternatively, 
other mechanisms to improve RaI half-life should be explored. The concept of 
organifi cation is interesting and it can be hypothesized that when RaI in coupled 
to another protein, half life may be positively infl uenced. However, transfection 
experiments with TPO may be thought of but are diffi cult from a clinical perspective. 
Another option may be the blocking of iodide effl ux by using chloride channel 
blockers.
5.2 Effects of redifferentiation therapy with bexarotene on iodide uptake and clinical outcome of 
radioiodide therapy 
The second subtheme of improving RaI therapy involved tumors in which iodide 
accumulation is lost.  The holy grail here is to re-establish functional NIS expression. 







above) and involves both genetic (transcriptional) defects and post-translational 
(traffi cking) defects. Mutations in the NIS gene have infrequently be reported and 
the most likely explanation is that the transcription of the NIS gene is hampered 
by either inactivation of the gene itself or more likely decreased promoter activity. 
The NIS promoter has multiple responsive elements and absence of one or more 
activators (like TTF-1 or TSH) will cause decreased transcription.  An interesting 
explanation is epigenetic changes in which methylation or histone deacetylation 
prevents transcription. Interesting studies have been published using pharmacological 
substances to revert these gene blockades. We have studied the effects of the retinoid 
receptor X (RXR) agonist Bexarotene (Chapters 6 and 7) on the reestablishment of 
RaI uptake in patients with metastatic DTC. Retinoids have been used earlier in DTC, 
but all clinical studies performed so far used 13-cis retinoic acid which binds only to 
the RAR subtype. Recent studies have elucidated the importance of other retinoic 
acid receptor subtypes, like the RXR in DTC.   We therefore decided to study the 
effects of 6-weeks treatment with the retinoid receptor RXR activator Bexarotene 
300 mg/day on I-131 uptake in 12 patients with metastatic DTC. Prior to, and after 
this intervention, RaI uptake was measured by whole body scintigraphy and single 
photon emission tomography (SPECT) 3 days after 185 MBq I-131. Diagnostic 
imaging was preceded by 2 consecutive injections with rhTSH. Bexarotene treatment 
induced I-131 uptake in metastases of 8/11 patients.  An interesting observation 
was that in one patient a new lesion became apparent after Bexarotene, which did 
not accumulate iodide earlier. This is an interesting illustration of the heterogeneity 
in DTC metastases with respect to iodide metabolism. However, uptake was only 
discernable at SPECT and had incomplete matching with metastases as visualized 
by CT scanning.
Although the amount of RaI uptake was limited in the 8 responders, we decided to 
give them the benefi t of the doubt and offer them therapy with high dose RaI. They 
received 7400 MBq radioiodine preceded by 6 weeks of treatment with Bexarotene 
300 mg/day. Six months after RaI therapy 6 patients had progressive disease, 
whereas 2 patients had stable disease.   The explanation for this partial success may 
be that Bexarotene did not infl uence other factors involved in RaI accumulation, 
like the effective half-life (see above). Alternatively, the regulation of NIS may be 
defective at multiple transcriptional and post-transcriptional levels which can only be 
partially restored by retinoids. Another possibility could be that the retinoic receptor 
expression pattern in the patients was not favorable with respect to Bexarotene 
therapy. To investigate this issue, we performed RAR and RXR staining in a subset of 
patients. However, we did not fi nd a relation between staining pattern and outcome 
of therapy. A limitation in this respect is that we only had materials of the primary 
tumor and it may be that the retinoid receptor expression pattern in the metastases 
was different. We observed incomplete matching between the metastases identifi ed 
by radiological imaging and post-therapeutic WBS. This observation illustrates 
the heterogeneity of iodide metabolism in DTC metastases and is a limitation for 
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redifferentiation therapy, because even if a subset of metastases becomes susceptible 
to RaI, this does not prevent the progression of other lesions.    
Perspective
We have shown that redifferentiation therapy in a clinical setting is indeed able to 
partially restore iodide uptake in DTC. A conceptual problem with redifferentiation 
therapy is that this therapy is aspecifi c: also other genes unrelated to the disease may 
be infl uenced by these compounds. This may be a serious problem, unless a specifi c 
molecular defect in the target pathway is identifi ed, like promyelocytic leukemia, 
where a translocation in the RAR is the base of retinoid therapy. The advent of 
designer drugs aimed at specifi c molecular defects in well dissected pathways, like 
the class of tyrosine kinase inhibitors, is an important development in cancer, and 
may prove to be successful in DTC as well.  
6. Conclusions of the studies described in this thesis
The low incidence, high survival and the specifi c clinical and biological aspects of 
DTC complicate the diagnosis, treatment and follow-up of patients with DTC. This 
the way in which research and patient care for DTC patients are organized should be 
seriously evaluated and improved. The recent publication of multi-national guidelines 
is an important development. The studies in this thesis have addressed some of the 
clinical and fundamental questions in DTC. Although they have resolved some of 
the questions, many new questions have risen, warranting ongoing research. 
The diagnosis of DTC, which is currently performed using conventional 
histological techniques, could be improved considerably by applying new markers. 
Our studies offer interesting perspectives for the introduction of a panel of new 
immunohistochemical markers that may improve the diagnosis.
Although serum Tg measurements are recommended as the most important 
diagnostic procedure in the follow-up of DTC, multiple analytical and statistical 
aspects are involved. Our studies illustrate the importance of defi ning institutional 
cut-off levels for Tg, using ROC techniques, to offer insight in the quantitative 
relationship between sensitivity and specifi city. We found Tg to be an independent 
prognostic marker for cure and mortality as well, which may help the clinician to 
identify high-risk patients.
The ability of DTC cells to accumulate iodide is the core of radioiodine diagnostic 
and therapeutic procedures. The introduction of rhTSH has been a great advantage 
for patients, to avoid thyroid hormone withdrawal. However, among others, the 
assumption that continuation of thyroid hormone treatment has no effects on iodide 
metabolism is likely not true. We found that T3 directly infl uences the expression 
and function of NIS. Although the clinical implication of this fi nding is not clear, we 







therapy on well identifi ed aspects of thyroid physiology should be investigated as 
good as possible.   
The most important problem in the treatment of DTC is the ineffectiveness of 
radioiodide therapy in a considerable proportion of patients with metastases. 
Strategies to improve radioiodide therapy should be based on the identifi cation of 
the molecular defects in iodide physiology in DTC. In patients in whom iodide 
uptake is still present but ineffective, interventions aimed at improving iodide 
kinetics are worthwhile. We demonstrated that the frequently propagated strategy 
to treat patients with lithium salts did not result in a better outcome of radioiodide 
therapy. Nor did we observe any effect of lithium on the in vitro iodide uptake. 
Other approaches to improve iodide kinetics are warranted. 
In patients in whom DTC metastases do not accumulate radioiodide, research is 
focusing on the re-expression of functional NIS. We found that the redifferentiating 
RXR ligand Bexarotene re-established radioiodide uptake in a group of patients. 
The intensity of radioiodide uptake was however low and only present in a subset of 
metastases. Subsequent therapy with a high activity of radioiodine was unsuccessful. 
Many mechanistic and conceptual questions with respect to redifferentiation therapy 
remain and the advent of a novel class of designer drugs aimed at well identifi ed 







Gedifferentieerd schildkliercarcinoom (DTC) heeft een lage incidentie en een 
relatief goede prognose. Deze relatief gunstige prognose is het gevolg van het 
biologische gedrag van de meesten van deze tumoren en de effectiviteit van de initiële 
therapie. Het therapeutische arsenaal voor DTC is echter zeer beperkt. Wanneer 
afstandsmetastasen aanwezig zijn, gewoonlijk in de longen of het skelet, is de 
prognose ongunstig, omdat de resultaten van therapie met radioactief jodium (RaJ), 
dat de enige therapeutische mogelijkheid is, beperkt zijn. Een belangrijk probleem 
bij progressieve ziekte of metastasen is de verminderde of afwezige opname van RaJ 
door schildklierkankercellen. In deze gevallen is de prognose slecht omdat andere 
behandelingen (uitwendige radiotherapie of chemotherapie) slechts een beperkt 
succes hebben. 
Vanwege de lage incidentie en de goede prognose zijn diagnostische en 
therapeutische strategieën moeilijk te onderzoeken: de follow-up tijd is te lang en de 
aantallen patiënten te klein om signifi cante eindpunten te bereiken in prospectieve, 
gerandomiseerde onderzoeken. Daardoor zijn veel gangbare behandel- en follow-up 
protocollen gebaseerd op grote retrospectieve series, meestal van enkele centra, met 
vele bronnen van bias. Een ander aspect is de gedecentraliseerde benadering van 
de ziekte. Ondanks de lage incidentie behandelen veel ziekenhuizen patiënten met 
DTC. Een van de voorbeelden van de gedecentraliseerde aanpak is het naast elkaar 
bestaan van verschillende stageringssystemen, wat vergelijkingen tussen centra 
moeilijk maakt. 
DTC is een bijzondere maligne ziekte met fascinerende biologische fenomenen, zoals 
de pathofysiologie van het jodide transport. Dit maakt DTC tot een aantrekkelijk 
model om de moleculaire aspecten van jodide transport te bestuderen, en om nieuwe 
targets te vinden om het jodide transport bij DTC te herstellen.
Deze unieke eigenschappen dragen echter ook bij aan de wat geïsoleerde positie van 
deze tumor: DTC is een kankersoort die minder aandacht krijgt in de ontwikkeling 
van nieuwe anti-kanker medicijnen. 
Een voorbeeld van een onopgelost diagnostisch dilemma is dat de diagnose van DTC 
voornamelijk afhankelijk is van conventionele histologische kleuringen. Ondanks 
experimentele onderzoeken met gen- en eiwit expressie profi elen is er in de laatste 
decennia geen belangrijke vernieuwing geweest in de diagnostiek. Dit heeft gevolgen 
voor de vele patiënten die zich presenteren met een schildklierknobbel, omdat in het 
bijzonder het onderscheid tussen folliculair schildkliercarcinoom (FTC) en folliculair 
adenoom (FA) onmogelijk te maken is met cytologisch onderzoek. Daarom zullen 
veel patiënten met een schildklierknobbel een operatie ondergaan die uiteindelijk 
geen kanker blijken te hebben.







DTC. Echter, de vele analytische en statistische aspecten van Tg bepalingen worden 
niet altijd verdisconteerd in de keuze van Tg afkap waarden, die zijn gedefi nieerd 
op basis van de uitkomsten van retrospectieve studies van enkele grote centra. Een 
belangrijke benadering zou zijn de defi nitie van afkapwaarden voor een bepaald 
instituut, hetgeen een van de doelstellingen van dit proefschrift is. Daarnaast is 
de prognostische betekenis van Tg, in aanvulling op conventionele prognostische 
factoren zoals TNM stagering, histologie en leeftijd een interessant en potentieel 
klinisch belangrijk element dat niet uitgebreid in de literatuur aan de orde is 
gekomen.
Een fascinerend aspect van DTC is de pathofysiologie van het jodide transport. Het 
belangrijkste molecuul bij het jodide transport is de sodium iodide symporter (NIS) 
die minder functioneel is bij DTC. Hoewel verminderde NIS expressie belangrijk is, 
werd in dit proefschrift beschreven en bevestigd dat gestoord transport van NIS naar 
de celmembraan ook een belangrijk fenomeen is, hetgeen niet alleen consequenties 
heeft voor toekomstig onderzoek maar ook voor de diagnose van DTC.
De introductie van recombinant humaan thyrotropine (rhTSH) is belangrijk om de 
bezwaren van schildklierhormoon onttrekking te voorkomen. De aanname dat het 
voortzetten van schildklierhormoon behandeling het jodide transport niet beïnvloedt 
is echter niet goed onderzocht.
Verschillende benaderingen om het jodide transport te verbeteren bij DTC kunnen 
onderscheiden worden. Veel aandacht is gericht op lithium zouten, en het toevoegen 
van lithium aan RaJ therapie bij DTC wordt aanbevolen in de literatuur. In het 
huidige proefschrift worden de diagnostische en therapeutische dilemmas in DTC 
benaderd vanuit een klinisch en experimenteel perspectief.
2. Het verbeteren van de diagnose van DTC
De histologische diagnose van DTC, en in het bijzonder folliculaire 
schildklieraandoeningen is een belangrijk dilemma dat behandeld wordt in 
Hoofdstuk 2 en dat grote implicaties voor de algemene gezondheidszorg heeft. 
Hoewel de prevalentie van DTC laag is, is de prevalentie van schildkliernodi hoog en 
verbeteringen in de huidige praktijk waarin patiënten met een folliculaire cytologie 
verwezen worden voor operatie zou veel operaties kunnen besparen. Veel genetische 
en immuunhistochemische kandidaat markers zijn geïdentifi ceerd, maar geen van 
deze is succesvol geïmplementeerd in routine diagnostiek.  
Wij hebben de diagnostische waarde bestudeerd van een panel van eiwitten 
(Galectin-3 (Gal-3), HBME-1, CK-19, CITED-1, Fibronectin-1 (FN-1), the 
sodium iodide symporter (NIS) en peroxisome proliferator activated receptor 
(PPAR) bij goedaardige- en kwaadaardige schildklieraandoeningen. Ons onderzoek 
verschilde van eerdere studies met betrekking tot het gebruik van semi-kwantitatieve 
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afkapwaarden geïdentifi ceerd met behulp van receiver operator curve (ROC) analyses 
en hiërarchische cluster analyse. 
We vonden een verschil in expressie van alle eiwitten tussen FA en FTC. De verschillen 
tussen FA en FTC enerzijds en Folliculaire variant Papillair Schildkliercarcinoom 
(FVPTC) aan de andere kant waren minder duidelijk, maar wij vonden wel een 
verschil in expressie van PPARγ, HBME-1, Gal-3, cNIS en FN-1. De accuratesse 
van HBME-1, FN-1 en Gal-3 voor de differentiaal diagnose van FVPTC en FA 
waren redelijk. De accuratesse voor het onderscheid tussen FA en FTC voor FN-1 
was 71%.
Wij konden de door andere onderzoekers beschreven intracellulaire overexpressie 
van NIS bij PTC en FTC bevestigen. De verschillende expressie van cNIS tussen 
subtypes van schildkliertumoren maakt dat dit een kandidaat is voor de differentiaal 
diagnose van deze aandoeningen. Intracellulaire NIS expressie werd ook gevonden 
door cluster analyse als een mogelijk nuttige marker voor het onderscheid tussen FA 
en maligne tumoren.
In experimentele modellen van DTC blijkt PPARγ verminderd tot expressie te 
komen. Het belang hiervan wordt geïllustreerd in de PPARγ/PAX8 chromosomale 
herschikking die oorspronkelijk werd waargenomen werd in een serie van FTC. 
We vonden een verminderde kernaankleuring van PPARγ in maligne tumoren, 
maar omdat het percentage van positief aankleurende cellen in goedaardige lesies 
varieerde van 50-100%, is de diagnostische accuratesse voor het onderscheiden van 
folliculaire aandoeningen beperkt. 
Cluster analyse liet zien dat een panel van antilichamen tegen Gal-3 en FN-1 een 
sensitiviteit heeft van 97% voor alle schildkliercarcinomen, met een specifi citeit van 
100%. HBME-1 bleek een nuttige marker te zijn voor het onderscheid tussen FA 
en FVPTC. Omdat het aantal FVPTC tumoren klein was, kon hiërarchische cluster 
analyse deze groep niet onderscheiden.
Wij concluderen dat Gal-3, FN-1 en cNIS een nuttig panel zijn bij de differentiaal 
diagnose van schildkliernodi. De afwezigheid van Gal-3, FN-1 en cNIS is sterk 
suggestief voor een benigne aandoening. HBME-1 kan bruikbaar zijn bij de 
differentiatie tussen FVPTC en FA.
Perspectief
De bevindingen van Hoofdstuk 2 moeten bevestigd worden in een follow-up 
onderzoek waarbij de kandidaat markers getest moeten worden op cytologische 
puncties. Dit materiaal wordt beoordeeld volgens conventionele criteria en klinische 
beslissingen zullen hierop gebaseerd zijn. De scores van het onderzoekspanel zullen 
vergeleken worden met de uiteindelijke histologische diagnose van die schildklierlesies 







3. De diagnostische en prognostische waarde van serum Tg bepalingen in de 
follow-up van DTC
Serum Tg bepalingen zijn de belangrijkste markers in de follow-up van DTC. Recent 
zijn richtlijnen voor de follow-up van DTC gepubliceerd door de British Thyroid 
Association, De American Thyroid Association en de European Thyroid Association. 
In Nederland is ook een consensus in wording onder verantwoordelijkheid van 
het CBO. De afkapwaarden voor Tg in deze documenten zijn vaak niet scherp 
gedefi nieerd en gebaseerd op retrospectieve onderzoeken van een beperkt aantal 
grote centra. Geadviseerd wordt dan ook om per instituut afkapwaarden te defi niëren. 
Het probleem met de defi nitie van Tg afkapwaarden is, zoals met elke diagnostische 
procedure, de gouden standaard om de afwezigheid van ziekte vast te stellen. Bij 
DTC is Tg een betere marker dan RaJ scintigrafi eën, dus waneer RaJ scintigrafi eën 
als gouden standaard worden gebruikt zal de specifi citeit van Tg dalen. Bovendien 
wordt de optimale Tg afkapwaarde bepaald door de meest acceptabele ratio tussen 
onnodige behandelingen en gemiste recidieven. Dit is een subjectieve keuze die 
verschillend kan uitvallen in verschillende landen of ziekenhuizen. Daarom is het 
belangrijk om een inzicht te krijgen in de kwantitatieve relatie tussen sensitiviteit en 
specifi citeit van Tg, hetgeen de basis is van ROC analyses. In Hoofdstuk 3 hebben we 
de diagnostische en prognostische waarde van serum Tg bepalingen onderzocht in een 
groep van 366 DTC patiënten die allen dezelfde initiële behandeling ondergingen. Wij 
vonden een excellente diagnostische accuratesse van serum Tg waarden gedurende 
TSH stimulatie, 6 maanden na initiële therapie (sensitiviteit 100%), bij een hogere 
afkapwaarde dan normaal gerapporteerd wordt. De verklaring voor deze hogere 
afkapwaarde zou gerelateerd kunnen zijn aan het lagere initiële ablatie percentage 
in het LUMC in vergelijking met andere instellingen, met analytische verschillen 
of door het gebruik van de ROC techniek. We vonden ook dat serum Tg spiegels 
voorafgaande aan RaJ ablatie een onafhankelijke voorspeller zijn van genezing. TSH 
gestimuleerde Tg metingen, 6 maanden na initiële therapie en 2 en 5 jaar na initiële 
therapie waren onafhankelijke voorspellers van DTC gerelateerde mortaliteit. Hoewel 
de specifi citeit van Tg voor DTC lager is dan 100% (wat verklaard kan worden door 
de bovengenoemde keuze van de gouden standaard in onze studie), zijn we het 
eens met het gebruik om een hoge activiteit RaJ toe te dienen aan patiënten met een 
verhoogde Tg spiegel. Naar onze mening is een goede benadering om de discussie 
over de specifi citeit van Tg te vermijden om Tg als een risico-indicator te beschouwen 
voor DTC recidief. De onafhankelijke prognostische waarde van serum Tg voor 
genezing en mortaliteit zijn argumenten om Tg op te nemen in een conventioneel 
panel van risicofactoren. Het percentage DTC patiënten met antilichamen tegen Tg 
(27% bij initiële therapie) is vergelijkbaar met andere studies. Tg antilichamen bleken 
echter geen diagnostische of prognostische waarde te hebben. 
Wij concluderen dat ons onderzoek het belang van het defi niëren van instituuts 
gebonden Tg afkapwaarden aantoont en dat serum Tg bepalingen het mogelijk 
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maken patiënten te onderscheiden met een verhoogd risico voor recidief DTC of 
overlijden, in aanvulling op conventionele risicofactoren.
Perspectief
Gezien de vele analytische en methodologische aspecten van Tg metingen denken 
we dat er een harmonisatie moet plaatsvinden van Tg bepalingsmethoden tussen 
instituten, bij voorkeur in een internationale context. Daarnaast is uniformering 
van behandelingsprotocollen en de formulering van gestandaardiseerde criteria 
voor DTC ziekte activiteit van belang, zodat gestructureerde follow-up van DTC 
patiënten en de defi nitie van Tg afkapwaarden in regionaal of internationaal verband 
kan plaatsvinden.
4. Triiodothyronine onderdrukt de in vitro opname van iodide en de expressie 
van NIS 
De introductie van rhTSH voor de diagnose, initiële therapie en (onder zekere 
voorwaarde) behandeling van DTC is zonder twijfel een belangrijke innovatie 
voor patiënten met DTC, om de nadelen van schildklierhormoon onttrekking te 
voorkomen. Hoewel in het algemeen de diagnostische eigenschappen van rhTSH 
vergelijkbaar zijn met schildklierhormoon onttrekking, is het mogelijk dat de kinetiek 
van jodide opname niet geheel gelijk is. Een van de aspecten is dat patiënten met 
rhTSH per defi nitie euthyroid zijn. De aanname is dat schildklierhormoon de jodide 
opname niet beïnvloedt. In Hoofdstuk 4 is onderzocht of deze aanname correct 
is. We gebruikten de ratten schildklier cellijn FRTL-5 en kweekten deze cellijn in 
de aan- of afwezigheid van fysiologische concentraties triiodothyronine (T3) en 
bestudeerden proliferatie, jodide opname en NIS mRNA en eiwitexpressie. We 
vonden inderdaad een verminderde jodide opname tijdens T3 gepaard gaande met 
een afgenomen NIS mRNA en eiwitexpressie.
Hoewel het is gesuggereerd dat jodide aanwezig in schildklierhormoon de specifi eke 
activiteit van RaJ verdunt en dat dit verantwoordelijk is voor de verminderde opname 
van RaJ geloven we dat dit niet de verklaring kan zijn voor onze bevindingen, omdat 
de hoeveelheid jodide in T3 verwaarloosbaar is ten opzichte van de concentratie 
koud jodide van 10 uM in onze experiment. Ook verschillen in jodide kinetiek op 
totaal lichaamsniveau, aangevoerd als een andere verklaring voor verschillen tussen 
rhTSH en onttrekking kunnen deze bevindingen niet verklaren. Onze resultaten 
wijzen op een effect van T3 op NIS gen expressie resulterend in een verminderde 
hoeveelheid NIS eiwit.
Er is discussie of de NIS promoter T3 responsieve elementen bevat. Een andere 
verklaring kan zijn dat de effecten van T3 via repressie van de TSH receptor promoter 







Wij concluderen dat wij aanwijzingen vonden voor een TSH en jodide onafhankelijk 
effect van T3 op NIS genexpressie. Het mechanisme moet nog opgehelderd worden 
evenals de vraag of dit fenomeen ook bij mensen een rol speelt. De klinische 
implicaties van de vinding zijn niet duidelijk, maar deze kan bijdragen aan de 
gesuggereerde verschillen in jodide accumulatie tussen rhTSH en conventioneel 
behandelde mensen.
Perspectief
Wij denken dat de introductie van rhTSH een belangrijke verbetering is voor 
patiënten met DTC. Het is echter belangrijk om relevante aspecten te bestuderen die 
betrokken zijn bij de fysiologie van het jodide metabolisme, waartoe ook T3 behoort. 
Een interessante ontwikkeling is de experimentele bevinding dat T3 ook tumor 
onderdrukkende eigenschappen kan hebben. In dit verband zou het voortzetten van 
schildklierhormoontherapie gedurende diagnose en behandeling van RaJ voordelen 
kunnen hebben. 
5. Het verbeteren van radioactief jodium therapie bij DTC
Therapeutische opties voor patiënten met metastasen van DTC zijn beperkt. RaJ 
is effectief bij ongeveer de helft van de patiënten met longmetastasen en een klein 
percentage patiënten met botmetastasen. De effectiviteit van RaJ is vaak verminderd 
door een beperkte jodide opname in metastasen. Strategieën om de therapeutische 
opties te verbreden kunnen onderscheiden worden in behandelingen gericht op het 
verbeteren van RaJ therapie en de identifi catie van nieuwe doelwitten.
Het verbeteren van RaJ therapie is een breed thema. Twee sub-themas kunnen 
onderscheiden worden. Ten eerste tumoren waarbij nog steeds RaJ opname aanwezig 
is, ten tweede tumoren waarbij de RaJ opname verloren is.
Bij tumoren die nog RaJ opnemen is de essentie van het verbeteren van RaJ therapie 
het verhogen van de dosis RaJ. De dosis van RaJ wordt bepaald door de hoeveelheid 
(activiteit) van RaJ die de tumor bereikt (specifi eke activiteit), de mate van opname in 
de tumor, het tumor volume en de effectieve halfwaarde tijd van RaJ die op zijn beurt 
bepaald wordt door de fysische halfwaardetijd en de biologische halfwaarde tijd. Al 
deze factoren kunnen geoptimaliseerd worden: de specifi eke activiteit kan verhoogd 
worden door een jodium beperkt dieet. De mate van opname kan verhoogd worden 
door hoge serum TSH concentraties. De halfwaarde tijd van RaJ bij DTC is een 
belangrijke factor. Het verloren gaan van de folliculaire architectuur en mogelijk 
de verminderde activiteit van thyroid peroxidase (TPO) kunnen bijdragen aan een 
verminderde halfwaardetijd en dus aan een lagere tumor dosis. We richtten ons op 
dit probleem en bestudeerden de effecten van lithium zouten op de accumulatie van 
jodide in Hoofdstuk 5. 
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5.1 Effecten van lithium op jodide opname en de klinische resultaten van RaJ therapie
De relatie tussen lithium zouten en de schildklier is al lang bekend, aangezien 
veel patiënten met een bipolaire depressie, die behandeld worden met lithium 
zouten hypothyreoidie ontwikkelen. Het mechanisme is onduidelijk maar 
sommige experimentele studies hebben gesuggereerd dat lithium de afgifte van 
schildklierhormoon uit de schildklier remt, of in andere woorden, jodide in de 
schildklier opgenomen houdt. Vanwege deze eigenschappen is lithium gebruikt 
om de dosis RaJ te verhogen in goed- en kwaadaardige schildklierziekten. Het 
probleem is echter dat het niet duidelijk is of lithium de klinische resultaten van 
RaJ therapie beïnvloedt. Wij hebben daarom de klinische effecten van RaJ met 
en zonder lithiumcarbonaat bestudeerd bij patiënten met DTC. Daarnaast is er 
onduidelijkheid over het mechanisme waarmee lithium de RaJ dosis verhoogd in 
DTC. Wij verrichtten een in vitro studie om de specifi eke effecten van lithium op 
NIS te bestuderen. 
We onderzochten 12 patiënten met metastasen van DTC die nog wel RaJ opnamen 
maar waarbij eerdere RaJ therapie onvoldoende had gewerkt. Deze eerdere therapie 
fungeerde als controle De patiënten ontvingen 1200 mg lithiumcarbonaat/dag gevolgd 
door RaJ therapie. Ondanks een toegenomen RaJ opname bij 7 patiënten werd geen 
gunstig effect van lithium waargenomen op het klinische beloop, vastgesteld door 
middel van Tg metingen en met radiologisch onderzoek. Een verklaring voor het 
gebrek aan succes kan zijn dat in het lange interval tussen de controle RaJ behandeling 
en de behandeling met lithium biologische veranderingen in de tumor zijn ontstaan 
of dat de eerste behandeling tumor cellen heeft geselecteerd die radioresistent zijn. 
Wij denken dat het onwaarschijnlijk is dat dit bij alle patiënten het geval is geweest, 
aangezien bij de RaJ therapie met lithium ook jodide accumulerende lesies zichtbaar 
waren. Daarnaast was er na de eerste RaJ therapie geen substantieel verschil in de 
stijgingssnelheid van Tg serum spiegels zichtbaar. De selectie van radioresistente 
cellen – kankercellen die niet meer in apoptose gaan na radiotherapie, een bekend 
fenomeen in de oncologie – is een andere verklaring voor het gebrek aan klinisch 
effect van RaJ met lithium. We bestudeerden de effecten van lithium in verschillende 
fysiologische concentraties op jodide opname in de ratten schildkliercellijn FRTL-5, 
in de gepolariseerde niercellijn MDCK, die stabiel was getransfecteerd met NIS en 
in de humane, NIS getransfecteerde FTC cellijn FTC133-NIS. Zowel de kinetiek 
van jodide opname als jodide effl ux werden bestudeerd. Het doel van deze studies 
was om te onderzoeken of lithium een direct effect op NIS heeft. Er werden geen 
effecten van lithiumchloride op jodide opname of effl ux gevonden. We hebben niet 
alle stappen van de jodide fysiologie onderzocht. Aangezien het gesuggereerd is dat 
voor het bevorderen van jodide concentraties in de schildklier organifi catie nodig is 
kunnen we niet uitsluiten dat in een 3-dimensionaal model van schildkliercellen lithium 
inderdaad de afgifte van georganifi ceerd jodide zou kunnen remmen, hetgeen een 







met een korte halfwaardetijd en afwezige organifi catie. 
De resultaten van ons onderzoek relativeren de eerder gerapporteerde gunstige 
effecten van lithium bij DTC.
Perspectief
Wij geloven dat lithiumzouten geen plaats hebben bij RaJ therapie voor DTC. 
Daarom moeten andere mechanismen om de RaJ halfwaardetijd te verlengen worden 
geëxploreerd. Het concept van organifi catie is interessant en het kan verondersteld 
worden dat wanneer RaJ aan een ander eiwit gekoppeld kan worden de halfwaardetijd 
positief beïnvloed kan worden. Transfectie experimenten met TPO zijn echter vanuit 
klinisch perspectief moeilijk voorstelbaar. Een andere optie zou het blokkeren van 
de jodide effl ux kunnen zijn door middel van chloride kanaal blokkers.
5.2 Effecten van redifferentiatietherapie met Bexarotene op jodide opname en klinische 
uitkomsten van RaJ therapie
Het tweede subthema van het verbeteren van radioactief jodium therapie bij 
DTC betreft tumoren waarbij de jodide opname is verloren. De ‘heilige graal’ is 
het bewerkstelligen van functionele expressie van NIS. De pathofysiologie van 
verminderde NIS expressie in DTC is gecompliceerd (zoals boven beschreven) en 
omvat zowel genetische (transcriptie) defecten als post-translationele (traffi cking) 
problemen. Mutaties in het NIS gen zijn zelden beschreven bij DTC. De meest 
waarschijnlijke verklaring is dat de transcriptie van het NIS gen verminderd is door 
inactivatie van het gen zelf of de promoter. De NIS promoter heeft meerdere 
responsive elements en afwezigheid van 1 of meerdere activatoren (zoals TTF-1 
of TSH) zal verminderde transcriptie veroorzaken. Een interessante verklaring 
wordt gevormd door epigenetische veranderingen waarbij methylering of histon 
deacetylering transcriptie verminderen. Er zijn onderzoeken beschreven waarbij 
de genetische blokkades die hierdoor ontstaan worden opgeheven met behulp 
van farmaca. In Hoofdstuk 6 en 7 hebben wij de effecten van de retinoid receptor 
X (RXR) agonist Bexarotene bestudeerd op het herstel van de jodideopname bij 
patiënten met metastasen van DTC. Retinoiden zijn eerder gebruikt bij patiënten 
met DTC, maar alle klinische studies tot-nu-toe zijn gedaan met 13-cis retinoic acid, 
dat alleen aan de retinoiden receptor A (RAR) bindt. Recente studies hebben het 
belang van andere retinoiden receptor subtypes in DTC aangetoond, zoals RXR. Wij 
hebben daarom de effecten bestudeerd van een behandeling van 6 weken met 300 mg 
Bexarotene/dag op de I-131 opname bij 12 patiënten met DTC. Voorafgaande aan 
en na deze interventie werd de RaJ opname gemeten op diagnostische scintigrafi eën 
3 dagen na toediening van 185 MBq RaJ. Deze scintigrafi eën werden voorafgegaan 
door 2 injecties met rhTSH. Bexarotene behandeling induceerde RaJ opname bij 
8/11 patiënten (1 patiënt overleed door oorzaken die niets met het onderzoek te 
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maken hadden). RaJ opname was echter alleen zichtbaar met single photon emission 
tomography en niet alle metastasen die zichtbaar waren bij CT lieten RaJ opname 
zien (incomplete matching). Een interessante waarneming was dat in 1 patiënt een 
nieuwe afwijking zichtbaar werd na Bexarotene, die eerder geen RaJ opnam. Dit is 
een illustratie van de heterogeniteit van DTC metastasen met betrekking tot RaJ 
opname. 
Hoewel de hoeveelheid RaJ opname beperkt was in de 8 responders, besloten we 
deze patiënten het voordeel van de twijfel te geven, en hen te behandelen met een 
hoge activiteit RaJ. Zij kregen 7400 MBq RaJ, voorafgegaan door 6 weken Bexarotene 
300 mg/dag. Zes maanden na de therapie bleken 6 patiënten progressieve ziekte te 
hebben, terwijl 2 patiënten stabiele ziekte hadden. De verklaring voor dit gedeeltelijke 
succes kan zijn dat Bexarotene andere factoren die van invloed zijn op de RaJ 
dosis (zoals de RaJ halfwaardetijd) niet heeft beïnvloed. Daarnaast kan het zijn dat 
bij de regulatie van NIS meerdere stoornissen op het niveau van transcriptie en 
posttranscriptie zijn die slechts gedeeltelijk hersteld kunnen worden door retinoiden. 
Een andere mogelijkheid is dat het retinoiden receptor expressieniveau niet gunstig 
is ten aanzien van Bexarotene therapie. Om dit te onderzoeken verrichten we 
kleuringen van de RAR en RXR bij een aantal patiënten. Wij vonden geen relatie 
tussen RAR en RXR kleuringspatroon en therapierespons. Een beperking van deze 
analyse is wel dat we alleen materiaal van de primaire tumor ter beschikking hadden 
en dat het expressiepatroon in de metastasen anders geweest zou kunnen zijn. 
We vonden een incomplete matching tussen de metastasen die zichtbaar waren op 
een post-RaJ therapie scintigram en CT. Dit betekent dat zelfs als een subgroep van 
metastasen weer RaJ opneemt na Bexarotene het waarschijnlijk is dat andere, niet 
RaJ opnemende metastasen progressief zijn.
Perspectief
Wij hebben aangetoond dat redifferentiatietherapie in een klinische context 
inderdaad kan leiden tot herstel van de RaJ opname bij DTC. Een conceptueel 
probleem bij redifferentiatietherapie is dat deze aselect is: ook andere genen die 
niet gerelateerd zijn aan de ziekte kunnen door deze stoffen beïnvloed worden. 
Dit zou belangrijke bijwerkingen tot gevolg kunnen hebben, tenzij een specifi ek 
moleculair defect zoals in de RAR receptor bij pro-myelocyten leukemie aan de 
orde is, dat hersteld kan worden met retinoiden therapie. De opkomst van speciaal 
ontworpen geneesmiddelen die gericht zijn op een specifi ek moleculair defect in 
goed geanalyseerde signaaltransductie routes, zoals de tyrosinekinasremmers, is een 







6. Conclusies van dit proefschrift
De incidentie, overleving en de specifi eke klinische en biologische aspecten van 
DTC compliceren de diagnose, behandeling en follow-up. Dit wordt nog verder 
bemoeilijkt door de wijze waarop onderzoek en patiëntenzorg voor DTC is 
georganiseerd. Dit zou grondig geëvalueerd en verbeterd moeten worden. De recente 
publicatie van multinationale richtlijnen is een goede, eerste stap. De onderzoeken 
van dit proefschrift hebben een aantal klinische en fundamentele aspecten van DTC 
aan de orde gesteld. Hoewel een aantal vragen beantwoord zijn, zijn ook vele nieuwe 
vragen gerezen die verder onderzoek nodig maken.
De diagnose van DTC, die momenteel met behulp van conventionele histologische 
technieken wordt gedaan, kan aanzienlijk verbeterd worden met nieuwe markers. 
Onze studies bieden belangrijke perspectieven voor de invoering van een nieuw 
panel van immuunhistochemische markers dat de diagnose kan verbeteren.
Hoewel serum Tg metingen aanbevolen worden als de belangrijkste diagnostische 
procedure in de follow-up van DTC, zijn er vele analytische en statistische aspecten 
die hierbij een rol spelen. Onze onderzoeken illustreren het belang van het defi niëren 
van institutionele afkapwaarden van Tg, gebruik makend van ROC technieken, om 
een inzicht te krijgen in de kwantitatieve relatie tussen sensitiviteit en specifi citeit. 
We vonden dat Tg een onafhankelijke prognostische marker is voor genezing en 
mortaliteit, hetgeen het mogelijk zou kunnen maken voor de arts om hoog-risico 
patiënten te identifi ceren. 
Het vermogen van DTC cellen om jodide te accumuleren is de kern van diagnostiek 
en therapie met RaJ. De introductie van rhTSH is een groot voordeel voor patiënten 
om de ongemakken van hypothyreoidie te voorkomen. Het is echter onwaarschijnlijk 
dat schildklierhormoon geen effect heeft op het jodide metabolisme. Wij stelden 
vast dat T3 een direct effect heeft op de expressie en functie van NIS. Hoewel 
de klinische consequenties niet duidelijk zijn, denken we dat een zorgvuldige 
evaluatie van de effecten van een nieuwe behandeling op alle bekende aspecten van 
schildklierfysiologie van belang is.
Het belangrijkste probleem bij de behandeling van DTC is de beperkte effectiviteit 
van RaJ bij een aanzienlijk percentage patiënten met metastasen. Strategieën om RaJ 
behandeling te verbeteren moeten gebaseerd zijn op de identifi catie van moleculaire 
defecten in de jodide fysiologie bij DTC. Bij patiënten bij wie er nog wel RaJ opname 
is – zij het met onvoldoende effect - zijn interventies gericht zijn op het verbeteren 
van de jodide kinetiek belangrijk. Wie lieten zien dat de vaak gepropageerde 
strategie om DTC patiënten met lithiumzouten te behandelen niet resulteerde in een 
verbeterde uitkomst van RaJ therapie. Noch vonden we een effect van lithium op de 
in vitro jodide opname. Andere benaderingen om de jodide kinetiek te verbeteren 
zijn nodig.
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Bij patiënten bij wie metastasen van DTC geen RaJ accumuleren is het 
onderzoek gericht op het herstel van functionele NIS expressie. We vonden dat 
redifferentiatietherapie met de RXR ligand Bexarotene tot herstel van de jodide 
opname leidde bij een groep patiënten met DTC metastasen. De intensiteit van de 
RaJ opname was echter laag en niet aanwezig in alle metastasen. Daaropvolgende 
therapie met een hoge activiteit RaJ was niet succesvol. Vele mechanistische en 
conceptuele vragen met betrekking tot redifferentiatietherapie blijven over en de 
opkomst van nieuwe klassen geneesmiddelen die specifi ek ontworpen zijn om een 
goed gekarakteriseerd moleculair defect te herstellen, zoals de klasse van tyrosine 
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